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Abstract 
Schistosomiasis is a chronic disease, caused by Schistosoma species, affecting 200 
million people worldwide and causing at least 300,000 deaths annually. Currently, no 
vaccines are available and Praziquantel is the standard anti-schistosomiasis drug. 
Praziquantel disrupts the tegument of adult worms, but not juvenile parasites and it does 
not prevent reinfection.  Praziquantel resistance is rare, but repeated treatment in the field 
and laboratory manipulation has increased parasitic resistance. Therefore, it is necessary 
to develop a vaccine that induces long-term immunity to schistosomiasis with the final goal 
of complete elimination. Driven by the need to improve disease treatment and prevention, 
the genomes of three human Schistosoma species have recently become publicly 
available (S. mansoni, S. japonicum Chinese strain and S. haematobium). The principal 
goal of the PhD research project is to employ machine learning and Bioinformatics 
methods to identify novel vaccine and drug targets against the human-infecting 
Schistosoma parasites from genome sequence information. 
In the first study, schistosome specific machine learning classifiers were developed for 
surface proteins and secretory peptides. Schistosome surface proteins, especially those 
expressed in tegument, represents the interface between host and parasite and its 
molecules are responsible for essential functions to parasite survival. Also, large number 
of proteins secreted by schistosomes are important for their survival in their hosts and 
infection. Knowledge of schistosome surface and secreted proteins is essential for 
understanding parasite host interaction and finding new candidate targets for vaccines and 
drugs or developing novel diagnostic methods. The web application SchistoProt has been 
developed, a schistosome specific classifier, for identifying schistosome specific surface 
proteins and secretory peptides that might be potential drug and vaccine targets.  
In the second study, a machine learning prediction tool is developed to predict 
schistosome specific immunoreactive peptides. The sequence properties of 
immunoreactive Schistosoma proteins have been determined and compared the 
significant sequence features of immunoreactive proteins and non-immunoreactive 
proteins of Schistosoma species. The SchistoTarget web application, for the in silico 
identification of Schistosoma immunoreactive proteins has been developed. SchistoTarget 
uses supervised machine learning methods and significant differential features distribution 
between immunoreactive and non-immunoreactive peptides. 
In the third study, a comparative analysis of the publicly available Schistosoma genomes 
S. mansoni, S. Japonicum, S. haematobium, the newly sequenced Schistosoma bovis 
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genome and the non-parasitic, free-living flatworm Schmidtea mediterranea reveals the 
interesting candidate genes for vaccine targets.  Selected genes from this study have been 
annotated as surface or secretory proteins using the developed web applications from 
previous two studies. Further, using Gene Ontology and Swiss-Prot annotations, 20 
putative vaccine and drug targets have been identified to be biologically validated by wet 
laboratory experiments in animals and then clinically. 
The in silico comparative genomics analysis approach for identifying new drug and vaccine 
candidates represents a valuable resource for the Schistosoma research community. The 
protocol developed in this PhD research project can be used as a blueprint for other 
important parasitic diseases including malaria.   
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Chapter 1 Introduction 
 
1.1 Schistosomiasis 
Infections by blood flukes (schistosomes) cause highly significant human diseases and are 
a major health concern in the Asia Pacific Region and Africa. Schistosomiasis is a chronic 
disease caused by Schistosoma species. It is considered by the World Health 
Organization as the second most socioeconomically devastating and second most 
common parasitic disease affecting 200 million people worldwide1,2 and causing at least 
300,000 deaths annually3. No vaccines are available and treatment relies mainly on one 
drug, praziquantel2. Eight Schistosoma species infect humans: S. mansoni, S. 
haematobium, S. japonicum, S. mekongi, S. malayensis, S. mattheei, S. guineeensis, and 
S. intercalatum4 (Figure 1.1). Recent applications of next-generation sequencing 
technologies and bioinformatic tools for large-scale investigations explore the systems 
biology of the organisms5. The genome sequences provide a unique resource for studying 
the evolution of schistosomes, to identify genes important for host-parasite interactions 
and to discover novel drug and vaccine targets. 
 
 
Figure 1.1 Phylogeny of Schistosoma. 
(Figure adapted4,6) 
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This chapter will first introduce background knowledge of the schistosome lifecycle, 
schistosomiasis treatment, infection and resistance, available schistosome genome data 
and potential vaccine targets. 
 
1.2 Schistosome Structure and Lifecycle 
Adult schistosomes are white or greyish worms with a cylindrical body of 7–20 mm in 
length. The body has two terminal suckers, a blind digestive tract, reproductive organs and 
a complex tegument. The tegument consists of a single, contiguous, double-bilayered 
membrane, which covers the entire worm7. Schistosomes are exposed to diverse 
environmental conditions during their life cycle. Unlike other trematodes, schistosomes 
have separate sexes. They change from an asexual form in the intermediate hosts such as 
snails. Then they change to a sexual form in the vascular system of the definitive host 
such as human8. 
The male’s body holds the longer and thinner female by forming a groove or 
gynaecophoric channel (Figure 1.2). The adult schistosomes live within the perivesical 
(Schistosoma haematobium) or mesenteric (other species) venous plexus as permanently 
embraced couples. Schistosomes feed on blood and globulins through anaerobic 
glycolysis, and the debris released in the host’s blood9. 
 
 
Figure 1.2 Paired adult S. mansoni worms. 
The darker female lying within the gynacophoric canal of the larger male worm. 
(From Schistosomiasis Research Group, http://www.path.cam.ac.uk/~schisto) 
 
Schistosomes require an intermediate aquatic snail host in their complex life cycle (Figure 
1.3). The sporocyst (snail stage) reproduces asexually, producing cercariae that are 
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constantly shed into the aquatic environment. These cercariae find the definite host 
(human or animal) in contact with the water and penetrate the skin. The larva transforms 
into a schistosomulum in the skin, that adapts its surface membrane, the tegument, for 
parasitism. The schistosomulum passes from the skin, through the lymphatic system and 
blood into the lungs and via the blood to the liver. Within the liver the parasites form sexual 
pairs and develop into adult worms. The adult worm pairs live and lay eggs in the vessels 
surrounding the intestine or urinary system. Mature eggs can penetrate host membranes 
such as rectal veins or the intestinal wall. Eggs are released from the host body and all 
eggs that come into contact with water hatch into miracidia and the cycle starts again10. 
 
 
Figure 1.3 The schistosome life-cycle. 
(From Schistosomiasis Image Library, www.dpd.cdc.gov) 
 
1.3 Schistosomiasis Treatment 
Currently, Praziquantel (PZQ) is the standard anti-schistosomiasis drug11. Praziquantel 
disrupts the tegument of adult worms, but not juvenile parasites9 and it does not prevent 
reinfection12. Praziquantel resistance is rare, but repeated treatment in the field and 
laboratory manipulation has increased parasitic resistance11,13,14. Therefore, it is necessary 
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to develop a vaccine that induces long-term immunity to schistosomiasis with the final goal 
of complete elimination15. 
One vaccine candidate is the rSh28GST antigen from S. haematobium, currently in phase 
I clinical trial and shown to be safe and immunogenic16. Other vaccine candidates are the 
Sm14, Sm29, Sm-TSP1 and Sm-TSP2 antigens from S. mansoni, currently in pre-clinical 
and clinical development17-19. 
  
1.4 Available Schistosoma Genomes 
Driven by the need to improve disease treatment and prevention, the genomes of three 
human Schistosoma species have recently become publicly available (S. mansoni20, S. 
japonicum Chinese strain21 and S. haematobium22). Comparison of these three genomes 
shows similar genome size, number of proteins and similar GC content and percentage of 
repetitive elements (Table 1.1). 
 
Table 1.1 Comparison of three publicly available Schistosoma genomes. 
Genomic features Schistosoma mansoni Schistosoma 
japonicum 
Schistosoma 
haematobium 
Estimate of genome size (Mb) 381 403 385 
Chromosome number (2n) 8 8 8 
Total number of base pairs within 
assembled contigs 
374,944,597 369,039,322 361,903,089 
N50 contig (length (bp); total number 
>500 bp) 
16,320; n = 50,292 6,121; n = 95,265 21,744; n = 36,826 
Total number of base pairs within 
assembled scaffolds 
381,096,674 402,705,545 385,110,549 
N50 scaffold (length (bp); total number 
>1,000 bp in length) 
832,5415; n = 19,022 176,869; n = 25,048 306,738; n = 7,475 
Proportion of genome that is coding (%) 4.72 4.32 4.43 
Number of putative coding genes 13,184 13,469 13,073 
Total GC content (%) 34.7 33.5 34.3 
Repeat rate (%) 45 40.1 47.2 
(Source
22
) 
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1.5 Schistosoma Surface Proteins and Secretory Peptides 
The body of the adult worm is covered by a complex multilaminate surface, the tegument, 
which enables schistosomes to survive in the hostile host environment for decades. 
Schistosomes also display effective strategies to evade the host immune responses23,24. A 
large number of proteins are excreted or secreted by schistosomas from their surface. 
These excretory proteins are important for their survival in their hosts. These proteins can 
stimulate the innate immune system and modulate various host immune responses when 
exposed to host tissues. Thus, schistosomas evade the host immune defense and become 
resistance to antibody-dependent cellular cytotoxicity and oxidative stress25,26. 
Identification of surface proteins and secreted peptides is important for both understanding 
parasite host interaction and finding new candidate vaccines targets27.  
 
1.6 Host-Parasite Interaction 
Significantly acclimated to parasitic life, schistosomes can live for a long time or decades 
even in a hostile environment as the circulatory system from vertebrate host28. The 
parasite has a close contact with circulating elements of the immune system29. In this 
effective host-parasite relationship, the host immune system plays an important role in 
both parasite development and elimination. CD4+ cells, hormones, and cytokines as TNF-
α, TGF-β, and IL-7 produced by the host, appear to aid the parasite development (Figure 
1.4), suggesting that schistosomes could accept host hormone signals for cell proliferation, 
development, mating, and reproduction while CD4+ cells, B cells, IFN-γ, and TNF-α have 
been implicated in parasite elimination in the irradiated cercariae vaccine model30,31. 
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Figure 1.4 A theoretical model of the impact of a few hormones and development elements 
from a mammalian host on certain developmental stages of schistosomes. 
 (Source30) 
 
1.7 Antigens for Vaccine Development 
The majority of the studies that planned to recognise membrane proteins in parasite 
tegument were performed in adult worms23,32. Schistosomula is the significant focus for 
host immunity. Protective antigens are found in S. mansoni schistosomula tegument 
(Smteg) since mice inoculation with Smteg formulated with Freunds' adjuvant33. The 
characterization of these defensive antigens is being performed utilising immune-
proteomics analysis and genome databases to distinguish candidates to be utilised in a 
vaccine formulation against schistosomiasis31,34. The results observed in these preclinical 
trials using tegument proteins are summarised in Table 1.2. 
 
Table 1.2 Schistosome tegument protein evaluated as vaccine candidates in preclinical 
studies. 
(Table adapted31,35) 
Protein Vaccine type 
Protection 
level 
Egg reduction 
Bioinformatic tool used in 
antigen selection 
Sm 21.7 
Recombinant 
protein 
41%–70% Not determined 
Not determined 
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Sm 21.7 DNA vaccine 41.5% 
62% (liver) 
67% (intestine) 
Not determined 
Cu/Zn 
superoxide 
dismutase 
DNA vaccine 44%–60% Not determined 
Not determined 
Sm TSP2 
Recombinant 
protein 
57% 
64% (liver) 
65% (feces) 
BLAST 
Sm29 
Recombinant 
protein 
51% 60% (intestine) 
InterProScan, SignalIP 3.0, 
Signal IP Neural, NetNGlyc 1.0, 
BLAST, WolfpSORT, SOSUI, 
Compute pI/Mw tool 
ECL (200 kDa 
protein) 
DNA vaccine 38.1% 
Not determined Not determined 
Sm 22.6 
Recombinant 
protein 
34.5% Not determined BLAST 
Sm TSP 1 
Recombinant 
protein 
34% 
52% (liver) 
69% (intestine) 
BLAST 
Sm 21.7 
Recombinant 
protein 
41%–70% 
Not determined Not determined 
Sm p80 
DNA vaccine 
Not 
determined 
Not determined Not determined 
Sm14e Recombinant 
protein 
Not 
determined 
Not determined Not determined 
CT-SOD DNA vaccine Not 
determined 
Not determined Not determined 
 
The immunomic screening of pathogens using protein microarrays for antigen discovery 
has progressed rapidly. The first protein microarray for schistosomes has been 
constructed for identification of valuable immunogens that could be developed as 
marketable vaccines15. Recently, another proteome microarray of S. mansoni proteins was 
produced36.  
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1.8 Hypothesis 
During the past decade, Schistosoma researchers targeted surface and secretory proteins 
for vaccine development. But, a very limited number of surface and secretory antigens 
were explored23,24,37-39. Recently, three human-infecting Schistosoma genomes become 
publicly available. Also, immunomics approach using schistosome protein microarray 
provide useful resource on antibody responses of the antigens. The genomics and 
immunomics datasets provide a unique foundation for an innovative approach to identify 
novel drug and vaccine targets but it has not been obvious how to identify the important 
protective schistosome antigens from genomic-based information.  
The hypothesis is that bioinformatics approach leads to identifying putative drug and 
vaccine targets against schistosomiasis using Schistosoma genomic-based information. In 
this PhD project, I have developed an integrative bioinformatics pipeline to identify putative 
drug and vaccine targets against schistosomiasis from protein sequences information.  
 
1.9 Research Aims  
The principal goals of the proposed project are to employ Bioinformatics methods to 
identify novel vaccine and drug targets against the human parasites Schistosoma spp.   
 
1.9.1 Aim 1: Identify schistosome-specific Surface Proteins and Secreted Peptides 
Develop schistosome-specific machine-learning classifier for the identification of surface 
proteins and secreted peptides. Apply newly developed classifier to in all in-house and 
publicly available schistosome genomes. 
 
1.9.2 Aim 2: Identify Schistosoma immunoreactive proteins 
Develop schistosome-specific machine-learning classifier for the identification of 
immunoreactive proteins using Scistosoma protein microarray data. 
 
1.9.3 Aim 3: Identify putative vaccine targets against schistosomiasis 
Develop an integrative bioinformatics pipeline to identify putative vaccine targets against 
schistosomiasis by comparative analysis of available genomic-based information. 
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1.10  Thesis outline 
In chapter 1, literatures are reviewed to extract background information required for 
schistosome proteins characteristics to select the potential antigens as drug and vaccine 
targets. The development of methods and associated tool, SchistoProt, to identify 
schistosome-specific surface proteins and secretory peptides are described in chapter 2. 
Chapter 3 describes a machine learning approach, the SchistoTarget web server, to 
identify Shistosoma proteins immunoreactivity using protein microarray data. A 
comparative analysis of Schistosoma genomes and an integrative bioinformatics pipeline 
to identify putative vaccine targets against schistosomiasis has been described in Chapter 
4. In this chapter, I have shown how potential antigens can be selected by comparing 
several parasite genomes and using the tools developed in chapters 2 and 3 and other 
available annotations. A general discussion on the research outcomes from the PhD 
project and future direction are provided in chapter 5. 
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Chapter 2 Identifying Schistosome-Specific Surface 
Proteins and Secretory Peptides 
 
2.1 Foreword 
This chapter describes a supervised machine learning based approach used for identifying 
Schistosoma-specific surface proteins and secreted peptides. A machine learning based 
web server, SchistoProt, has been developed to classify Schistosoma protein sequences 
into surface/non-surface proteins and secretory/non-secretory peptides. The methods, 
prediction accuracy, usage and architecture of SchistoProt have been depicted in this 
chapter. 
 
2.2 Abstract 
Schistosomiasis is a debilitating chronic disease caused by Schistosoma parasitic worms. 
It is considered by the World Health Organization as the second most devastating parasitic 
disease, with a strong need for vaccine development. Knowledge of schistosome surface 
and secreted proteins is essential for understanding parasite-host interactions, for studying 
anti-Schistosoma protective immunity, for finding new candidate vaccine targets, and for 
developing novel diagnostic methods. 
SchistoProt, a web-based classifier for the in silico identification of schistosome surface 
proteins and secreted peptides, have been inroduced. The classifier is highly accurate and 
fast, and allows the analysis of large whole-proteome datasets. Positive training sets 
(known surface and non-secretory proteins) were extracted from the literature and the 
NCBI non-redundant protein database. A negative training set was compiled from nuclear 
and histone related proteins. SchistoProt provides a user-friendly web-interface and results 
are presented in interactive tables and figures. On an independent test-set of 400 
Schistosoma proteins, SchistoProt achieved a sensitivity of 85% and specificity of 81% for 
surface proteins and a sensitivity of 92% and specificity of 93% for secretory peptides. The 
software showed significantly increased prediction accuracy compared with existing tools. 
SchistoProt is implemented in Python and the web-server is freely accessible at 
http://schistoprot.bioapps.org. Source code and documentation are available from 
https://github.com/shihabhasan/schistoprot. 
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SchistoProt is an easy-to-use, highly accurate and fast web-server for the in silico 
identification of Schistosoma surface proteins and secreted peptides. The software has 
been optimized for large datasets and enables whole-proteome analysis. SchistoProt can 
assist rational vaccine design by facilitating the rapid prioritization of candidate vaccine 
targets. The software also identifies proteins potentially important for parasite-host 
interaction and therefore enables researchers to gain new insights into the molecular 
mechanisms of Schistosoma infection.  
 
2.3 Introduction  
Schistosomiasis is an infectious disease caused by parasitic Schistosoma worms1,2. More 
than 700 million individuals are at risk of acquiring schistosomiasis in more than 70 
countries. It is considered by the World Health Organization as the second most 
socioeconomically devastating and second most common parasitic disease after malaria3. 
Chemotherapy via praziquantel is an effective treatment, but mass treatment does not 
prevent reinfection and there is an increasing concern of the development of drug 
resistance. The development of vaccines that induce long-term immunity therefore remain 
the most potentially effective means for controlling schistosomiasis. However, despite the 
poor containment of the disease and devastating medical and economic impact, no 
Schistosoma vaccines are available and we are just starting to understand the molecular 
mechanisms of host infection, host-parasite interaction and anti-schistosome protective 
immunity.  
Driven by the need to improve disease treatment and prevention, the genomes of three 
human Schistosoma species have recently become publicly available20-22. The surface of 
larval and adult schistosomes, the tegument, represents the host-parasite interface and 
proteins expressed in the tegument are responsible for essential functions for parasite 
survival in the host23. The tegument includes a single multinucleated cytoplasmic layer, 
which is linked to underlying nucleated cell bodies by cytoplasmic connections, that covers 
the entire worm40. Proteomic analysis of S. mansoni surface proteins showed the presence 
of enolase, an enzyme involved in energy metabolism, and structural molecules such as 
calcium ATPase which can inhibit platelet activation37,41. The leukocyte marker CD44, host 
complement proteins C3 and C4, and the membrane protease calpain have also been 
identified in S. mansoni surface proteins42.  
Proteins secreted by schistosomes are also essential for infection, e.g. by modulating host 
immune responses43. A number of endo- and exo-peptidases, trypsin-type serine 
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peptidase(s), and metallo-peptidases, have been revealed in the secretory proteins of S. 
mansoni44. These secretory proteins can stimulate the innate immune system and 
modulate various host immune responses which help the parasite evade immune defence 
mechanism when exposed to the host environment25. Knowledge of Schistosoma surface 
proteins and secreted peptides is therefore essential for improving our understanding of 
host-parasite interaction and for rational vaccine design.  
Existing approaches for the in silico prediction of surface and secretory proteins use 
hidden Markov models (HMMs), Bayesian networks, neural networks or position weight 
matrices (PSSMs)45-49. Two of the first and most widely used tools for the prediction of 
transmembrane proteins and signal peptides are TMHMM and SignalP, respectively. 
TMHMM employs a HMM to represent the different sequence regions of transmembrane 
helices47. SignalP relies on a combination of several artificial neural networks to predict the 
presence and location of signal peptide cleavage sites48. The recently developed 
combined classifier Phobius uses a HMM to model the sequence properties of both signal 
peptides and transmembrane proteins45. Philius predicts transmembrane topology and 
signal peptides using dynamic Bayesian networks46. PrediSi is based on position weight 
matrices to identify signal peptides and their cleavage positions and has been developed 
for the rapid analysis of whole-proteome datasets49. All of these approaches are general 
classifiers which perform well for a wide range of bacterial and eukaryotic species, but 
show a modest prediction accuracy for Schistosoma species27.  Liao et al. have recently 
demonstrated that a Schistosoma-specific classifier can significantly increase the 
prediction accuracy for identifying secreted proteins27. However, at present, no genus-
specific classifier is available for predicting Schistosoma secretory peptides and surface 
proteins, which would be invaluable for improving our knowledge of Schistosoma host-
parasite interactions, parasite pathogenesis and anti-schistosomiasis protective immunity. 
Such a tool will further assist researchers in discovering urgently needed anti-schistosomal 
vaccines. 
To address this need, the SchistoProt web server, a genus-specific, highly accurate 
machine learning classifier for identifying Schistosoma surface proteins and secretory 
peptides, have been developed. The server relies on 3 supervised machine learning 
techniques, evaluates a wide range of different sequence properties for classification, and 
is freely available at http://schistoprot.bioapps.org. 
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2.4 Methods  
2.4.1 Supervised machine learning classification  
Machine learning is learning is a field of computer science that provides systems 
(computers) the ability to automatically learn and improve from experience without being 
explicitly programmed. Supervised machine learning classification is the machine learning 
task of identifying to which of a set of classes a new observation belongs from labelled 
training data which consists of a set of training samples whose classes are known50.  
 
2.4.2 Training set 
To classify Schistosoma proteins into surface/non-surface and secreted/non-secreted 
classes SchistoProt uses 3 different supervised machine learning techniques. First, the 3 
classifiers had to be trained on a so called positive and negative training set to learn the 
specific properties of each class. The positive training set of tegument/surface proteins 
consisted of 414 sequences, which have been extracted from the published 
literature7,15,24,36,39,51,52 and from experimentally validated (not computationally predicted) 
protein sequences from the NCBI non-redundant protein database. For the negative 
training set (non-surface proteins), 435 nuclear, histone and mitochondrial related proteins 
were collected from the literature24,27 and from validated sequences from the NCBI non-
redundant protein database. As a positive training set for secreted proteins, a total of 375 
proteins were collected from the literature27,38,43,51 and from validated sequences from the 
NCBI non-redundant protein database. For the negative training set (non-secretory 
proteins) 746 nuclear and histone related proteins were collected from the literature24,27 
and from validated sequences from the NCBI non-redundant protein database. Only 
experimentally validated proteins were included in both datasets to obtain high-quality and 
reliable training sets. PISCES53 was applied to remove proteins with sequence identity 
over 20% to reduce biases towards overrepresented proteins. A total of 249 surface 
proteins, 277 non-surface proteins, 205 secreted proteins and 258 non-secreted proteins 
remained in the final training sets. Seven proteins were present in both the surface and 
secretory positive training datasets. 
 
2.4.3 Independent test set T400 
To evaluate the classification accuracy of SchistoProt, an independent test set (named 
T400) comprising 400 Schistosoma proteins has been compiled. 100 surface proteins, 100 
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secreted proteins, 100 non-surface and 100 non-secreted proteins from the NCBI non-
redundant proteins database were randomly selected. Using sequence similarity 
comparisons, it is ensured that none of the 400 selected proteins was present in the 
training sets.  
 
2.4.4 Features used for SchistoProt classification 
Initially, 481 features from each protein were extracted. Out of these 481 features, 81 
features represent sequence characteristics and structural and biochemical attributes (  
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Supplementary Table 2.1). The remaining 400 features are k-mers of 2 amino acid 
residues (2-mers) for 20 amino acids (Supplementary Table 2.2). 2-mers refer to all the 
possible subsequences of length 2 from a protein sequence. Features are extracted from 
each protein sequence using different available bioinformatics tools and newly developed 
Python scripts (Table 2.1). The features were approximately normally distributed which 
was tested based on the comparisons of mean and median values, and the shape of the 
data (Supplementary Table 2.3). The distribution of features between surface/non-surface 
proteins and between secreted/non-secreted peptides in the training set were compared 
by t-test. Only features that were significantly associated with one class (p<0.01, 
FDR<0.05) are used in SchistoProt (More Conservative mode) for the identification of 
surface proteins and secreted peptides, respectively.  
 
Table 2.1 Tools used to extract protein features. 
Tool Purpose URL 
Pepstats 
Calculation of statistics for proteins such as 
molecular weight, isoelectric point etc. 
http://www.ebi.ac.uk/Tools/seqstats/emboss_pepstats/ 
Protparam 
Computation of various physical and chemical 
parameters 
http://web.expasy.org/protparam/ 
Garnier Prediction of protein secondary structure 
http://emboss.sourceforge.net/apps/release/6.2/emboss/
apps/garnier.html 
NetCGlyc C-mannosylation sites http://www.cbs.dtu.dk/services/NetCGlyc/ 
NetChop Proteasomal cleavages (MHC ligands) http://www.cbs.dtu.dk/services/NetChop/ 
NetNGlyc N-linked glycosylation sites http://www.cbs.dtu.dk/services/NetNGlyc/ 
ANCHOR 
Prediction of Protein Binding Regions in 
Disordered Proteins 
http://anchor.enzim.hu/ 
ProP Arginine and lysine propeptide cleavage sites http://www.cbs.dtu.dk/services/ProP/ 
TargetP 
Prediction of the subcellular location of 
eukaryotic proteins 
http://www.cbs.dtu.dk/services/TargetP/ 
BepiPred 
Prediction of the location of linear B-cell 
epitopes 
http://www.cbs.dtu.dk/services/BepiPred/ 
Class I Immunogenecity Prediction of MHC Class I immunogenicity http://tools.iedb.org/immunogenicity/ 
2.4.5 Feature scaling  
The range of values of the different features included in SchistoProt varies widely. To 
ensure that each feature contributes approximately proportionately and, therefore, avoid 
biases introduced by features with greater numeric ranges54, all features are scaled into 
the range of 0 to 1.  
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2.4.6 Selection of best performing machine-learning technique 
Initially, 16 different machine learning techniques for all training sets were applied. 
Classifiers were run using the Scikit-learn (Version 0.18.1) library in Python55 with 
optimized parameters (Supplementary Text 2.1). The following classifiers were used: (i) 
Gradient Boosting Machine (GBM); (ii) Support Vector Machine (SVM) with radial basis 
function (RBF SVM) kernel with C=16, gamma=0.01; (iii) K-Neighbors; (iv) Decision tree 
with max_depth=13; (v) Random forest with max_depth=13, n_estimators=13 for surface 
classifier and max_depth=15, n_estimators=15 for secretory classifier, and 
max_features=481; (vi) Ada boost; (vii) Gaussian Naive Bayes (GNB); (viii) Linear 
Discriminant Analysis (LDA); (ix) Quadratic Discriminant Analysis (QDA); (x) Ridge 
regression; (xi) Stochastic gradient descent (SGD); (xii) Perceptron; (xiii) Passive 
aggressive; (xiv) Bernoulli Naive Bayes (BNB); (xv) Nearest Centroid; and (xvi) Multi-layer 
Perceptron (MLP).  
Each training sequence was represented by the corresponding feature vectors. The 16 
classifiers were then evaluated by stratified k-fold (10-fold) cross-validation. Using 
stratified k-fold cross-validation, the folds were selected such that the mean response 
value was approximately equal in all folds56.  In 10-fold cross-validation, 90% of the data 
were used for training and the remaining 10% for testing. The cross-validation process 
was repeated 10 times and the average predication accuracy calculated. 
SchistoProt relies on the 3 supervised machine learning techniques which achieved the 
highest prediction accuracies in the 10-fold cross-validation. Gradient Boosting Machine 
(GBM), Random Forest and Bernoulli Naive Bayes (BNB) classifiers were selected for the 
classification of surface proteins. GBM, Ada Boost and BNB were selected for the 
classification of secretory proteins. The 3 machine-learning techniques are combined into 
a single classifier using a majority rule. A protein is assigned to positive class if it is 
predicted by at least 2 of the 3 classifiers as positive, otherwise, SchistoProt assigns the 
protein as negative class i.e., only one or no classifiers predict the protein as positive. 
 
2.4.7 Performance evaluation 
The classification accuracy of SchistoProt was evaluated by sensitivity, specificity and 
overall accuracy57. These measures are defined as: sensitivity = TP/(TP+FN), specificity = 
TN/(TN+FP), overall accuracy = (TP + TN) / (TP + TN + FP + FN), where TP (True 
Positive) and TN (True Negative) are the number of correctly predicted positive and 
negative proteins, respectively, and FP (False Positive) and FN (False Negative) are the 
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number of incorrectly predicted positive and negative proteins, respectively. Additionally, 
the discriminatory power of classifiers was evaluated by the Area Under the Receiver 
Operating Characteristic (ROC) curve (AUC). 
 
2.5 Results 
2.5.1 SchistoProt overview 
SchistoProt uses 3 supervised machine-learning classifiers to discriminate between 
surface and non-surface proteins and between secreted and non-secreted peptides. 
Generated predictions are stored in a database which facilitates rapid reuse of results 
without rerunning the time-consuming classifiers. This saves considerable runtime if the 
same sequences are uploaded multiple times, e.g. by different users.  
SchistoProt takes FASTA formatted sequence files or pasted protein sequences as input. 
If the proteins are already present in the database, the pre-computed results are returned. 
Otherwise SchistoProt extracts corresponding features from each query sequence using 
several available bioinformatics tools and newly developed Python scripts (Table 2.1). 
Features include sequence characteristics, biochemical attributes and structural properties 
(Supplementary Table 2.1). These features are scaled and used to discriminate between 
surface and non-surface proteins and between secreted and non-secreted peptides.  
SchistoProt combines 3 supervised machine learning techniques and classifies proteins 
based on a majority rule. The results of the classification are returned to the user and 
stored in the database for future reuse (Figure 2.1). Results are presented as interactive 
tables, charts and figures. 
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Figure 2.1 SchistoProt workflow. 
Query sequences submitted by a user are compared to a database of pre-computed results. If a 
query sequence is present in the database, SchistoProt reports the pre-computed predictions; 
otherwise, a machine-learning classification is performed and the results are stored in the 
database for future reuse. Results are presented online as interactive tables, charts and figures.  
 
2.5.2 Features significantly associated with surface proteins and secreted peptides 
Associations between 81 biochemical and structural sequence features and surface 
proteins and secreted peptides have been examined using a t-test. Fifty-four features were 
significantly differentially distributed between surface and non-surface proteins (p<0.01, 
FDR<0.05) (Figure 2.2; Table 2.2). Surface proteins showed a higher frequency of lysine, 
isoleucines, secondary pathway signal peptides, and secondary helices. Surface proteins 
were also found to be more stable, aromatic and Class I immunogenic than non-surface 
proteins. Arginine and proline were underrepresented in surface proteins. 
Fifty-seven features showed differential distribution between secretory and non-secretory 
proteins (p<0.01, FDR<0.05) (Figure 2.3; Table 2.3). Secretory proteins showed a higher 
frequency of grand average of hydropathy (GRAVY), non-polar moles, lysine and the 
hydrophobic amino acids glycine, valine, isoleucine, phenylalanine, methionine, and 
tryptophan. Secretory proteins were also more stable than non-secretory proteins. 
Secondary turns, polar moles and serines were higher in non-secretory proteins. 
129 of 2-mers were significantly differentially distributed between surface and non-surface 
proteins (p<0.01, FDR<0.05) (Supplementary Table 2.4). 122 of 2-mers were significantly 
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differentially distributed between secretory and non-secretory proteins (p<0.01, FDR<0.05) 
(Supplementary Table 2.5). 
 
 
Figure 2.2 Features associated with surface proteins. 
Means in the surface positive and surface negative training sets were compared by t-test. Shown 
are all features with p<0.01. (A) Heatmap of features significantly differentially distributed between 
surface and non-surface proteins. Columns represent each protein of the training set, rows 
represent features. (B) Quantiles distribution of significantly different features for surface and non-
surface proteins. Values are depicted in color code, ranging from green (low) to red (high).  
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Figure 2.3 Features associated with secreted peptides. 
Means in the secretory positive and secretory negative training sets were compared by t-test. 
Shown are all features with p<0.01. (A) Heatmap of features significantly differentially distributed 
between secreted and non-secreted peptides. Columns represent each protein of the training set, 
rows represent features. (B) Quantiles distribution of significantly different features for secreted 
and non-secreted peptides. Values are depicted in color code, ranging from green (low) to red 
(high).  
 
Table 2.2 Features differentially distributed between surface and non-surface proteins. 
Means between positive and negative training sets were compared by t-test. Shown are all 
features with p<0.01. P-values were corrected for multiple testing using Bonferroni correction and 
False Discovery Rate (FDR). 
Features 
Mean 
surface 
proteins 
Mean non-
surface 
proteins 
P-value 
Bonferroni 
corrected 
P-value 
FDR 
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Dayhoff statistic of serine 0.9535 1.4182 6.76E-44 5.48E-42 2.77E-42 
Percentage of serine 6.6747 9.9273 6.85E-44 5.55E-42 2.77E-42 
Secondary turn fraction 0.2081 0.2614 1.69E-42 1.37E-40 4.57E-41 
Instability Index 35.4030 47.1189 1.40E-33 1.13E-31 2.84E-32 
Proteasomal cleavages (MHC 
ligands) 82.6185 167.0181 5.58E-30 4.52E-28 9.03E-29 
Molecular Weight 
29115.753
5 57811.0814 5.66E-29 4.59E-27 7.65E-28 
Count of linear B-cell epitopes 76.3253 187.0397 8.47E-28 6.86E-26 9.80E-27 
Dayhoff statistic of proline 0.6589 0.9940 3.59E-23 2.91E-21 3.63E-22 
Percentage of proline 3.4262 5.1686 2.00E-19 1.62E-17 1.80E-18 
Probability of Expression 
Inclusion Bodies 0.6906 0.7873 5.49E-17 4.45E-15 4.45E-16 
N-linked glycosylation sites 1.1566 3.5957 3.29E-16 2.67E-14 2.42E-15 
Secretory pathway signal peptide 
(SP) 0.3167 0.1128 5.06E-16 4.10E-14 3.42E-15 
Dayhoff statistic of lysine 1.1220 0.8335 1.14E-14 9.23E-13 7.10E-14 
Molar Extinction Coefficient A280 
29577.269
1 57284.1516 1.24E-14 1.00E-12 7.17E-14 
Percentage of lysine 7.4053 5.5013 1.77E-13 1.43E-11 9.54E-13 
Mitochondrial targeting peptide 
(mTP) 0.1514 0.2827 3.26E-13 2.64E-11 1.65E-12 
Binding Regions in Disordered 
Proteins 0.6426 3.0361 7.32E-13 5.93E-11 3.49E-12 
Dayhoff statistic of asparagine 1.0742 1.3795 1.14E-12 9.19E-11 5.11E-12 
Arginine and lysine propeptide 
cleavage sites 0.0683 0.4188 1.27E-11 1.03E-09 5.43E-11 
Percentage of polar mole 46.2646 50.2015 2.59E-11 2.10E-09 1.05E-10 
Dayhoff statistic of histidine 1.0947 1.4063 2.77E-11 2.24E-09 1.07E-10 
Percentage of non polar mole 53.7354 49.7985 3.06E-11 2.48E-09 1.13E-10 
Average hydrogen sparing 9.9920 9.8428 1.12E-10 9.09E-09 3.79E-10 
Percentage of histidine 2.1894 2.8127 1.12E-10 9.10E-09 3.79E-10 
Percentage of asparagine 4.6189 5.9321 1.52E-10 1.23E-08 4.84E-10 
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Dayhoff statistic of methionine 1.5714 1.1603 1.55E-10 1.26E-08 4.84E-10 
Percentage of secondary helix 41.9157 30.2960 2.22E-10 1.80E-08 6.67E-10 
Percentage of small mole 47.3355 50.2022 2.45E-10 1.98E-08 7.08E-10 
Percentage of methionine 2.6714 1.9725 1.04E-09 8.40E-08 2.90E-09 
Average oxygen sparing 2.4703 2.5076 1.17E-08 9.48E-07 3.16E-08 
Average nitrogen sparing 1.3538 1.3879 2.96E-08 2.39E-06 7.73E-08 
Percentage of arginine 4.7430 5.5201 9.81E-08 7.95E-06 2.42E-07 
Dayhoff statistic of arginine 0.9680 1.1265 9.85E-08 7.98E-06 2.42E-07 
Average sulphur sparing 0.0500 0.0405 1.06E-07 8.62E-06 2.54E-07 
Percentage of isoleucine 7.2918 5.9486 2.28E-07 1.85E-05 5.17E-07 
Dayhoff statistic of isoleucine 1.6204 1.3219 2.30E-07 1.86E-05 5.17E-07 
Secondary helix fraction 0.3279 0.3015 6.44E-07 5.22E-05 1.41E-06 
Percentage of aliphatic mole 23.5608 21.5818 3.17E-06 0.0003 6.76E-06 
Secondary sheet fraction 0.2465 0.2278 4.79E-06 0.0004 9.95E-06 
Dayhoff statistic of valine 1.0390 0.8925 5.81E-06 0.0005 1.15E-05 
Percentage of valine 6.8571 5.8904 5.83E-06 0.0005 1.15E-05 
Grand average of hydropathy 
(GRAVY) -0.1669 -0.3786 2.46E-05 0.0020 4.75E-05 
Percentage of alanine 6.4305 5.3151 0.0001 0.0087 0.0002 
Dayhoff statistic of alanine 0.7477 0.6180 0.0001 0.0088 0.0002 
Percentage of glycine 6.0926 5.1145 0.0004 0.0302 0.0007 
Dayhoff statistic of glycine 0.7253 0.6089 0.0004 0.0304 0.0007 
Average carbon sparing 5.0559 4.9950 0.0006 0.0499 0.0011 
Class I Immunogenicity score 0.1592 -2.6561 0.0007 0.0530 0.0011 
C-mannosylation sites 0.0281 0.1047 0.0010 0.0840 0.0017 
Dayhoff statistic of glutamine 0.9200 1.0214 0.0022 0.1771 0.0035 
Percentage of tryptophan 1.1583 1.1895 0.0034 0.2773 0.0054 
Percentage of glutamine 3.5879 3.9833 0.0038 0.3038 0.0058 
Other subcellular location 0.5970 0.6544 0.0048 0.3925 0.0074 
Dayhoff statistic of tryptophan 0.8910 0.9150 0.0049 0.4001 0.0074 
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Table 2.3 Features differentially distributed between secretory and non-secretory proteins. 
Means between positive and negative training sets were compared by t-test and p-values were 
adjusted for multiple testing using Bonferroni correction and False Discovery Rate (FDR). 
Features 
Mean 
secretory 
proteins 
Mean non-
secretory 
proteins 
P-value 
Bonferroni 
corrected 
P-value 
FDR  
Dayhoff statistic of serine 0.9223 1.5033 1.24E-37 1.00E-35 1.00E-35 
Percentage of serine 6.4565 10.5232 5.45E-31 4.41E-29 2.21E-29 
Binding Regions in Disordered 
Proteins 0.6829 6.7519 8.56E-31 6.93E-29 2.31E-29 
Instability Index 37.3205 49.4272 3.61E-30 2.92E-28 7.31E-29 
Secretory pathway signal peptide 
(SP) 0.4327 0.0876 9.31E-30 7.54E-28 1.51E-28 
Percentage of non polar mole 52.4495 46.9683 6.92E-26 5.61E-24 9.35E-25 
Other subcellular location 0.4646 0.7877 1.30E-24 1.05E-22 1.50E-23 
Secondary helix fraction 0.3092 0.2698 4.20E-24 3.40E-22 4.25E-23 
Percentage of polar mole 47.5505 53.0317 8.95E-24 7.25E-22 8.06E-23 
Secondary turn fraction 0.2240 0.2662 1.13E-21 9.12E-20 9.12E-21 
Aromaticity 0.0953 0.0718 7.79E-19 6.31E-17 5.74E-18 
Count of linear B-cell epitopes 105.2098 285.0078 5.03E-17 4.07E-15 3.39E-16 
Average carbon sparing 5.0469 4.8997 1.55E-16 1.25E-14 9.65E-16 
Arginine and lysine propeptide 
cleavage sites 0.0976 0.6822 8.64E-14 7.00E-12 5.00E-13 
Dayhoff statistic of arginine 0.9398 1.2147 3.20E-13 2.59E-11 1.64E-12 
Percentage of arginine 4.6052 5.9521 3.24E-13 2.62E-11 1.64E-12 
Percentage of aromatic mole 12.0057 9.9595 6.48E-13 5.25E-11 3.09E-12 
Grand average of hydropathy 
(GRAVY) -0.3258 -0.5314 6.24E-12 5.06E-10 2.81E-11 
Percentage of small mole 48.4774 51.8143 2.22E-11 1.80E-09 9.47E-11 
Average oxygen sparing 2.4879 2.5318 8.16E-11 6.61E-09 3.30E-10 
Absorbance A280 1.1818 0.8254 1.84E-10 1.49E-08 7.08E-10 
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Proteasomal cleavages (MHC 
ligands) 102.4829 196.5853 1.23E-09 9.97E-08 4.53E-09 
Dayhoff statistic of phenylalanine 1.1884 0.9220 1.86E-09 1.51E-07 6.57E-09 
Probability of Expression 
Inclusion Bodies 0.7104 0.7896 1.96E-09 1.59E-07 6.62E-09 
Percentage of phenylalanine 4.2782 3.3190 4.52E-09 3.66E-07 1.46E-08 
Molecular Weight 
36616.529
5 70164.3000 1.21E-08 9.80E-07 3.77E-08 
Mitochondrial targeting peptide 
(mTP) 0.1489 0.1938 1.29E-08 1.05E-06 3.88E-08 
Average sulphur sparing 0.0549 0.0427 1.74E-08 1.41E-06 5.03E-08 
Percentage of proline 4.1500 5.1613 2.17E-08 1.76E-06 5.89E-08 
Dayhoff statistic of proline 0.7981 0.9925 2.18E-08 1.77E-06 5.89E-08 
Average hydrogen sparing 9.8966 9.7668 3.51E-08 2.84E-06 9.16E-08 
Average nitrogen sparing 1.3686 1.4017 7.82E-08 6.33E-06 1.98E-07 
Percentage of lysine 7.2160 6.0889 8.52E-08 6.90E-06 2.03E-07 
Dayhoff statistic of lysine 1.0933 0.9226 8.52E-08 6.90E-06 2.03E-07 
Percentage of isoleucine 6.2476 5.4087 1.01E-07 8.17E-06 2.28E-07 
Dayhoff statistic of isoleucine 1.3883 1.2019 1.01E-07 8.20E-06 2.28E-07 
Dayhoff statistic of tryptophan 1.0873 0.6816 1.04E-07 8.45E-06 2.28E-07 
Percentage of tryptophan 1.4135 0.8861 2.03E-07 1.65E-05 4.34E-07 
Percentage of glycine 6.1741 5.0614 5.31E-07 4.30E-05 1.08E-06 
Dayhoff statistic of glycine 0.7350 0.6026 5.33E-07 4.31E-05 1.08E-06 
Percentage of aliphatic mole 21.3916 19.8003 8.75E-07 7.09E-05 1.73E-06 
Percentage of tiny mole 27.0767 29.3396 1.00E-06 8.11E-05 1.93E-06 
Class I Immunogenicity score -0.2818 -5.8851 8.77E-06 
0.0007101
5 1.65E-05 
Dayhoff statistic of tyrosine 1.1290 0.8749 9.47E-06 
0.0007672
3 1.74E-05 
Percentage of secondary helix 37.4439 31.8217 1.42E-05 
0.0011477
8 2.55E-05 
Dayhoff statistic of methionine 1.4054 1.1315 6.38E-05 0.0051643 0.0001 
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Percentage of tyrosine 3.8388 2.9748 7.93E-05 
0.0064232
2 0.0001 
Average Residue Weight 113.3850 112.2477 9.44E-05 
0.0076490
6 0.0002 
Percentage of methionine 2.3891 1.9236 0.0001 
0.0115401
4 0.0002 
Percentage of valine 6.3702 5.6791 0.0003 
0.0229345
6 0.0004 
Dayhoff statistic of valine 0.9652 0.8605 0.0003 
0.0229452
4 0.0004 
N-linked glycosylation sites 1.8878 4.5969 0.0006 
0.0518811
8 0.0010 
C-mannosylation sites 0.0244 0.0930 0.0018 
0.1477108
7 0.0028 
Percentage of cysteine 3.0994 2.3482 0.0024 0.1953022 0.0036 
Dayhoff statistic of cysteine 1.0687 0.8097 0.0029 
0.2386676
5 0.0043 
Dayhoff statistic of aspartic acid 0.9571 1.0481 0.0073 0.5944364 0.0105 
Percentage of aspartic acid 5.2637 5.7646 0.0074 
0.5966487
1 0.0105 
 
 
2.5.3 Performance evaluation of 16 machine-learning techniques 
The classification accuracy of 16-different supervised machine learning techniques has 
been evaluated. Classification performance was assessed on a training set of known 
Schistosoma surface proteins and secreted peptides using stratified k-fold (10-fold) cross-
validation (Supplementary Table 2.6;  
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Supplementary Table 2.7). The 3 top performing methods achieved individual classification 
accuracies in the range of 0.65 - 0.78 for surface proteins and 0.71 - 0.80 for secreted 
peptides (Figure 2.4; Table 2.4).  The combination of these 3 techniques achieved a 
superior accuracy of 87 for surface/non-surface and 94 for secretory/non-secretory 
classifiers (Figure 2.4; Table 2.4) and is used in the SchistoProt webserver.  
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Figure 2.4 Comparison of different supervised machine learning techniques for the 
identification of Schistosoma surface proteins and secreted peptides. 
(A) Prediction accuracy for surface proteins. (B) Prediction accuracy for secreted peptides. 
Classifiers were trained on the training set of known Schistosoma surface proteins and secreted 
peptides and evaluated by stratified k-fold (10-fold) cross-validation. 
 
Table 2.4 Comparison of prediction accuracy of 16 supervised machine learning 
techniques. 
Classifiers were evaluated on the training set of known surface (n=249), non-surface (n=277) and 
known secreted (n=205), non-secreted (n=258) proteins by stratified k-fold (10-fold) cross-
validation. Additionally, the classification accuracy of the SchistoProt classifier was evaluated, 
which is based on the combination of the high performing 3 machine learning techniques. AUC: 
Area Under the Roc Curve. 
Machine Learning Technique 
Surface 
Classification 
Overall Accuracy 
Surface 
Classification 
AUC 
Secretory 
Classification 
Overall Accuracy 
Secretory 
Classification 
AUC 
Gradient Boosting Machine (GBM) 0.6581 0.6474 0.8015 0.8027 
RBF SVM 0.5266 0.5000 0.5573 0.5000 
k-Nearest Neighbors 0.4734 0.5000 0.5118 0.5000 
Decision Tree 0.6366 0.6330 0.5077 0.4923 
Random Forest 0.6670 0.6583 0.5460 0.5176 
Ada Boost 0.5889 0.6082 0.7107 0.7301 
Gaussian Naive Bayes (GNB) 0.4734 0.5000 0.4534 0.5000 
Linear Discriminant Analysis (LDA) 0.4791 0.5000 0.4449 0.5005 
Quadratic Discriminant Analysis (QDA) 0.4791 0.5000 0.5573 0.5000 
Ridge Regression 0.5266 0.5000 0.4427 0.5000 
Stochastic Gradient Descent (SGD) 0.4848 0.5108 0.4427 0.5000 
Perceptron 0.4753 0.5018 0.4671 0.5219 
Passive Aggressive  0.4753 0.5018 0.5967 0.6299 
Bernoulli Naive Bayes (BNB) 0.7809 0.7837 0.7128 0.7173 
Nearest Centroid 0.4734 0.5000 0.4427 0.5000 
Multi-layer Perceptron (MLP) 0.4809 0.5011 0.4844 0.5106 
Combined 3 techniques (SchistoProt) 0.8715 0.8647 0.9425 0.9721 
 
2.5.4 Prediction accuracy of SchistoProt evaluated on independent test set 
The performance of SchistoProt was first evaluated on the training set by stratified 10-fold 
cross-validation (Figure 2.4; Table 4). The final classifier (trained on the entire training set) 
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was then evaluated on an independent test set of 400 Schistosoma proteins (T400). The 
classification accuracy for surface proteins was compared with Phobius45 and TMHMM47, 
two general hidden Markov model based tools for the identification of surface proteins. 
Classification accuracy for secretory peptides was compared with SignalP48, Phobius45 
and PrediSi49. For surface proteins, SchistoProt achieved a sensitivity, specificity and 
overall accuracy of 0.85, 0.81 and 0.83, respectively (Table 2.5). For secretory proteins 
sensitivity, specificity and overall accuracy were 0.92, 0.93 and 0.93, respectively (Table 
2.5). SchistoProt showed a significantly higher prediction accuracy compared to the 
existing tools Phobius, TMHMM, PrediSi and SignalP. 
 
Table 2.5 Performance comparison with existing prediction tools. 
Prediction accuracy of existing tools and SchistoProt was evaluated on the training set of 249 
surface proteins, 277 non-surface proteins, 205 secreted and 258 non-secreted peptides. 
Additionally, the classification accuracy was evaluated on the independent test set of 100 surface 
proteins, 100 non-surface proteins, 100 secreted and 100 non-secreted peptides (T400). 
Surface Proteins 
Tool Dataset True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
Sensitivity Specificity Overall 
Accuracy 
Phobius Training set 75 236 41 174 0.30 0.85 0.59 
Test set  27 82 18 73 0.27 0.82 0.55 
Philius Training set 67 236 41 182 0.27 0.85 0.58 
Test set  23 85 15 77 0.23 0.85 0.54 
TMHMM Training set 72 244 33 177 0.29 0.88 0.60 
Test set  24 86 14 76 0.24 0.86 0.51 
SchistoProt Training set 249 277 0 0 1 1 1 
Test set  85 81 19 15 0.85 0.81 0.83 
Secreted Peptides 
Tool Dataset True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
Sensitivity Specificity Overall 
Accuracy 
Phobius Training set 66 255 3 139 0.32 0.99 0.69 
Test set  24 99 1 76 0.24 0.99 0.62 
SignalP Training set 61 256 2 144 0.30 0.99 0.68 
Test set 19 99 1 81 0.19 0.99 0.59 
PrediSi Training set 60 255 3 145 0.29 0.99 0.68 
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Test set  24 100 0 76 0.24 1 0.62 
SchistoProt Training set 205 258 0 0 1 1 1 
Test set  92 93 7 8 0.92 0.93 0.93 
 
2.5.5 User-interface 
SchistoProt provides an easy-to-use graphical user interface (GUI), an extensive help 
page and user forum page. As input, multiple protein sequences can be uploaded or 
pasted in fasta format. By default, SchistoProt includes 183 selected features (54 of 
biochemical and structural features and 129 of 2-mers) for surface proteins prediction and 
179 selected features (57 of biochemical and structural features and 122 of 2-mers) for 
secretory peptides prediction (More Conservative mode).  However, optional all available 
481 features can be used (Less Conservative mode). An interactive results page is 
generated. A table lists the sequence ID of each query sequence, the prediction 
(surface/non-surface or secreted/non-secreted) and classification score (number of 
positive classifiers). A second table lists the individual predictions obtained for each of the 
3 classifiers. Additionally, the decision score and probability are shown. The distribution of 
sequence features in each query protein are presented in a table and in interactive charts 
and plots (strip chart, heatmap and bar chart) (Figure 2.5 and Figure 2.6). 
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Figure 2.5 SchistoProt graphical user interface (GUI). 
(A) Input forms for upload query protein sequences; (B) SchistoProt predictions are presented as 
table with protein ID, prediction class and score. Additionally, the decision score and probability are 
presented (not shown in screenshot). (C) Individual predictions obtained for each of the 3 used 
machine-learning techniques. Shown are the ID of each query sequence, prediction class, decision 
score and probability; (D) Feature table presenting the frequencies of the features in each query 
protein.  
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Figure 2.6 Graphical presentation of SchistoProt predictions. 
SchistoProt presents results as (A) Strip Chart and (B) Stacked Bar. For each feature and each 
selected query protein the figures show the mean frequency of the feature in the positive and 
negative training sets and the frequency of the feature in the selected protein.  
 
2.5.6 Architecture and run-time performance 
The SchistoProt server is developed in Python using the Django web framework (Figure 
2.7). The server can handle whole-proteome datasets and there is no limit for the number 
of uploaded query sequences. The server performs background task processing and can 
process multiple user sessions in parallel. After data submission a link is provided, which 
gives access to the predictions if the users browser window has been closed.  
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Figure 2.7 ShistoProt web server architecture. 
SchistoProt has been designed following a 3 tiers framework: i) The client interface, ii) The web 
server and iii) Data storage and background processing. The client interface has been realized 
using HTML web-pages, cascading style sheets (CSS) and JavaScript. The web server relies on 
the Django Python web framework and the NginX high-performance HTTP-server. Gunicorn and 
Supervisor are used for managing and running multiple workers. Background processing has been 
realized via Celery and Redis. Data is persistently stored in a SQLite database.  
 
Computed results are stored in a SQLite database for later re-use. This saves 
considerable runtime if the same sequences are uploaded multiple times, e.g. by different 
users. SchistoProt requires 227.84 seconds for processing 100 query sequences if the 
sequences are not found in the database, whereas it takes only 1.16 seconds if all 100 
sequences are present in the database.  
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2.6 Conclusion 
SchistoProt is an easy-to-use, accurate and fast classifier for the in silico identification of 
Schistosoma surface proteins and secreted peptides. The software has been optimized for 
large datasets and allows rapid whole-proteome analysis. The obtained results 
demonstrate that a genus-specific classifier is superior to general tools for the in silico 
prediction of Schistosoma surface proteins. Furthermore, as others have also found27, a 
genus-specific classifier is also superior for the identification of secreted proteins. 
SchistoProt assists researchers in identifying genes important for host-parasite interaction, 
studying anti-schistosome protective immunity, and identifying candidate vaccine targets. It 
therefore represents a valuable tool for improving our understanding of Schistosoma 
pathogenicity and host-parasite interaction, and for informing the rational design of much-
needed Schistosoma vaccines.  
 
Supporting information 
Supplementary Text 2.1 16 different supervised machine learning classifiers and 
their parameter settings used to select optimum classifiers in SchistoProt. 
Classifiers are run using the Scikit-learn (Version 0.18.1) library in Python with default parameters. 
 
Gradient Boosting Machine (GBM). Gradient Boosting Method (GBM) is an additive 
model in a forward stage-wise fashion; it allows for the optimization of arbitrary 
differentiable loss functions.an additive model in a forward stage-wise fashion; it allows for 
the optimization of arbitrary differentiable loss functions. The parameters settings were 
loss='deviance', learning_rate=0.1, n_estimators=100, subsample=1.0, 
criterion='friedman_mse', min_samples_split=2, min_samples_leaf=1, 
min_weight_fraction_leaf=0.0, max_depth=3, min_impurity_split=1e-07, init=None, 
random_state=None, max_features=None, verbose=0, max_leaf_nodes=None, 
warm_start=False, presort='auto'. 
 
RBF SVM. Support Vector Machine (SVM) is a classifier which learns by finding the 
separating hyperplane that maximizes the margin between two classes of a training set. 
RBF SVM is Support Vector Machine with radial bias function (RBF) kernel. The 
parameters settings were C=12, cache_size=200, class_weight=None, coef0=0.0, 
decision_function_shape=None, degree=3, gamma=2, kernel='rbf', max_iter=-1, 
probability=False, random_state=None, shrinking=True, tol=0.001 and verbose=False. 
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k-Nearest Neighbors. The principle behind k-nearest neighbor methods is to find a 
predefined number of training samples closest in distance to the new point, and predict the 
label from these. The parameters settings were algorithm='auto', leaf_size=30, 
metric='minkowski', metric_params=None, n_jobs=1, n_neighbors=12, p=2 and 
weights='uniform'. 
 
Decision Tree. Decision Trees are a non-parametric supervised learning method used for 
classification. The goal is to create a model that predicts the value of a target variable by 
learning simple decision rules inferred from the data features. The parameters settings 
were class_weight=None, criterion='gini', max_depth=12, max_features=None, 
max_leaf_nodes=None, min_samples_leaf=1, min_samples_split=2, 
min_weight_fraction_leaf=0.0, presort=False, random_state=None and splitter='best'. 
 
Random Forest. A random forest is a meta estimator that fits a number of decision tree 
classifiers on various sub-samples of the dataset and use averaging to improve the 
predictive accuracy and control over-fitting. The parameters settings were bootstrap=True, 
class_weight=None, criterion='gini', max_depth=12, max_features=80, 
max_leaf_nodes=None, min_samples_leaf=1, min_samples_split=2, 
min_weight_fraction_leaf=0.0, n_estimators=12, n_jobs=1, oob_score=False, 
random_state=None, verbose=0 and warm_start=False. 
 
Ada Boost. An Ada Boost classifier is a meta-estimator that begins by fitting a classifier 
on the original dataset and then fits additional copies of the classifier on the same dataset 
but where the weights of incorrectly classified instances are adjusted such that subsequent 
classifiers focus more on difficult cases. The parameters settings were 
algorithm='SAMME.R', base_estimator=None, learning_rate=1.0, n_estimators=50 and 
random_state=None. 
 
Naive Bayes. Naive Bayes methods are a set of supervised learning algorithms based on 
applying Bayes’ theorem with the “naive” assumption of independence between every pair 
of features. The parameters settings were the default parameters of GaussianNB() in 
Scikit-learn. 
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Linear Discriminant Analysis (LDA). Linear Discriminant Analysis (LDA) tries to identify 
attributes that account for the most variance between classes by a linear surface. The 
parameters settings were n_components=None, priors=None, shrinkage=None, 
solver='svd', store_covariance=False and tol=0.0001. 
 
Quadratic Discriminant Analysis (QDA). Quadratic Discriminant Analysis (QDA) is used 
in machine learning classification to separate measurements of two or more classes of 
objects or events by a quadric surface. The parameters settings were priors=None, 
reg_param=0.0, store_covariances=False and tol=0.0001. 
 
Ridge Regression. Ridge Regression is a technique for analyzing multiple regression 
data that suffer from multicollinearity. The parameters settings were alpha=1.0, 
class_weight=None, copy_X=True, fit_intercept=True, max_iter=None, normalize=False, 
random_state=None, solver='auto' and tol=0.001. 
 
Stochastic Gradient Descent (SGD). Stochastic Gradient Descent (SGD) is a simple yet 
very efficient approach to discriminative learning of linear classifiers under convex loss 
functions such as (linear) Support Vector Machines and Logistic Regression. The 
parameters settings were alpha=0.0001, average=False, class_weight=None, epsilon=0.1, 
eta0=0.0, fit_intercept=True, l1_ratio=0.15, learning_rate='optimal', loss='hinge', n_iter=5, 
n_jobs=1, penalty='l2', power_t=0.5, random_state=None, shuffle=True, verbose=0 and 
warm_start=False. 
 
Perceptron. Perceptron is a type of linear classifier that makes its predictions based on a 
linear predictor function combining a set of weights with the feature vector. It does not 
require a learning rate and it is not regularized (penalized). The parameters settings were 
alpha=0.0001, class_weight=None, eta0=1.0, fit_intercept=True, n_iter=5, n_jobs=1, 
penalty=None, random_state=0, shuffle=True, verbose=0 and warm_start=False. 
 
Passive Aggressive. The passive aggressive algorithms are a family of algorithms for 
large-scale learning. They are similar to the Perceptron in that they do not require a 
learning rate. However, contrary to the Perceptron, they include a regularization parameter 
C. The parameters settings were C=1.0, class_weight=None, fit_intercept=True, 
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loss='hinge', n_iter=5, n_jobs=1, random_state=None, shuffle=True, verbose=0 and 
warm_start=False. 
 
Bernoulli Naive Bayes. Naive Bayes methods are a set of supervised learning algorithms 
based on applying Bayes’ theorem with the “naive” assumption of independence between 
every pair of features. Bernoulli Naive Bayes implements the naive Bayes training and 
classification algorithms for data that is distributed according to multivariate Bernoulli 
distributions; i.e., there may be multiple features but each one is assumed to be a binary-
valued (Bernoulli, boolean) variable. Therefore, this class requires samples to be 
represented as binary-valued feature vectors; if handed any other kind of data, a Bernoulli 
Naive Bayes instance may binarize its input (depending on the binarize parameter). The 
parameters settings were alpha=1.0, binarize=0.0, class_prior=None and fit_prior=True. 
 
Nearest Centroid. Nearest Centroid classifier is a classification model that assigns to 
observations the label of the class of training samples whose mean (centroid) is closest to 
the observation. The parameters settings were metric='euclidean' and 
shrink_threshold=None. 
 
Multi-layer Perceptron (MLP). A multilayer perceptron (MLP) is a network of simple 
neurons called perceptrons. The perceptron computes a single output from multiple real-
valued inputs by forming a linear combination according to its input weights and then 
possibly putting the output through some nonlinear activation function. The parameters 
settings were hidden_layer_sizes=(100, ), activation='relu', solver='adam', alpha=0.0001, 
batch_size='auto', learning_rate='constant', learning_rate_init=0.001, power_t=0.5, 
max_iter=200, shuffle=True, random_state=None, tol=0.0001, verbose=False, 
warm_start=False, momentum=0.9, nesterovs_momentum=True, early_stopping=False, 
validation_fraction=0.1, beta_1=0.9, beta_2=0.999, epsilon=1e-08. 
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Supplementary Table 2.1 List of 81 features used in SchistoProt for protein classification. 
SchistoProt uses 481 features for protein classification. 
Of these 481 features, 81 features represent biochemical and structural properties (shown in this 
table). The remaining 400 features represent 2-mers of the 20 amino acids (Supplementary 
Table 2.2). 
Percentage of alanine Secondary sheet fraction DayhoffStat of threonine 
Percentage of cysteine Average Residue Weight DayhoffStat of valine 
Percentage of aspartic acid Average carbon sparing DayhoffStat of tryptophan 
Percentage of glutamic acid Average nitrogen sparing DayhoffStat of tyrosine 
Percentage of phenylalanine Average sulphur sparing Percentage of tiny mole 
Percentage of glycine Average oxygen sparing Percentage of small mole 
Percentage of histidine Average hydrogen sparing Percentage of aliphatic mole 
Percentage of isoleucine Charge Percentage of aromatic mole  
Percentage of lysine 
Molar Extinction Coefficient 
A280 Percentage of polar mole 
Percentage of leucine Absobance A280 Percentage of non polar mole 
Percentage of methionine 
Probability of Expression 
Inclusion Bodies Percentage of charged mole 
Percentage of asparagine DayhoffStat of alanine Percentage of acidic mole 
Percentage of proline DayhoffStat of cysteine Percentage of basic mole 
Percentage of glutamine DayhoffStat of aspartic acid Percentage of secondary helix 
Percentage of arginine DayhoffStat of glutamic acid Percentage of secondary sheet 
Percentage of serine DayhoffStat of phenylalanine Percentage of secondary turns 
Percentage of threonine DayhoffStat of glycine Percentage of secondary coil 
Percentage of valine DayhoffStat of histidine C-mannosylation sites 
Percentage of tryptophan DayhoffStat of isoleucine 
Proteasomal cleavages (MHC 
ligands) 
Percentage of tyrosine DayhoffStat of lysine N-linked glycosylation sites 
Molecular Weight DayhoffStat of leucine 
Arginine and lysine propeptide 
cleavage sites 
Aromaticity DayhoffStat of methionine 
Binding Regions in Disordered 
Proteins 
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Instability Index DayhoffStat of asparagine 
Mitochondrial targeting peptide 
(mTP) 
Isoelectric Point DayhoffStat of proline 
Secretory pathway signal 
peptide (SP) 
Grand average of hydropathy 
(GRAVY) DayhoffStat of glutamine Other subcellular location 
Secondary helix fraction DayhoffStat of arginine Linear B-cell epitopes 
Secondary turn fraction DayhoffStat of serine Class I Immunogenicity Score 
 
 
Supplementary Table 2.2 List of 400 2-mers used in SchistoProt for protein classification. 
SchistoProt uses 400 2-mers of the 20 amino acids for protein classification. 
AA DA FA HA KA MA PA RA TA WA 
AC DC FC HC KC MC PC RC TC WC 
AD DD FD HD KD MD PD RD TD WD 
AE DE FE HE KE ME PE RE TE WE 
AF DF FF HF KF MF PF RF TF WF 
AG DG FG HG KG MG PG RG TG WG 
AH DH FH HH KH MH PH RH TH WH 
AI DI FI HI KI MI PI RI TI WI 
AK DK FK HK KK MK PK RK TK WK 
AL DL FL HL KL ML PL RL TL WL 
AM DM FM HM KM MM PM RM TM WM 
AN DN FN HN KN MN PN RN TN WN 
AP DP FP HP KP MP PP RP TP WP 
AQ DQ FQ HQ KQ MQ PQ RQ TQ WQ 
AR DR FR HR KR MR PR RR TR WR 
AS DS FS HS KS MS PS RS TS WS 
AT DT FT HT KT MT PT RT TT WT 
AV DV FV HV KV MV PV RV TV WV 
AW DW FW HW KW MW PW RW TW WW 
AY DY FY HY KY MY PY RY TY WY 
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CA EA GA IA LA NA QA SA VA YA 
CC EC GC IC LC NC QC SC VC YC 
CD ED GD ID LD ND QD SD VD YD 
CE EE GE IE LE NE QE SE VE YE 
CF EF GF IF LF NF QF SF VF YF 
CG EG GG IG LG NG QG SG VG YG 
CH EH GH IH LH NH QH SH VH YH 
CI EI GI II LI NI QI SI VI YI 
CK EK GK IK LK NK QK SK VK YK 
CL EL GL IL LL NL QL SL VL YL 
CM EM GM IM LM NM QM SM VM YM 
CN EN GN IN LN NN QN SN VN YN 
CP EP GP IP LP NP QP SP VP YP 
CQ EQ GQ IQ LQ NQ QQ SQ VQ YQ 
CR ER GR IR LR NR QR SR VR YR 
CS ES GS IS LS NS QS SS VS YS 
CT ET GT IT LT NT QT ST VT YT 
CV EV GV IV LV NV QV SV VV YV 
CW EW GW IW LW NW QW SW VW YW 
CY EY GY IY LY NY QY SY VY YY 
 
 
Supplementary Table 2.3 Test for normality of extracted features. 
Extracted features were reasonably normally distributed and evaluated by mean, median and 
shape of the data. 
Features 
Surface Positive Surface Negative Secretory Positive Surface Negative 
Mean  Median Mean  Median Mean  Median Mean  Median 
Percentage of alanine 6.4305 6.3830 5.3151 5.2811 5.7148 5.3055 5.494 5.235 
Percentage of cysteine 2.3275 1.9048 2.0747 2.0356 3.0994 2.1739 2.348 2.141 
Percentage of aspartic 
acid 5.3793 5.4968 5.3024 5.2910 5.2637 5.2910 5.765 5.788 
Percentage of glutamic 
acid 6.1375 6.0150 5.7452 5.5215 6.4329 6.0748 6.226 5.649 
Percentage of 4.4845 4.2254 4.0333 3.8095 4.2782 4.0426 3.319 3.103 
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phenylalanine 
Percentage of glycine 6.0926 5.9211 5.1145 4.7619 6.1741 5.7971 5.061 4.594 
Percentage of histidine 2.1894 1.9737 2.8127 2.7907 2.4751 2.3936 2.780 2.853 
Percentage of isoleucine 7.2918 7.0270 5.9486 5.8824 6.2476 6.2500 5.409 5.323 
Percentage of lysine 7.4053 7.1560 5.5013 5.3299 7.2160 7.1713 6.089 5.649 
Percentage of leucine 9.4119 9.3750 9.7429 9.6741 8.7737 8.8106 8.713 8.751 
Percentage of 
methionine 2.6714 2.5210 1.9725 1.8433 2.3891 2.3256 1.924 1.754 
Percentage of 
asparagine 4.6189 4.4728 5.9321 5.6561 5.6168 5.2632 5.870 5.651 
Percentage of proline 3.4262 3.3210 5.1686 4.8507 4.1500 4.1026 5.161 5.039 
Percentage of glutamine 3.5879 3.3613 3.9833 3.8462 3.8524 3.7634 3.914 3.650 
Percentage of arginine 4.7430 4.5249 5.5201 5.3719 4.6052 4.5564 5.952 5.718 
Percentage of serine 6.6747 6.5476 9.9273 9.6927 6.4565 6.1404 10.523 10.598 
Percentage of threonine 5.5285 5.3903 5.4771 5.3456 5.6319 5.4054 5.913 5.944 
Percentage of valine 6.8571 7.1038 5.8904 5.8932 6.3702 5.9908 5.679 5.601 
Percentage of 
tryptophan 1.1583 1.0204 1.1895 1.0309 1.4135 1.3575 0.886 0.826 
Percentage of tyrosine 3.5834 3.5714 3.3484 3.3175 3.8388 3.7415 2.975 2.797 
Molecular Weight 
29115.753
5 
23245.070
0 
57811.081
4 
46478.210
0 
36616.529
5 
28121.050
0 
70164.30
0 
39179.14
0 
Aromaticity 0.0923 0.0946 0.0857 0.0859 0.0953 0.0961 0.072 0.069 
Instability Index 35.4030 35.4633 47.1189 47.1017 37.3205 36.8936 49.427 50.182 
Isoelectric Point 7.3051 7.0162 7.3483 7.1319 7.1757 7.0069 7.280 7.214 
Grand average of 
hydropathy (GRAVY) -0.1669 -0.2414 -0.3786 -0.3954 -0.3258 -0.3435 -0.531 -0.504 
Secondary helix fraction 0.3279 0.3146 0.3015 0.3077 0.3092 0.3077 0.270 0.267 
Secondary turn fraction 0.2081 0.2069 0.2614 0.2580 0.2240 0.2234 0.266 0.267 
Secondary sheet fraction 0.2465 0.2444 0.2278 0.2283 0.2331 0.2296 0.224 0.222 
Average Residue Weight 112.9585 112.7301 112.8086 113.1947 113.3850 113.9302 112.248 112.230 
Average carbon sparing 5.0502 5.0287 4.9950 5.0138 5.0465 5.0537 4.893 4.895 
Average nitrogen 
sparing 1.3523 1.3500 1.3879 1.3846 1.3685 1.3630 1.400 1.404 
Average sulphur sparing 0.0500 0.0469 0.0405 0.0387 0.0549 0.0484 0.043 0.040 
Average oxygen sparing 2.4674 2.4684 2.5076 2.5086 2.4877 2.4820 2.528 2.535 
Average hydrogen 
sparing 9.9805 9.9663 9.8428 9.8665 9.8956 9.9000 9.753 9.748 
Charge 2.8715 2.5000 5.6444 6.0000 2.6122 3.0000 6.990 4.000 
Molar Extinction 
Coefficient A280 
29577.269
1 
22920.000
0 
57284.151
6 
45840.000
0 
42351.707
3 
35870.000
0 
58138.10
1 
33635.00
0 
Absobance A280 1.0292 0.9830 1.0176 0.9710 1.1818 1.1370 0.825 0.831 
Probability of Expression 
Inclusion Bodies 0.6906 0.6820 0.7873 0.8100 0.7104 0.7160 0.790 0.812 
DayhoffStat of alanine 0.7477 0.7420 0.6180 0.6140 0.6645 0.6170 0.639 0.609 
DayhoffStat of cysteine 0.8026 0.6570 0.7154 0.7020 1.0687 0.7500 0.810 0.739 
DayhoffStat of aspartic 
acid 0.9780 0.9990 0.9641 0.9620 0.9571 0.9620 1.048 1.053 
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DayhoffStat of glutamic 
acid 1.0229 1.0030 0.9575 0.9200 1.0721 1.0120 1.038 0.942 
DayhoffStat of 
phenylalanine 1.2457 1.1740 1.1204 1.0580 1.1884 1.1230 0.922 0.862 
DayhoffStat of glycine 0.7253 0.7050 0.6089 0.5670 0.7350 0.6900 0.603 0.547 
DayhoffStat of histidine 1.0947 0.9870 1.4063 1.3950 1.2376 1.1970 1.390 1.427 
DayhoffStat of isoleucine 1.6204 1.5620 1.3219 1.3070 1.3883 1.3890 1.202 1.183 
DayhoffStat of lysine 1.1220 1.0840 0.8335 0.8080 1.0933 1.0870 0.923 0.856 
DayhoffStat of leucine 1.2719 1.2670 1.3166 1.3070 1.1857 1.1910 1.177 1.183 
DayhoffStat of 
methionine 1.5714 1.4830 1.1603 1.0840 1.4054 1.3680 1.132 1.032 
DayhoffStat of 
asparagine 1.0742 1.0400 1.3795 1.3150 1.3062 1.2240 1.365 1.314 
DayhoffStat of proline 0.6589 0.6390 0.9940 0.9330 0.7981 0.7890 0.993 0.969 
DayhoffStat of glutamine 0.9200 0.8620 1.0214 0.9860 0.9878 0.9650 1.004 0.936 
DayhoffStat of arginine 0.9680 0.9230 1.1265 1.0960 0.9398 0.9300 1.215 1.167 
DayhoffStat of serine 0.9535 0.9350 1.4182 1.3850 0.9223 0.8770 1.503 1.514 
DayhoffStat of threonine 0.9063 0.8840 0.8979 0.8760 0.9233 0.8860 0.969 0.975 
DayhoffStat of valine 1.0390 1.0760 0.8925 0.8930 0.9652 0.9080 0.860 0.849 
DayhoffStat of 
tryptophan 0.8910 0.7850 0.9150 0.7930 1.0873 1.0440 0.682 0.636 
DayhoffStat of tyrosine 1.0539 1.0500 0.9848 0.9760 1.1290 1.1000 0.875 0.823 
Percentage of tiny mole 27.0538 27.4850 27.9087 27.5860 27.0767 26.9770 29.340 28.991 
Percentage of small 
mole 47.3354 47.9670 50.2023 49.8570 48.4774 48.0920 51.814 51.828 
Percentage of aliphatic 
mole 23.5608 23.2290 21.5818 21.7070 21.3916 21.4180 19.800 20.223 
Percentage of aromatic 
mole  11.4157 11.3640 11.3840 11.1940 12.0057 12.0620 9.959 9.770 
Percentage of polar 
mole 46.2646 46.9270 50.2014 49.9660 47.5505 47.4890 53.032 53.403 
Percentage of non polar 
mole 53.7354 53.0730 49.7986 50.0340 52.4495 52.5110 46.968 46.598 
Percentage of charged 
mole 25.8545 26.3160 24.8817 25.0860 25.9929 25.6100 26.811 26.244 
Percentage of acidic 
mole 11.5168 11.6880 11.0476 11.0220 11.6966 11.4940 11.991 11.558 
Percentage of basic 
mole 14.3378 14.2080 13.8341 13.6530 14.2963 14.2860 14.821 14.224 
Percentage of secondary 
helix 42.3711 41.6000 30.7578 30.5000 37.8907 35.9000 32.271 29.600 
Percentage of secondary 
sheet 27.9847 26.2000 26.3910 25.9000 24.7020 24.3000 24.460 24.900 
Percentage of secondary 
turns 21.7229 20.7000 25.4444 25.2000 27.2054 23.9000 26.657 26.450 
Percentage of secondary 
coil 17.0791 17.1000 22.5426 21.7000 17.6337 18.0000 22.703 22.400 
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C-mannosylation sites 0.0281 0.0000 0.1047 0.0000 0.0244 0.0000 0.093 0.000 
Proteasomal cleavages 
(MHC ligands) 82.6185 66.0000 167.0181 130.0000 102.4829 81.0000 196.585 110.500 
N-linked glycosylation 
sites 1.1566 1.0000 3.5957 2.0000 1.8878 2.0000 4.609 2.000 
Arginine and lysine 
propeptide cleavage 
sites 0.0683 0.0000 0.4188 0.0000 0.0976 0.0000 0.682 0.000 
Binding Regions in 
Disordered Proteins 0.6426 0.0000 3.0361 1.0000 0.6829 0.0000 6.752 3.000 
Mitochondrial targeting 
peptide (mTP) 0.1514 0.0880 0.2827 0.1560 0.1489 0.0740 0.194 0.116 
Secretory pathway 
signal peptide (SP) 0.3167 0.1060 0.1128 0.0650 0.4327 0.1650 0.088 0.065 
Other subcellular 
location 0.5970 0.7610 0.6544 0.7660 0.4646 0.4770 0.788 0.866 
Linear B-cell epitopes 76.3253 58.0000 187.0397 136.0000 105.2098 82.0000 285.008 149.000 
Class I Immunogenicity 
Score 0.1592 0.1060 -2.6561 -1.6475 -0.2818 -0.1848 -5.885 -2.556 
 
 
Supplementary Table 2.4  List of 129 2-mers differentially distributed between surface and 
non-surface proteins. 
Means between positive and negative training sets were compared by t-test. Shown are all 
features with p<0.01. P-values were corrected for multiple testing using False Discovery Rate 
(FDR). 
Features 
Mean surface 
proteins 
Mean non-surface 
proteins 
P-value FDR 
SS 0.0048 0.0122 2.94E-28 1.18E-25 
SN 0.0027 0.0060 2.23E-20 4.45E-18 
PS 0.0022 0.0052 2.69E-19 3.58E-17 
NS 0.0027 0.0058 3.32E-16 3.32E-14 
LS 0.0062 0.0102 1.88E-14 1.49E-12 
PL 0.0023 0.0048 2.23E-14 1.49E-12 
SQ 0.0019 0.0040 1.11E-13 6.34E-12 
SR 0.0028 0.0053 3.78E-12 1.82E-10 
SP 0.0021 0.0043 4.10E-12 1.82E-10 
ST 0.0037 0.0066 1.23E-11 4.92E-10 
QP 0.0008 0.0023 3.34E-11 1.22E-09 
LN 0.0037 0.0061 1.91E-10 6.35E-09 
DS 0.0030 0.0052 3.46E-10 1.06E-08 
HS 0.0015 0.0031 5.14E-10 1.47E-08 
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KV 0.0054 0.0027 5.86E-10 1.56E-08 
GK 0.0051 0.0025 1.22E-09 3.05E-08 
RR 0.0023 0.0043 1.62E-09 3.82E-08 
PR 0.0011 0.0026 4.14E-09 9.19E-08 
PP 0.0016 0.0039 6.93E-09 1.46E-07 
SD 0.0033 0.0053 9.47E-09 1.89E-07 
QS 0.0023 0.0040 2.80E-08 5.34E-07 
IV 0.0052 0.0029 3.36E-08 6.11E-07 
RS 0.0027 0.0046 3.78E-08 6.54E-07 
II 0.0065 0.0033 4.06E-08 6.54E-07 
KA 0.0055 0.0031 4.09E-08 6.54E-07 
NN 0.0024 0.0045 1.06E-07 1.63E-06 
GA 0.0045 0.0023 1.53E-07 2.27E-06 
SE 0.0036 0.0055 2.71E-07 3.87E-06 
EK 0.0054 0.0032 3.60E-07 4.97E-06 
ME 0.0022 0.0009 4.51E-07 6.01E-06 
LP 0.0034 0.0053 5.47E-07 7.06E-06 
AM 0.0017 0.0007 1.11E-06 1.39E-05 
SL 0.0066 0.0091 2.84E-06 3.43E-05 
MK 0.0024 0.0012 2.92E-06 3.43E-05 
VI 0.0051 0.0033 3.46E-06 3.79E-05 
NP 0.0018 0.0030 3.48E-06 3.79E-05 
DK 0.0046 0.0027 3.51E-06 3.79E-05 
PG 0.0016 0.0028 4.49E-06 4.73E-05 
KK 0.0059 0.0032 4.91E-06 5.04E-05 
IA 0.0047 0.0031 5.49E-06 5.49E-05 
AK 0.0045 0.0027 5.96E-06 5.82E-05 
AI 0.0049 0.0031 6.79E-06 6.47E-05 
SV 0.0045 0.0064 7.12E-06 6.63E-05 
VP 0.0021 0.0037 8.33E-06 7.57E-05 
KL 0.0076 0.0053 1.03E-05 9.16E-05 
KT 0.0044 0.0027 2.60E-05 0.0002 
SA 0.0035 0.0050 2.77E-05 0.0002 
LG 0.0060 0.0042 3.86E-05 0.0003 
PI 0.0020 0.0033 4.23E-05 0.0003 
RP 0.0015 0.0025 4.33E-05 0.0003 
EN 0.0026 0.0039 5.22E-05 0.0004 
HL 0.0020 0.0030 5.31E-05 0.0004 
PV 0.0023 0.0037 6.51E-05 0.0005 
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YH 0.0006 0.0013 6.55E-05 0.0005 
IK 0.0053 0.0037 7.09E-05 0.0005 
RL 0.0048 0.0064 7.75E-05 0.0006 
YI 0.0029 0.0016 8.82E-05 0.0006 
VV 0.0057 0.0039 9.21E-05 0.0006 
WC 0.0000 0.0003 9.29E-05 0.0006 
NH 0.0009 0.0016 9.57E-05 0.0006 
TF 0.0030 0.0018 0.0001 0.0007 
HN 0.0008 0.0016 0.0001 0.0007 
IE 0.0045 0.0031 0.0001 0.0009 
IG 0.0046 0.0030 0.0001 0.0009 
AS 0.0036 0.0049 0.0002 0.0010 
GI 0.0047 0.0032 0.0002 0.0012 
PE 0.0021 0.0031 0.0002 0.0012 
AV 0.0050 0.0034 0.0002 0.0012 
VK 0.0048 0.0033 0.0002 0.0012 
FI 0.0044 0.0028 0.0002 0.0013 
LR 0.0042 0.0055 0.0003 0.0015 
YM 0.0011 0.0005 0.0004 0.0020 
TR 0.0020 0.0030 0.0005 0.0025 
GD 0.0037 0.0025 0.0005 0.0025 
KN 0.0040 0.0028 0.0005 0.0026 
NR 0.0020 0.0028 0.0005 0.0028 
TS 0.0041 0.0055 0.0005 0.0028 
IF 0.0031 0.0020 0.0007 0.0036 
AD 0.0032 0.0022 0.0007 0.0037 
FP 0.0012 0.0022 0.0008 0.0038 
YP 0.0011 0.0019 0.0010 0.0048 
IY 0.0027 0.0017 0.0010 0.0049 
RF 0.0015 0.0023 0.0011 0.0051 
VT 0.0045 0.0032 0.0012 0.0057 
MA 0.0021 0.0013 0.0013 0.0061 
CC 0.0012 0.0006 0.0013 0.0061 
NL 0.0043 0.0054 0.0013 0.0062 
DF 0.0018 0.0026 0.0014 0.0062 
IP 0.0025 0.0035 0.0014 0.0062 
KF 0.0029 0.0020 0.0014 0.0064 
PH 0.0007 0.0013 0.0015 0.0065 
DH 0.0008 0.0014 0.0015 0.0067 
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HY 0.0007 0.0011 0.0016 0.0068 
CV 0.0018 0.0010 0.0017 0.0071 
RH 0.0011 0.0018 0.0017 0.0072 
DM 0.0017 0.0010 0.0020 0.0083 
DG 0.0038 0.0026 0.0026 0.0105 
HQ 0.0007 0.0011 0.0027 0.0111 
GH 0.0011 0.0017 0.0027 0.0111 
PN 0.0020 0.0028 0.0032 0.0126 
PQ 0.0013 0.0020 0.0032 0.0127 
EP 0.0018 0.0026 0.0033 0.0131 
FH 0.0007 0.0012 0.0034 0.0131 
KG 0.0030 0.0021 0.0035 0.0133 
HF 0.0009 0.0015 0.0036 0.0138 
FG 0.0031 0.0022 0.0037 0.0140 
WR 0.0010 0.0006 0.0038 0.0141 
GV 0.0042 0.0031 0.0038 0.0141 
KD 0.0039 0.0029 0.0043 0.0157 
CP 0.0008 0.0013 0.0044 0.0160 
IS 0.0051 0.0061 0.0045 0.0163 
WS 0.0006 0.0010 0.0046 0.0163 
FS 0.0031 0.0040 0.0050 0.0178 
CK 0.0017 0.0010 0.0051 0.0179 
DA 0.0033 0.0025 0.0063 0.0217 
KC 0.0019 0.0011 0.0063 0.0217 
MG 0.0015 0.0009 0.0072 0.0245 
MQ 0.0011 0.0006 0.0072 0.0245 
KM 0.0015 0.0010 0.0074 0.0249 
QA 0.0028 0.0020 0.0075 0.0251 
MD 0.0016 0.0010 0.0076 0.0252 
AF 0.0032 0.0023 0.0083 0.0271 
TI 0.0041 0.0031 0.0084 0.0272 
NE 0.0032 0.0040 0.0085 0.0273 
EM 0.0014 0.0009 0.0088 0.0281 
SH 0.0016 0.0022 0.0089 0.0281 
FL 0.0051 0.0039 0.0090 0.0281 
VG 0.0042 0.0032 0.0090 0.0281 
LV 0.0065 0.0051 0.0091 0.0284 
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Supplementary Table 2.5 List of 122 2-mers differentially distributed between secretory and 
non-secretory proteins. 
Means between positive and negative training sets were compared by t-test. Shown are all 
features with p<0.01. P-values were corrected for multiple testing using False Discovery Rate 
(FDR). 
Features 
Mean secretory 
proteins 
Mean non-
secretory proteins 
P-value FDR 
SS 0.0048 0.0151 1.19E-31 4.75E-29 
TS 0.0031 0.0071 4.04E-18 8.08E-16 
PS 0.0026 0.0057 3.16E-17 3.32E-15 
SN 0.0031 0.0068 3.32E-17 3.32E-15 
SR 0.0026 0.0056 1.56E-15 1.25E-13 
ST 0.0041 0.0077 3.75E-13 2.50E-11 
RR 0.0023 0.0052 8.57E-13 4.90E-11 
SP 0.0026 0.0051 1.30E-11 6.50E-10 
RS 0.0028 0.0053 6.73E-11 2.99E-09 
HS 0.0015 0.0033 2.75E-10 1.10E-08 
SA 0.0028 0.0052 3.49E-10 1.27E-08 
DS 0.0031 0.0055 5.41E-10 1.80E-08 
SD 0.0035 0.0058 2.32E-09 7.15E-08 
SQ 0.0020 0.0038 8.95E-09 2.56E-07 
RL 0.0038 0.0062 1.18E-08 3.15E-07 
GQ 0.0036 0.0015 1.76E-08 4.40E-07 
IS 0.0037 0.0058 2.34E-08 5.51E-07 
LS 0.0065 0.0096 2.50E-08 5.56E-07 
NS 0.0036 0.0062 3.31E-08 6.96E-07 
NN 0.0026 0.0053 3.90E-08 7.79E-07 
YG 0.0035 0.0015 1.15E-07 2.20E-06 
TP 0.0021 0.0036 1.30E-07 2.36E-06 
SF 0.0020 0.0035 2.78E-07 4.84E-06 
IG 0.0044 0.0025 6.69E-07 1.11E-05 
CG 0.0028 0.0012 7.29E-07 1.17E-05 
SL 0.0058 0.0082 1.71E-06 2.64E-05 
PV 0.0022 0.0037 1.87E-06 2.77E-05 
IK 0.0046 0.0028 2.32E-06 3.32E-05 
KN 0.0045 0.0026 2.48E-06 3.43E-05 
VF 0.0030 0.0015 3.02E-06 4.00E-05 
ES 0.0034 0.0051 3.10E-06 4.00E-05 
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HT 0.0009 0.0018 3.80E-06 4.75E-05 
KM 0.0015 0.0007 4.21E-06 5.10E-05 
PR 0.0017 0.0029 5.45E-06 6.24E-05 
YK 0.0029 0.0016 5.46E-06 6.24E-05 
DD 0.0030 0.0050 5.97E-06 6.64E-05 
KW 0.0016 0.0006 7.32E-06 7.91E-05 
WN 0.0012 0.0004 9.14E-06 9.62E-05 
FD 0.0034 0.0020 1.17E-05 0.0001 
PY 0.0026 0.0013 1.48E-05 0.0001 
KY 0.0033 0.0019 2.30E-05 0.0002 
CK 0.0025 0.0012 2.46E-05 0.0002 
ND 0.0024 0.0037 2.67E-05 0.0002 
NF 0.0028 0.0016 2.91E-05 0.0003 
GC 0.0022 0.0012 3.45E-05 0.0003 
FI 0.0034 0.0020 3.73E-05 0.0003 
VG 0.0048 0.0031 4.20E-05 0.0004 
GK 0.0048 0.0029 4.74E-05 0.0004 
SV 0.0042 0.0059 6.71E-05 0.0005 
SG 0.0042 0.0060 6.75E-05 0.0005 
KF 0.0031 0.0018 7.10E-05 0.0006 
MK 0.0024 0.0013 8.06E-05 0.0006 
GS 0.0036 0.0052 8.42E-05 0.0006 
HH 0.0005 0.0012 9.42E-05 0.0007 
VS 0.0040 0.0056 0.0001 0.0008 
AY 0.0025 0.0014 0.0001 0.0009 
AR 0.0023 0.0036 0.0002 0.0011 
WA 0.0011 0.0004 0.0002 0.0012 
PP 0.0021 0.0037 0.0002 0.0012 
YW 0.0006 0.0002 0.0002 0.0013 
NY 0.0034 0.0018 0.0002 0.0014 
MP 0.0007 0.0014 0.0002 0.0014 
KC 0.0027 0.0013 0.0002 0.0014 
TC 0.0022 0.0013 0.0002 0.0014 
KV 0.0045 0.0029 0.0002 0.0015 
FN 0.0028 0.0018 0.0002 0.0015 
LK 0.0066 0.0049 0.0003 0.0016 
QS 0.0028 0.0041 0.0003 0.0017 
FG 0.0027 0.0016 0.0003 0.0018 
CC 0.0019 0.0006 0.0004 0.0020 
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EP 0.0017 0.0027 0.0004 0.0023 
TR 0.0019 0.0029 0.0004 0.0024 
EW 0.0011 0.0004 0.0005 0.0025 
RP 0.0017 0.0026 0.0006 0.0031 
LP 0.0037 0.0050 0.0006 0.0031 
PD 0.0020 0.0030 0.0006 0.0032 
AW 0.0009 0.0004 0.0009 0.0046 
KL 0.0072 0.0057 0.0010 0.0050 
AS 0.0037 0.0050 0.0010 0.0050 
IV 0.0038 0.0026 0.0010 0.0051 
HE 0.0019 0.0011 0.0011 0.0054 
ML 0.0025 0.0014 0.0013 0.0065 
VV 0.0047 0.0033 0.0015 0.0073 
HG 0.0024 0.0015 0.0016 0.0074 
NW 0.0010 0.0004 0.0016 0.0074 
MV 0.0015 0.0009 0.0016 0.0076 
PN 0.0022 0.0031 0.0017 0.0077 
KR 0.0035 0.0047 0.0017 0.0077 
VC 0.0025 0.0015 0.0018 0.0082 
GY 0.0026 0.0016 0.0019 0.0086 
KD 0.0038 0.0026 0.0020 0.0087 
VW 0.0011 0.0007 0.0020 0.0089 
CN 0.0023 0.0013 0.0021 0.0089 
NP 0.0021 0.0030 0.0021 0.0089 
FK 0.0030 0.0019 0.0023 0.0098 
HL 0.0019 0.0028 0.0026 0.0107 
IF 0.0026 0.0017 0.0028 0.0117 
FT 0.0028 0.0020 0.0032 0.0130 
VP 0.0024 0.0034 0.0035 0.0143 
DK 0.0043 0.0030 0.0036 0.0143 
ET 0.0042 0.0027 0.0039 0.0156 
VD 0.0041 0.0030 0.0046 0.0179 
IC 0.0017 0.0010 0.0047 0.0183 
MY 0.0007 0.0004 0.0049 0.0189 
NR 0.0022 0.0029 0.0051 0.0194 
FW 0.0005 0.0002 0.0054 0.0205 
SH 0.0019 0.0026 0.0055 0.0206 
HP 0.0011 0.0016 0.0057 0.0209 
WV 0.0007 0.0003 0.0059 0.0215 
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LR 0.0039 0.0048 0.0060 0.0215 
II 0.0045 0.0032 0.0060 0.0215 
YI 0.0019 0.0012 0.0063 0.0227 
IW 0.0010 0.0005 0.0065 0.0229 
AT 0.0027 0.0035 0.0068 0.0237 
DH 0.0010 0.0015 0.0068 0.0238 
WM 0.0004 0.0001 0.0069 0.0238 
YV 0.0024 0.0017 0.0076 0.0259 
WP 0.0009 0.0004 0.0076 0.0259 
LF 0.0036 0.0026 0.0079 0.0264 
PI 0.0020 0.0026 0.0084 0.0279 
LI 0.0054 0.0043 0.0098 0.0323 
LD 0.0043 0.0053 0.0099 0.0323 
 
Supplementary Table 2.6 Evaluation of 16 classifiers by stratified 10-fold cross-validation 
on positive training set of Schistosoma surface proteins. 
Red colour represents higher accuracy and green colour represents lower accuracy.  
Machine Learning Technique 
    
Accuracy rounds for 10-fold cross-validation 
 
Overall 
Accuracy 
 
1 2 3 4 5 6 7 8 9 10 
 Gradient Boosting Machine (GBM) 0.6604 0.7547 0.6981 0.5849 0.6415 0.7547 0.6038 0.6315 0.7115 0.5394 0.6581 
RBF SVM 0.5283 0.5283 0.5283 0.5283 0.5283 0.5283 0.5283 0.5192 0.5192 0.5294 0.5266 
k-Nearest Neighbors 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4808 0.4808 0.4706 0.4734 
Decision Tree 0.6226 0.6981 0.5472 0.6038 0.6038 0.8113 0.5849 0.6923 0.6923 0.5098 0.6366 
Random Forest 0.6604 0.7547 0.6981 0.7547 0.6226 0.7170 0.6038 0.5192 0.6731 0.6667 0.6670 
Ada Boost 0.5660 0.5094 0.4528 0.7170 0.8113 0.7170 0.5094 0.5385 0.5577 0.5098 0.5889 
Gaussian Naive Bayes (GNB) 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4808 0.4808 0.4706 0.4734 
Linear Discriminant Analysis (LDA) 0.5283 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4808 0.4808 0.4706 0.4791 
Quadratic Discriminant Analysis 
(QDA) 0.4717 0.4717 0.4717 0.5283 0.4717 0.4717 0.4717 0.4808 0.4808 0.4706 0.4791 
Ridge Regression 0.5283 0.5283 0.5283 0.5283 0.5283 0.5283 0.5283 0.5192 0.5192 0.5294 0.5266 
Stochastic Gradient Descent (SGD) 0.4717 0.5094 0.4717 0.4717 0.4717 0.5094 0.4717 0.5192 0.4808 0.4706 0.4848 
Perceptron 0.4717 0.4717 0.4717 0.4717 0.4717 0.4906 0.4717 0.4808 0.4808 0.4706 0.4753 
Passive Aggressive 0.4717 0.4717 0.4717 0.4717 0.4717 0.4906 0.4717 0.4808 0.4808 0.4706 0.4753 
Bernoulli Naive Bayes (BNB) 0.7547 0.8113 0.8302 0.8302 0.7736 0.8679 0.7170 0.8654 0.7308 0.6275 0.7809 
Nearest Centroid 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4717 0.4808 0.4808 0.4706 0.4734 
Multi-layer Perceptron (MLP) 0.4717 0.4717 0.4906 0.4717 0.4717 0.4717 0.5283 0.4808 0.4808 0.4706 0.4809 
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Supplementary Table 2.7 Evaluation of 16 classifiers by stratified 10-fold cross-validation 
on negative training set of Schistosoma non-surface proteins. 
Red colour represents higher accuracy and green colour represents lower accuracy.  
Machine Learning Technique 
    
Accuracy rounds for 10-fold cross-validation 
 
Overall 
Accuracy 
 
1 2 3 4 5 6 7 8 9 10 
 
Gradient Boosting Machine (GBM) 0.8936 0.7447 0.7447 0.8085 0.7872 0.8043 0.8043 0.7391 0.8000 0.8889 0.8015 
RBF SVM 0.5532 0.5532 0.5532 0.5532 0.5532 0.5652 0.5652 0.5652 0.5556 0.5556 0.5573 
k-Nearest Neighbors 0.5532 0.5532 0.4468 0.4468 0.5532 0.5652 0.4348 0.5652 0.5556 0.4444 0.5118 
Decision Tree 0.5106 0.5532 0.5319 0.4894 0.4894 0.3913 0.4565 0.5435 0.5333 0.5778 0.5077 
Random Forest 0.6383 0.5106 0.5106 0.5745 0.5957 0.6522 0.5217 0.4783 0.5111 0.4667 0.5460 
Ada Boost 0.7660 0.7872 0.6809 0.7234 0.5532 0.6739 0.8261 0.6739 0.6000 0.8222 0.7107 
Gaussian Naive Bayes (GNB) 0.4468 0.4468 0.4468 0.5532 0.4468 0.4348 0.4348 0.4348 0.4444 0.4444 0.4534 
Linear Discriminant Analysis (LDA) 0.4468 0.4468 0.4468 0.4468 0.4681 0.4348 0.4348 0.4348 0.4444 0.4444 0.4449 
Quadratic Discriminant Analysis 
(QDA) 
0.5532 0.5532 0.5532 0.5532 0.5532 0.5652 0.5652 0.5652 0.5556 0.5556 0.5573 
Ridge Regression 0.4468 0.4468 0.4468 0.4468 0.4468 0.4348 0.4348 0.4348 0.4444 0.4444 0.4427 
Stochastic Gradient Descent 
(SGD) 
0.4468 0.4468 0.4468 0.4468 0.4468 0.4348 0.4348 0.4348 0.4444 0.4444 0.4427 
Perceptron 0.4468 0.4468 0.4468 0.4468 0.4681 0.4348 0.4348 0.4348 0.6000 0.5111 0.4671 
Passive Aggressive 0.4468 0.4468 0.5319 0.5745 0.8298 0.7174 0.6087 0.4783 0.6889 0.6444 0.5967 
Bernoulli Naive Bayes (BNB) 0.6809 0.6383 0.7021 0.7872 0.7872 0.6957 0.6739 0.6739 0.7556 0.7333 0.7128 
Nearest Centroid 0.4468 0.4468 0.4468 0.4468 0.4468 0.4348 0.4348 0.4348 0.4444 0.4444 0.4427 
Multi-layer Perceptron (MLP) 0.4468 0.4468 0.4468 0.4468 0.4468 0.5652 0.5652 0.4348 0.5778 0.4667 0.4844 
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Chapter 3  Identifying Schistosome-Specific Proteins 
Immunoreactivity 
 
3.1 Foreword 
The following chapter explores a machine learning approach to classify Schistosoma 
protein immunoreactivity. A modified approach of the method described in chapter 2 used 
on Schistosoma protein microarray data to classify proteins between immunoreactive and 
non-immunoreactive. SchistoTarget, a machine learning based classifier, have been 
developed to identify Schistosoma proteins immunoreactivity. This chapter describes the 
method, usage and prediction accuracy of SchistoTarget. 
 
3.2 Abstract 
Schistosomiasis is considered by the World Health Organization as the second most 
socioeconomically devastating and second most common parasitic disease, affecting 200 
million people worldwide and causing at least 300,000 deaths annually. No vaccines are 
available and novel vaccine candidates against schistosomiasis are required. Recently 
several Schistosoma immunomics studies employing protein microarrays have provided 
essential information for vaccine target identification.  
In this project, it is showed that Schistosoma proteins recognised by the host immune 
system have specific sequence properties that can be used to discriminate between 
immunoreactive and non-reactive proteins.  This project results demonstrate that 
computational predictive methods can likely provide valuable information for the discovery 
of effective novel vaccine targets. To help prioritizing candidate vaccine targets, the 
SchistoTarget webserver have been developed, which uses machine learning methods for 
the identification of Schistosoma proteins recognised by the host immune system. The 
server achieves a sensitivity of 65% and specificity of 72% and provides a user-friendly 
web-interface. Results are presented in interactive tables and figures. SchistoTarget is 
publicly available at http://schistotarget.bioapps.org. Source code and documentation are 
available from https://github.com/shihabhasan/schistotarget. 
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3.3 Introduction 
Schistosomiasis is one of the major neglected tropical diseases (NTDs) causing significant 
morbidity and mortality of humans residing in tropical countries58. Human treatment with 
praziquantel (PZQ) is used to control schistosomiasis59 but mass treatment does not 
prevent reinfection60. For a long term disease control there is an urgent need for vaccines,  
which are not yet available2. Recent advances have utilized immunomics approaches in 
efforts to discover novel vaccine antigens15,36. Immunomics provides an invaluable  
resource for obtaining antibody signatures15. Antibody signatures reflect different disease 
pathologies61. The IgE response has been shown to correlate with both allergic reactions 
and immunity to Schistosoma. IgG4 responses are prevalent against allergen-like IgE-
binding antigens and IgG1 responses are prevalent against recombinant S. mansoni 
proteins62.  
Schistosoma protein sequence features enable the in silico identification of protein class 
efficiently by using machine learning techniques27. Machine learning based in silico 
antigen discovery strategy can lead to effective identification of potentially novel 
schistosomiasis vaccine antigens. 
 
3.4 Methods 
3.4.1 Data set 
As training set, host immune response to Schistosoma proteins was obtained from a 
recently published immunonomics study using a protein microarray. A total of 217 protein 
sequences have been collected of which 215 were RTS (rapid translation system) proteins 
and 2 are purified recombinant proteins15. After removing the isoform proteins 214 
sequences remained, where 78 proteins were IgE reactive, 43 were IgG1 reactive, 96 
proteins were IgG3 reactive and 21 proteins were IgG4 reactive. Some proteins 
overlapped between different antibody signatures. After merging these sequences to 
immonoreactive (recognized by at least one antibody response) and non-immunoreactive 
(no antibody response recognized) classes, 110 sequences remained as immonoreactive 
class and 90 sequences remained as non-immunoreactive class. This pilot immunonomics 
study15 leads to a relatively small size of the training set. 
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3.4.2 Features selection 
482 features from each protein were extracted. Of these, 82 features represented 
sequence characteristics and structural and biochemical attributes (Supplementary Table 
3.1). The remaining 400 features were 2-mers of amino acids (Supplementary Table 3.2). 
Features were extracted from each protein sequence using different available 
bioinformatics tools and in-house Python scripts (Table 3.1). The data followed 
approximately a normal distribution which was assessed by comparing mean and median 
values and the shape of the data ( 
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Supplementary Table 3.3). The distributions of features across different antibody types 
were compared by t-test with a significance level of 0.05.  
 
Table 3.1 Tools used to extract protein features. 
Tool Purpose URL 
Pepstats Calculation of statistics for proteins such 
as molecular weight, isoelectric point etc. 
http://www.ebi.ac.uk/Tools/seqstats/embos
s_pepstats/ 
Protparam Computation of various physical and 
chemical parameters 
http://web.expasy.org/protparam/ 
Garnier Prediction of protein secondary structure http://emboss.sourceforge.net/apps/releas
e/6.2/emboss/apps/garnier.html 
NetCGlyc C-mannosylation sites http://www.cbs.dtu.dk/services/NetCGlyc/ 
NetChop Proteasomal cleavages (MHC ligands) http://www.cbs.dtu.dk/services/NetChop/ 
NetNGlyc N-linked glycosylation sites http://www.cbs.dtu.dk/services/NetNGlyc/ 
ANCHOR Prediction of Protein Binding Regions in 
Disordered Proteins 
http://anchor.enzim.hu/ 
ProP Arginine and lysine propeptide cleavage 
sites 
http://www.cbs.dtu.dk/services/ProP/ 
TargetP Prediction of the subcellular location of 
eukaryotic proteins 
http://www.cbs.dtu.dk/services/TargetP/ 
BepiPred Prediction of the location of linear B-cell 
epitopes 
http://www.cbs.dtu.dk/services/BepiPred/ 
Class I 
Immunogenecity 
Prediction of MHC Class I immunogenicity http://tools.iedb.org/immunogenicity/ 
TMHMM 
Prediction of transmembrane helices in 
proteins 
http://www.cbs.dtu.dk/services/TMHMM/ 
 
 
3.4.3 Features scaling  
The range of values of the different features included in SchistoTarget varies widely. To 
ensure that each feature contributes approximately proportionately and, therefore, to avoid 
biases introduced by features with greater numeric ranges54, all features are scaled into 
the range of 0 to 1.  
 
3.4.4 Selection of best performing machine-learning technique 
The size of the training set is relatively which may be very challenging for machine 
learning problem. I have applied more machine learning techniques compared to the 
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previous approach described in Chapter 2 and 21 different machine learning techniques 
were evaluated on the training set. Classifiers were run using the Scikit-learn (Version 
0.18.2) library in Python55. Theses 21 classifiers were: (i) Gradient Boosting Machine 
(GBM), (ii) Ada Boost, (iii) Support Vector Machine with Radial Bias Function kernel (RBF 
SVM), (iv) Support Vector Machine with Linear kernel (Linear SVM), (v) k-Nearest 
Neighbors, (vi) Decision Tree, (vii) Random Forest, (viii) Extra Trees Classifier, (ix) 
Gaussian Naive Bayes (GNB), (x) Multinomial Naive Bayes (MNB), (xi) Bernoulli Naive 
Bayes (BNB), (xii) Linear Discriminant Analysis (LDA), (xiii) Quadratic Discriminant 
Analysis (QDA), (xiv) Ridge Regression, (xv) Stochastic Gradient Descent (SGD), (xvi) 
Perceptron, (xvii) Passive Aggressive, (xviii) Nearest Centroid, (xix) Multi-layer Perceptron 
(MLP), (xx) Bagging Classifier, (xxi) Gaussian Process Classifier.  
Each training sequence was represented by a 67-dimensional feature vector (22 of 
biochemical and structural features and 45 of 2-mers). The 21 classifiers were evaluated 
by stratified k-fold (10-fold) cross-validation. In stratified k-fold cross-validation, folds were 
selected such that the mean response values were approximately equal in all folds56. 
Finally, the mean accuracy was computed for all 10 iterations. 
Due to small training data set, a single classifier can provide high false positive prediction 
rate, it is not feasible to select a single classifier. To reduce the false positive prediction 
rate, SchistoTarget combined the 2 supervised machine learning techniques which 
achieved the highest prediction accuracies during the 10-fold cross-validation. The 
classifiers were combined classifier using a majority-voting rule. A protein is assigned to 
positive class only if it is predicted by the 2 classifiers as positive; otherwise, SchistoTarget 
assigns the protein as negative class i.e., only one or no classifiers predict the protein as 
positive.    
 
3.4.5 Performance evaluation 
The classification accuracy of SchistoTarget was evaluated by sensitivity, specificity and 
overall accuracy57. These measures are defined as: sensitivity = TP/(TP+FN), specificity = 
TN/(TN+FP), overall accuracy = (TP + TN) / (TP + TN + FP + FN), where TP (True 
Positive) and TN (True Negative) are the number of correctly predicted positive and 
negative proteins, respectively, and FP (False Positive) and FN (False Negative) are the 
number of incorrectly predicted positive and negative proteins, respectively. Additionally, 
the discriminatory power of classifiers was evaluated by the Area Under the Receiver 
Operating Characteristic (ROC) curve (AUC). Classification performance of SchistoTarget 
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was assessed on the same training set by leave-one-out cross-validation method (Tables 
S6 and S7) as independent test data set is not available. Leave-one-out cross-validation is 
a simple cross-validation method. Each learning set is created by taking all the samples 
except one, the test set being the sample left out. Thus, for n samples, we have n different 
training sets and n different tests set. This cross-validation procedure does not waste 
much data as only one sample is removed from the training set. So, leave-one-out cross-
validation is also a k-fold cross-validation where k is equal to the number of samples in the 
data set55,63. 
 
3.5 Results 
3.5.1 SchistoTarget overview 
SchistoTarget incorporates two machine learning techniques (Gaussian Naive Bayes and 
Bernoulli Naive Bayes) to discriminate between immunoreactive and non-reactive proteins. 
Generated predictions are stored in a database which facilitates rapid reuse of results 
without re-running the time-consuming classifiers. This saves considerable runtime if the 
same sequences are uploaded multiple times, e.g. by different users.  
SchistoTarget takes FASTA formatted sequence files or pasted protein sequences as 
input. If the proteins are already present in the database, the pre-computed results are 
returned. Otherwise SchistoTarget extracts features from each query sequence using 
several available bioinformatics tools and newly developed Python scripts. Features 
include sequence characteristics, biochemical attributes, structural properties and 2-mers. 
These features are then scaled and used to discriminate between immunoreactive and 
non-reactive proteins using a majority-voting rule of 2 supervised machine learning 
techniques (Gaussian Naive Bayes and Bernoulli Naive Bayes). The results of the 
classification are returned to the user and stored in the database for future reuse. Results 
are presented as interactive tables, charts and figures. No installation, configuration, 
registration or login is required. Data are kept privately and automatically deleted and 
processing has completed. 
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3.5.2 Discriminating features of Schistosoma proteins recognized by different host 
antibody types system  
Associations between 82 biochemical and structural protein features and antibody 
responses were examined using a t-test. Only a small number of features were 
significantly differentially distributed (p<0.05) (Figure 3.1; Table 3.2) among 4 antibody 
responses (IgE, IgG1, IgG3 and IgG4). IgE reactive antigens showed a higher frequency 
of basic mole, and nitrogen sparing than IgG1 reactive antigens. Glutamine frequency was 
higher in IgG4 than IgE reactive antigens. The percentage of basic mole and arginine and 
lysine propeptide cleavage sites were less in IgG1 antigens than IgG3 antigens, whereas a 
higher frequency of grand average of hydropathy (GRAVY) was found in IgG1 antigens. 
IgG4 antigens had a higher isoelectric point than IgG1 antigens. IgG3 antigens showed a 
higher frequency of acidic moles, glutamic acid, oxygen sparing, grand average of 
hydropathy (GRAVY) than IgG4 antigens. Isoelectric point, isoleucine and glutamine 
frequencies were higher in IgG4 antigen than IgG3 antigens. 
 
Figure 3.1 The distribution of features among different schistosome antibody signature 
response proteins. 
Means between different antibody signatures were compared by t-test. Only features with p<0.05 
are shown.  
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Table 3.2 Features differentially distributed between schistosome antibody signatures. 
Means between positive and negative training sets were compared by t-test.  All features with 
p<0.05 are shown.  
Antibody 
Signature 
Comparison 
Features 
  
P-value 
IgE vs IgG1 
 Mean IgE Mean IgG1  
Percentage of basic mole 14.3755 12.8767 0.0266 
Average nitrogen sparing 1.3734 1.3428 0.0297 
IgE vs IgG4 
 Mean IgE Mean IgG4  
Percentage of glutamine 3.7129 2.7942 0.0438 
IgG1 vs IgG3 
 Mean IgG1 Mean IgG3  
Percentage of basic mole 12.8767 14.1125 0.0293 
Grand average of hydropathy 
(GRAVY) 
-0.0984 -0.2279 0.0351 
Arginine and lysine propeptide 
cleavage sites 
0.0465 0.1789 0.0479 
IgG1 vs IgG4 
 Mean IgG1 Mean IgG4  
Isoelectric Point 7.7028 8.6851 0.0302 
IgG3 vs IgG4 
 Mean IgG3 Mean IgG4  
Average oxygen sparing 2.4759 2.4258 0.0159 
Isoelectric Point 7.8824 8.6851 0.0249 
Percentage of glutamic acid 5.0762 3.7709 0.0308 
Grand average of hydropathy 
(GRAVY) 
-0.2279 -0.0359 0.0314 
Percentage of acidic mole 9.8632 7.9474 0.0316 
Percentage of isoleucine 7.4746 8.7245 0.0317 
Percentage of glutamine 3.7011 2.7942 0.0431 
 
 
Further, 82 biochemical and structural sequence features for immunoreactive (combined 
IgE, IgG1, IgG3 and IgG4) and non-immunoreactive schistosome proteins were extracted. 
Twenty-two features were significantly differentially distributed between immunoreactive 
and non-immunoreactive proteins (p<0.05) (Figure 3.2; Table 3.3). Immunoreactive 
proteins showed a higher frequency of cysteine, isoleucine, asparagine, secondary turns, 
and transmembrane helices. Immunoreactive proteins were also found to be more 
aromatic and less acidic than non-immunoreactive proteins. Glutamic acid, alanine and 
secondary helix and were underrepresented in immunoreactive proteins. 45 of 2-mers 
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were significantly differentially distributed between immunoreactive and non-
immunoreactive proteins (p<0.05) ( 
Supplementary Table 3.4). 
 
 
Figure 3.2 Features associated with schistosome immunoreactive proteins. 
Means in the immunoreactivity positive and immunoreactivity negative training sets were compared 
by t-test. All features with p<0.05 are shown. (A) Heatmap of features significantly differentially 
distributed between immunoreactive and non-immunoreactive proteins. Columns represent each 
protein of the training set; rows represent features. (B) Quantiles distribution of significantly 
different features for immunoreactive and non-immunoreactive proteins. Values are depicted in 
color code, ranging from green (low) to red (high).  
 
Table 3.3 Features differentially distributed between immunoreactive and non- 
immunoreactive schistosome proteins. 
Means between positive and negative training sets were compared by t-test. All features with 
p<0.05 are shown.  
Features 
Mean 
immunoreactive 
antigens 
Mean non- 
immunoreactive 
antigens 
P-value 
False 
Discovery 
Rate (FDR) 
Dayhoff statistic of glutamic acid 0.8332 1.0177 0.0006 0.0231 
Isoelectric Point 7.8531 7.0421 0.0007 0.0231 
Percentage of glutamic acid 4.9990 6.1063 0.0008 0.0231 
Secondary sheet fraction 0.2156 0.2395 0.0013 0.0262 
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Percentage of secondary turns 28.1055 23.9200 0.0024 0.0367 
Percentage of acidic mole 10.0226 11.4822 0.0027 0.0367 
Dayhoff statistic of cysteine 1.0421 0.7919 0.0063 0.0740 
Percentage of cysteine 3.0220 2.2966 0.0077 0.0792 
Percentage of secondary helix 31.5573 38.3267 0.0089 0.0810 
Other subcellular location than 
mitochondrial or secretory 
pathway 0.4914 0.6185 
0.0145 
0.1191 
Percentage of secondary sheet 30.5209 26.7700 0.0187 0.1199 
Dayhoff statistic of alanine 0.5751 0.6732 0.0215 0.1199 
Percentage of alanine 4.9460 5.7901 0.0216 0.1199 
Percentage of isoleucine 7.3791 6.4514 0.0219 0.1199 
Dayhoff statistic of isoleucine 1.6397 1.4336 0.0219 0.1199 
Probability of Expression 
Inclusion Bodies 0.7549 0.7154 
0.0278 
0.1427 
Count of transmembrane helices 1.1364 0.7556 0.0363 0.1614 
Percentage of phenylalanine 4.5930 4.2025 0.0370 0.1614 
Dayhoff statistic of phenylalanine 1.2759 1.1673 0.0386 0.1614 
Dayhoff statistic of asparagine 1.3330 1.2128 0.0394 0.1614 
Percentage of asparagine 5.7317 5.2146 0.0415 0.1621 
Percentage of aromatic mole 12.1507 11.3922 0.0464 0.1728 
 
 
3.5.3 Performance evaluation of 21 machine-learning techniques 
The classification accuracy of 21 supervised machine learning techniques was evaluated. 
Classification performance was assessed on a training set of known Schistosoma surface 
proteins and secreted peptides using stratified k-fold (10-fold) cross-validation 
(Supplementary Table 3.5). The 21 classifiers achieved classification accuracies in the 
range of 0.45 - 0.73 (Fig. 3). The combination of the 2 top performing techniques 
(Gaussian Naive Bayes and Bernoulli Naive Bayes) reduced the false positive prediction 
rate, achieving a classification accuracy of 0.71 (Figure 3.3;   
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Table 3.4). The top 2 performing classifiers were therefore incorporated in the 
SchistoTarget webserver.  
 
 
Figure 3.3 Comparison of different supervised machine learning techniques for the 
identification of Schistosoma immunoreactive and non-immunoreactive proteins. 
Classifiers were trained on the training set of known Schistosoma immunoreactive and non- 
immunoreactive proteins and evaluated by stratified k-fold (10-fold) cross-validation. 
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Table 3.4 Comparison of prediction accuracy of 21 supervised machine learning techniques 
for Schistosoma immunoreactive proteins. 
Classifiers were evaluated on the training set of known immunoreactive (n=110) and non-
immunoreactive (n=90) schistosome proteins by stratified k-fold (10-fold) cross-validation. 
Additionally, the classification accuracy of the SchistoTarget classifier was evaluated, which is 
based on the combination of the high performing 2 machine learning techniques. AUC: Area Under 
the Roc Curve. 
Machine Learning Technique 
Immunoreactivity 
Classification Overall 
Accuracy 
Surface 
Classification AUC 
Gradient Boosting Machine (GBM) 0.5650 0.5904 
Ada Boost 0.5550 0.5510 
RBF SVM 0.5200 0.5000 
Linear SVM 0.4500 0.5000 
k-Nearest Neighbors 0.4500 0.5000 
Decision Tree 0.5150 0.5379 
Random Forest 0.5050 0.5308 
Extra Trees Classifier 0.5200 0.5414 
Gaussian Naive Bayes (GNB) 0.7350 0.7187 
Multinomial Naive Bayes (MNB) 0.4850 0.5288 
Bernoulli Naive Bayes (BNB) 0.6900 0.6859 
Linear Discriminant Analysis (LDA) 0.5350 0.5207 
Quadratic Discriminant Analysis (QDA) 0.5700 0.5384 
Ridge Regression 0.4500 0.5000 
Stochastic Gradient Descent (SGD) 0.5850 0.5692 
Perceptron 0.5500 0.5556 
Passive Aggressive 0.5500 0.5576 
Nearest Centroid 0.5400 0.5020 
Multi-layer Perceptron (MLP) 0.5150 0.5217 
Bagging Classifier 0.4850 0.5126 
Gaussian Process Classifier 0.4500 0.5000 
SchistoTarget Voting Classifier (GNB & BNB) 0.7100 0.7131 
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3.5.4 Prediction accuracy of SchistoTarget 
SchistoTarget combines 2 supervised machine learning techniques (Gaussian Naive 
Bayes and Bernoulli Naive Bayes) and classifies proteins based on a majority-voting rule. 
The performance of SchistoTarget was first evaluated on the training set by stratified 10-
fold cross-validation. The final classifier was then evaluated by leave-one-out cross-
validation method on the entire data set. SchistoTarget achieved a sensitivity, specificity 
and overall accuracy of 0.65, 0.72 and 0.69 respectively (Table 3.5;  
Supplementary Table 3.6).  
 
Table 3.5 Comparison of prediction accuracy for immunoreactive schistosome proteins. 
Prediction accuracy was evaluated on the training set of 110 immunoreactive proteins and 90 non-
immunoreactive proteins using the leave-one-out cross-validation method. 
Classifier 
True 
Positive 
True 
Negative 
False 
Positive 
False 
Negative 
Sensitivity Specificity 
Overall 
Accuracy 
Gaussian Naive 
Bayes (GNB) 
98 51 39 12 0.89 0.57 0.75 
Bernoulli Naive 
Bayes (BNB) 
76 56 35 34 0.69 0.62 0.66 
SchistoTarget 
Majority-voting 
Classifier (GNB 
& BNB) 
72 65 25 38 0.65 0.72 0.69 
 
 
3.5.5 User-interface and architecture  
SchistoTarget provides an easy-to-use graphical user interface (GUI), an extensive help 
page and user forum. As input, multiple protein sequences can be uploaded or pasted in 
fasta format. Results are presented in an interactive results page. A table lists the 
sequence ID of each query sequence, the prediction (immunoreactive/non-
immunoreactive) and classification score (number of positive classifiers). A second table 
lists the individual predictions obtained for each of the 2 classifiers. Additionally, the 
classification probabilities are shown. The distribution of sequence features in each query 
protein is presented in a table and in interactive charts and plots (strip chart, heatmap and 
bar chart).  
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SchistoTarget is developed in Python using the Django web framework. The server can 
handle whole-proteome data sets and there is no limit for the number of uploaded query 
sequences. The server performs background task processing and can process multiple 
user sessions in parallel. After data submission, a link is provided which gives access to 
the predictions.  
 
3.6 Conclusion 
SchistoTarget is an easy-to-use and fast classifier for the in silico identification of 
Schistosoma immunoreactive proteins and their features. However, the size of the training 
set, which is relatively small with regards to the different antibody responses, could be 
criticized. This is, however, owed to the currently insufficient data situation. If more data 
are available in future, it is possible to increase sensitivity, specificity and overall accuracy 
of SchistoTarget. The software has been optimized for large data sets and allows rapid 
whole-proteome analysis. SchistoTarget assists researchers in identifying genes important 
for host-parasite interaction, studying anti-schistosome protective immunity, and identifying 
candidate vaccine targets. It therefore represents a valuable tool for improving our 
understanding of Schistosoma pathogenicity and host-parasite interaction, and for 
informing the rational design of much-needed schistosomiasis vaccines. 
 
Supporting information 
Supplementary Table 3.1 List of 82 features used in SchistoTarget for protein classification. 
SchistoProt uses 482 features for protein classification. Of these 482 features, 82 features 
represent biochemical and structural properties (shown in this table). The remaining 400 features 
represent bi-mers of the 20 amino acids (Supplementary Table 3.2). 
Percentage of alanine  Secondary sheet fraction  DayhoffStat of threonine 
 Percentage of cysteine  Average Residue Weight  DayhoffStat of valine 
 Percentage of aspartic acid  Average carbon sparing  DayhoffStat of tryptophan 
 Percentage of glutamic acid  Average nitrogen sparing  DayhoffStat of tyrosine 
 Percentage of phenylalanine  Average sulphur sparing  Percentage of tiny mole 
 Percentage of glycine  Average oxygen sparing  Percentage of small mole 
 Percentage of histidine  Average hydrogen sparing  Percentage of aliphatic mole 
 Percentage of isoleucine  Charge  Percentage of aromatic mole  
 Percentage of lysine 
 Molar Extinction Coefficient 
A280  Percentage of polar mole 
 Percentage of leucine  Absobance A280  Percentage of non polar mole 
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 Percentage of methionine 
 Probability of Expression 
Inclusion Bodies  Percentage of charged mole 
 Percentage of asparagine  DayhoffStat of alanine  Percentage of acidic mole 
 Percentage of proline  DayhoffStat of cysteine  Percentage of basic mole 
 Percentage of glutamine  DayhoffStat of aspartic acid  Percentage of secondary helix 
 Percentage of arginine  DayhoffStat of glutamic acid  Percentage of secondary sheet 
 Percentage of serine  DayhoffStat of phenylalanine  Percentage of secondary turns 
 Percentage of threonine  DayhoffStat of glycine  Percentage of secondary coil 
 Percentage of valine  DayhoffStat of histidine  C-mannosylation sites 
 Percentage of tryptophan  DayhoffStat of isoleucine 
 Proteasomal cleavages (MHC 
ligands) 
 Percentage of tyrosine  DayhoffStat of lysine  N-linked glycosylation sites 
 Molecular Weight  DayhoffStat of leucine 
 Arginine and lysine propeptide 
cleavage sites 
 Aromaticity  DayhoffStat of methionine 
 Binding Regions in Disordered 
Proteins 
 Instability Index  DayhoffStat of asparagine 
 Mitochondrial targeting peptide 
(mTP) 
 Isoelectric Point  DayhoffStat of proline 
 Secretory pathway signal 
peptide (SP) 
 Grand average of hydropathy 
(GRAVY)  DayhoffStat of glutamine  Other subcellular location 
 Secondary helix fraction  DayhoffStat of arginine  Linear B-cell epitopes 
 Secondary turn fraction  DayhoffStat of serine  Class I Immunogenicity Score 
Count of transmembrane helices   
 
 
Supplementary Table 3.2 List of 400 2-mers used in SchistoTarget for protein classification. 
SchistoTarget uses 400 bi-mers of the 20 amino acids for protein classification. 
AA DA FA HA KA MA PA RA TA WA 
AC DC FC HC KC MC PC RC TC WC 
AD DD FD HD KD MD PD RD TD WD 
AE DE FE HE KE ME PE RE TE WE 
AF DF FF HF KF MF PF RF TF WF 
AG DG FG HG KG MG PG RG TG WG 
AH DH FH HH KH MH PH RH TH WH 
AI DI FI HI KI MI PI RI TI WI 
AK DK FK HK KK MK PK RK TK WK 
AL DL FL HL KL ML PL RL TL WL 
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AM DM FM HM KM MM PM RM TM WM 
AN DN FN HN KN MN PN RN TN WN 
AP DP FP HP KP MP PP RP TP WP 
AQ DQ FQ HQ KQ MQ PQ RQ TQ WQ 
AR DR FR HR KR MR PR RR TR WR 
AS DS FS HS KS MS PS RS TS WS 
AT DT FT HT KT MT PT RT TT WT 
AV DV FV HV KV MV PV RV TV WV 
AW DW FW HW KW MW PW RW TW WW 
AY DY FY HY KY MY PY RY TY WY 
CA EA GA IA LA NA QA SA VA YA 
CC EC GC IC LC NC QC SC VC YC 
CD ED GD ID LD ND QD SD VD YD 
CE EE GE IE LE NE QE SE VE YE 
CF EF GF IF LF NF QF SF VF YF 
CG EG GG IG LG NG QG SG VG YG 
CH EH GH IH LH NH QH SH VH YH 
CI EI GI II LI NI QI SI VI YI 
CK EK GK IK LK NK QK SK VK YK 
CL EL GL IL LL NL QL SL VL YL 
CM EM GM IM LM NM QM SM VM YM 
CN EN GN IN LN NN QN SN VN YN 
CP EP GP IP LP NP QP SP VP YP 
CQ EQ GQ IQ LQ NQ QQ SQ VQ YQ 
CR ER GR IR LR NR QR SR VR YR 
CS ES GS IS LS NS QS SS VS YS 
CT ET GT IT LT NT QT ST VT YT 
CV EV GV IV LV NV QV SV VV YV 
CW EW GW IW LW NW QW SW VW YW 
CY EY GY IY LY NY QY SY VY YY 
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Supplementary Table 3.3 Normality distribution checking for the extracted data. 
Data are almost normally distributed and evaluated by mean, median and shape of the data. 
Mean and median have almost similar values for a feature with approximately normal shape of the 
data. 
Feature 
Immuno Positive Immuno Negative 
Mean Median 
Standard 
Deviation 
Kurtosis 
Skewnes
s 
Mean Median 
Standard 
Deviation 
Kurtosis 
Skewnes
s 
 Percentage of alanine 4.9460 4.4956 2.3568 0.2901 0.8463 5.7901 5.2642 2.5102 0.2602 0.6220 
 Percentage of cysteine 3.0220 2.4306 2.1133 2.8361 1.6600 2.2966 1.8299 1.6574 2.6131 1.4920 
 Percentage of aspartic acid 5.0236 4.9948 2.0623 1.8743 0.7225 5.3758 5.4338 1.8780 0.8794 0.1791 
 Percentage of glutamic acid 4.9990 4.9823 2.7380 2.6950 1.2204 6.1063 5.8917 2.6067 3.9283 1.2635 
 Percentage of phenylalanine 4.5930 4.1259 2.0381 0.4035 0.8782 4.2025 4.0025 2.0705 0.3701 0.4769 
 Percentage of glycine 5.4447 5.0862 3.1032 8.0763 2.0363 5.4479 5.0910 2.4012 0.0792 0.3163 
 Percentage of histidine 2.6242 2.6089 1.4432 0.4540 0.6047 2.6124 2.3285 1.5831 0.9920 0.9871 
 Percentage of isoleucine 7.3791 6.7308 2.7637 -0.4327 0.5126 6.4514 6.2926 2.4350 2.2771 1.0099 
 Percentage of lysine 6.5663 6.2163 2.8988 2.0140 1.1418 6.3987 6.3794 2.5442 -0.3862 0.1364 
 Percentage of leucine 9.4004 9.2548 2.8875 -0.3224 0.3897 9.3486 9.4222 2.7692 0.1017 -0.0001 
 Percentage of methionine 2.2153 1.9231 1.2054 5.0717 1.4361 2.7059 2.5063 1.4801 2.5599 1.0468 
 Percentage of asparagine 5.7317 5.4054 2.3095 0.6017 0.8131 5.2146 4.9925 2.2694 -0.5089 0.1316 
 Percentage of proline 4.2063 3.9270 2.0887 2.0587 0.9692 4.2217 4.1538 2.0758 0.5447 0.5708 
 Percentage of glutamine 3.6698 3.4583 1.8007 1.4821 0.9847 3.5941 3.3181 1.6891 1.4598 0.9514 
 Percentage of arginine 4.9328 4.7234 2.2366 0.6487 0.7228 4.8926 5.0618 1.9721 0.4596 0.2966 
 Percentage of serine 8.4559 8.2968 2.9268 0.3450 0.5354 8.3761 7.8780 3.0811 2.7190 1.1497 
 Percentage of threonine 5.6593 5.3818 2.3014 5.9142 1.4271 6.0851 5.9140 2.9220 5.4414 1.8769 
 Percentage of valine 6.1972 6.0142 2.2328 -0.2809 0.4527 6.3023 6.0983 2.0770 0.3521 0.4318 
 Percentage of tryptophan 1.0581 0.8386 0.8933 0.7123 0.9957 1.0812 0.9653 0.9016 0.4217 0.8970 
 Percentage of tyrosine 3.8754 3.5099 2.0150 0.3557 0.7145 3.4962 3.3177 1.9057 -0.4719 0.3314 
 Molecular Weight 
30352.3
545 
24990.2
536 
24641.2
583 
28.7604 4.8485 
34698.0
430 
23858.4
935 
35868.0
100 
20.7509 4.0724 
 Aromaticity 0.0953 0.0950 0.0345 0.0331 0.4103 0.0878 0.0926 0.0353 -0.4870 -0.3911 
 Instability Index 42.0484 41.8757 11.9973 0.3417 0.2284 40.8218 39.3156 12.3232 3.9877 1.2130 
 Isoelectric Point 7.8531 8.2767 1.6127 -0.9500 -0.5434 7.0421 6.8187 1.5540 -1.1323 0.2454 
 Grand average of hydropathy 
(GRAVY) 
-0.2133 -0.2887 0.5217 -0.5459 0.4188 -0.2766 -0.3215 0.4265 0.8844 0.7603 
 Secondary helix fraction 0.3250 0.3134 0.0725 0.7785 0.8200 0.3088 0.3088 0.0603 -0.3885 0.1177 
 Secondary turn fraction 0.2384 0.2373 0.0456 2.3530 0.7045 0.2326 0.2371 0.0528 1.1719 0.2957 
 Secondary sheet fraction 0.2156 0.2190 0.0427 0.3213 -0.0785 0.2395 0.2381 0.0532 0.9198 0.3453 
 Average Residue Weight 
113.284
1 
113.710
4 
3.3662 1.1479 -0.6265 
112.862
5 
112.786
3 
3.1426 0.2051 0.3896 
 Average carbon sparing 5.0553 5.0430 0.2215 0.6251 0.0071 5.0102 5.0192 0.2123 -0.2067 0.1783 
 Average nitrogen sparing 1.3707 1.3738 0.0866 -0.4734 0.2081 1.3619 1.3678 0.0810 0.7657 0.2418 
 Average sulphur sparing 0.0524 0.0476 0.0255 2.6940 1.4091 0.0500 0.0447 0.0222 1.2956 0.9765 
 Average oxygen sparing 2.4744 2.4806 0.0938 -0.5299 0.0163 2.4972 2.4955 0.0745 -0.0476 -0.3603 
 Average hydrogen sparing 9.9481 9.9653 0.2899 2.0631 -0.3977 9.8919 9.8751 0.2795 1.0549 0.0112 
 Charge 6.5364 5.7500 10.4574 5.7992 1.2321 1.9111 2.5000 9.5953 10.3497 -1.8698 
 Molar Extinction Coefficient A280 
30297.0
000 
25440.0
000 
27181.7
115 
22.4812 3.8429 
33264.2
222 
20455.0
000 
34010.2
804 
6.7368 2.3425 
 Absobance A280 1.0174 1.0490 0.5002 -0.3825 0.3096 0.9809 0.8675 0.5428 -0.0794 0.5694 
 Probability of Expression Inclusion 0.7549 0.7690 0.1236 -0.7942 -0.3205 0.7154 0.7055 0.1306 -0.8351 0.2821 
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Bodies 
 DayhoffStat of alanine 0.5751 0.5225 0.2741 0.2908 0.8468 0.6732 0.6120 0.2919 0.2604 0.6226 
 DayhoffStat of cysteine 1.0421 0.8380 0.7287 2.8371 1.6602 0.7919 0.6310 0.5715 2.6121 1.4920 
 DayhoffStat of aspartic acid 0.9134 0.9080 0.3750 1.8756 0.7229 0.9774 0.9880 0.3415 0.8802 0.1794 
 DayhoffStat of glutamic acid 0.8332 0.8300 0.4564 2.6964 1.2207 1.0177 0.9820 0.4345 3.9230 1.2628 
 DayhoffStat of phenylalanine 1.2759 1.1460 0.5662 0.4041 0.8783 1.1673 1.1115 0.5752 0.3696 0.4770 
 DayhoffStat of glycine 0.6482 0.6055 0.3694 8.0837 2.0369 0.6485 0.6060 0.2859 0.0787 0.3166 
 DayhoffStat of histidine 1.3120 1.3045 0.7216 0.4543 0.6048 1.3062 1.1640 0.7916 0.9914 0.9870 
 DayhoffStat of isoleucine 1.6397 1.4960 0.6142 -0.4327 0.5125 1.4336 1.3985 0.5411 2.2771 1.0102 
 DayhoffStat of lysine 0.9948 0.9415 0.4392 2.0135 1.1418 0.9695 0.9665 0.3855 -0.3872 0.1355 
 DayhoffStat of leucine 1.2704 1.2505 0.3902 -0.3218 0.3900 1.2633 1.2735 0.3742 0.1007 -0.0001 
 DayhoffStat of methionine 1.3031 1.1310 0.7090 5.0732 1.4366 1.5918 1.4745 0.8707 2.5606 1.0470 
 DayhoffStat of asparagine 1.3330 1.2570 0.5371 0.6024 0.8136 1.2128 1.1610 0.5278 -0.5088 0.1313 
 DayhoffStat of proline 0.8089 0.7555 0.4017 2.0562 0.9686 0.8119 0.7990 0.3992 0.5449 0.5705 
 DayhoffStat of glutamine 0.9409 0.8865 0.4617 1.4829 0.9849 0.9216 0.8510 0.4331 1.4590 0.9514 
 DayhoffStat of arginine 1.0067 0.9640 0.4565 0.6491 0.7230 0.9985 1.0330 0.4025 0.4589 0.2966 
 DayhoffStat of serine 1.2080 1.1850 0.4181 0.3457 0.5356 1.1966 1.1255 0.4402 2.7188 1.1500 
 DayhoffStat of threonine 0.9278 0.8820 0.3773 5.9195 1.4278 0.9975 0.9700 0.4790 5.4437 1.8772 
 DayhoffStat of valine 0.9390 0.9110 0.3383 -0.2808 0.4527 0.9549 0.9240 0.3147 0.3525 0.4319 
 DayhoffStat of tryptophan 0.8139 0.6450 0.6872 0.7118 0.9956 0.8317 0.7425 0.6935 0.4212 0.8969 
 DayhoffStat of tyrosine 1.1398 1.0320 0.5927 0.3560 0.7147 1.0283 0.9760 0.5605 -0.4725 0.3312 
 Percentage of tiny mole 27.5279 27.9580 4.8215 -0.0968 0.2073 27.9957 28.2925 5.0673 3.3005 0.4420 
 Percentage of small mole 48.6866 48.4270 5.5506 0.7401 0.0657 49.1102 49.3975 5.9865 1.6542 0.0798 
 Percentage of aliphatic mole 22.9766 21.7800 5.2906 0.5344 0.6711 22.1023 22.0165 4.7267 1.2252 0.3727 
 Percentage of aromatic mole  12.1507 12.0480 3.5985 -0.2282 0.2444 11.3922 11.0735 4.1381 -0.6118 -0.1578 
 Percentage of polar mole 47.6625 48.5210 8.9475 -0.8078 -0.2007 48.6557 49.1500 7.4530 0.5382 -0.2236 
 Percentage of non polar mole 52.3375 51.4790 8.9475 -0.8078 0.2007 51.3443 50.8500 7.4530 0.5382 0.2236 
 Percentage of charged mole 24.1459 23.8320 6.7123 0.0048 0.3699 25.3858 25.4105 6.1156 -0.0890 -0.0567 
 Percentage of acidic mole 10.0227 9.6410 3.8062 0.1813 0.5373 11.4822 11.4960 3.5580 0.2016 0.2888 
 Percentage of basic mole 14.1234 13.8280 4.1306 0.9507 0.7495 13.9037 13.4670 3.5688 -0.1384 0.1823 
 Percentage of secondary helix 31.5573 31.5500 14.7100 1.1188 0.6554 38.3267 35.9500 18.3979 0.6728 0.7992 
 Percentage of secondary sheet 30.5209 29.2500 10.7518 -0.4100 0.2397 26.7700 25.5000 10.7425 1.4639 0.8489 
 Percentage of secondary turns 28.1055 26.2500 10.1855 0.6029 0.7428 23.9200 22.5000 9.0675 0.5007 0.4316 
 Percentage of secondary coil 18.4218 18.9500 5.9684 -0.5868 -0.0558 20.3978 20.8000 7.8305 4.2234 1.0398 
 C-mannosylation sites 0.0818 0.0000 0.3354 20.3746 4.4394 0.0222 0.0000 0.1482 42.4083 6.5929 
 Proteasomal cleavages (MHC 
ligands) 
86.3727 70.5000 74.8790 29.3441 4.9212 
100.177
8 
68.5000 
105.044
8 
20.7688 4.0528 
 N-linked glycosylation sites 1.6818 1.0000 1.6861 2.4337 1.4043 1.7889 1.0000 2.3726 10.7747 2.7148 
 Arginine and lysine propeptide 
cleavage sites 
0.1545 0.0000 0.5450 15.4349 3.9018 0.2222 0.0000 0.5359 4.7371 2.3880 
 Binding Regions in Disordered 
Proteins 
1.5000 0.0000 2.7319 5.4284 2.3414 1.8333 0.0000 3.4649 26.1005 4.2541 
 Mitochondrial targeting peptide 
(mTP) 
0.1895 0.1300 0.2077 3.6552 1.9481 0.1475 0.0875 0.1587 5.7522 2.2332 
 Secretory pathway signal peptide 
(SP) 
0.3705 0.1125 0.3949 -1.4161 0.6660 0.2987 0.1075 0.3438 -0.2866 1.1940 
 Other subcellular location 0.4914 0.5385 0.3361 -1.6682 -0.0716 0.6185 0.7530 0.3110 -0.8473 -0.8272 
 Linear B-cell epitopes 
90.6182 71.5000 99.7642 28.4428 4.5888 
114.455
6 
76.0000 
163.394
3 
39.0369 5.5912 
 Class I Immunogenicity Score -0.8027 -0.6406 2.7047 0.7151 -0.3906 -0.4581 -0.7095 3.4638 8.9492 1.4390 
 Count of transmembrane helices 1.1364 0.0000 1.8939 2.3316 1.7894 0.7556 0.0000 1.8861 16.1960 3.6811 
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Supplementary Table 3.4 List of 2-mers differentially distributed between immunoreactive 
and non- immunoreactive schistosome proteins. 
Means between positive and negative training sets were compared by t-test. All features with 
p<0.05 are shown.  
Features 
Mean immunoreactive 
antigens 
Mean non- 
immunoreactive 
antigens 
P-value 
EA 0.0019 0.0045 0.0001 
QW 0.0007 0.0001 0.0004 
GE 0.0019 0.0036 0.0015 
IF 0.0037 0.0018 0.0022 
CI 0.0025 0.0012 0.0033 
FI 0.0052 0.0030 0.0040 
ML 0.0012 0.0025 0.0043 
EV 0.0028 0.0044 0.0045 
VC 0.0023 0.0011 0.0055 
DA 0.0022 0.0037 0.0067 
LN 0.0051 0.0035 0.0095 
SI 0.0066 0.0049 0.0110 
CN 0.0022 0.0010 0.0123 
ES 0.0035 0.0053 0.0134 
TM 0.0006 0.0018 0.0137 
LD 0.0052 0.0033 0.0143 
PV 0.0030 0.0019 0.0188 
RP 0.0024 0.0014 0.0194 
AR 0.0019 0.0031 0.0206 
CK 0.0020 0.0011 0.0209 
YN 0.0022 0.0014 0.0214 
NA 0.0030 0.0021 0.0229 
IP 0.0037 0.0025 0.0231 
AE 0.0024 0.0039 0.0246 
LE 0.0035 0.0048 0.0292 
DT 0.0020 0.0031 0.0298 
NN 0.0040 0.0027 0.0311 
VY 0.0027 0.0017 0.0331 
CV 0.0021 0.0012 0.0341 
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HD 0.0014 0.0008 0.0356 
TL 0.0041 0.0058 0.0386 
MH 0.0011 0.0005 0.0391 
TF 0.0022 0.0034 0.0410 
HM 0.0003 0.0008 0.0411 
RE 0.0019 0.0030 0.0419 
DN 0.0031 0.0022 0.0427 
WT 0.0008 0.0003 0.0430 
GD 0.0024 0.0037 0.0440 
EE 0.0031 0.0045 0.0447 
KQ 0.0038 0.0029 0.0450 
KH 0.0019 0.0011 0.0465 
VE 0.0025 0.0036 0.0473 
EG 0.0017 0.0027 0.0478 
IY 0.0032 0.0021 0.0481 
FD 0.0022 0.0032 0.0484 
 
Supplementary Table 3.5 Comparison of prediction accuracy of 21 supervised machine 
learning techniques for immunoreactive proteins. 
Classifiers were evaluated on the training set of known immunoreactive (n=110) and non-
immunoreactive (n=90) proteins by stratified k-fold (10-fold) cross-validation. 
Machine Learning Technique 
    
Accuracy rounds for 10-fold 
cross-validation 
 
Overall 
Accuracy 
 
1 2 3 4 5 6 7 8 9 10 
 Gradient Boosting Machine (GBM) 0.5 0.5 0.8 0.65 0.55 0.45 0.65 0.5 0.6 0.45 0.5650 
Ada Boost 0.5 0.6 0.6 0.5 0.55 0.45 0.55 0.55 0.7 0.55 0.5550 
RBF SVM 0.55 0.55 0.45 0.55 0.55 0.45 0.45 0.55 0.55 0.55 0.5200 
Linear SVM 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.4500 
k-Nearest Neighbors 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.4500 
Decision Tree 0.4 0.5 0.6 0.4 0.55 0.6 0.4 0.45 0.6 0.65 0.5150 
Random Forest 0.4 0.5 0.55 0.4 0.45 0.7 0.4 0.5 0.7 0.45 0.5050 
Extra Trees Classifier 0.45 0.5 0.55 0.65 0.5 0.55 0.45 0.5 0.6 0.45 0.5200 
Gaussian Naive Bayes (GNB) 0.5 0.65 0.7 0.7 0.7 0.9 0.8 0.75 0.95 0.7 0.7350 
Multinomial Naive Bayes (MNB) 0.55 0.45 0.55 0.5 0.4 0.5 0.45 0.45 0.5 0.5 0.4850 
Bernoulli Naive Bayes (BNB) 0.55 0.7 0.65 0.85 0.65 0.65 0.95 0.55 0.65 0.7 0.6900 
Linear Discriminant Analysis (LDA) 0.45 0.8 0.55 0.5 0.5 0.5 0.45 0.5 0.5 0.6 0.5350 
Quadratic Discriminant Analysis (QDA) 0.55 0.55 0.6 0.45 0.55 0.7 0.55 0.65 0.55 0.55 0.5700 
Ridge Regression 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.4500 
Stochastic Gradient Descent (SGD) 0.45 0.6 0.45 0.6 0.65 0.45 0.75 0.5 0.65 0.75 0.5850 
Perceptron 0.35 0.6 0.5 0.6 0.55 0.5 0.55 0.45 0.75 0.65 0.5500 
Passive Aggressive 0.5 0.55 0.6 0.45 0.5 0.55 0.7 0.4 0.6 0.65 0.5500 
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Nearest Centroid 0.55 0.45 0.55 0.55 0.55 0.55 0.55 0.55 0.55 0.55 0.5400 
Multi-layer Perceptron (MLP) 0.55 0.5 0.5 0.45 0.45 0.75 0.5 0.6 0.35 0.5 0.5150 
Bagging Classifier 0.4 0.35 0.55 0.65 0.6 0.6 0.5 0.4 0.4 0.4 0.4850 
Gaussian Process Classifier 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.4500 
Voting Classifier (GNB & BNB) 0.55 0.65 0.75 0.85 0.65 0.7 0.95 0.6 0.7 0.7 0.7100 
 
 
Supplementary Table 3.6 Comparison of prediction accuracy for immunoreactive proteins. 
Prediction accuracy was evaluated on the training set of 110 immunoreactive proteins and 90 non-
immunoreactive proteins using leave-one-out cross-validation method. 
Immunoreactive Proteins Non-immunoreactive Proteins 
Round  Sequence ID 
 
Expected 
label  
 
Predicted 
GNB 
 
Predicted 
BNB 
Majority-
Voting Round  Sequence ID 
 
Expected 
label  
 
Predicted 
GNB 
 
Predicted 
BNB 
Majority-
Voting 
1 Sj_AY815690 1 0 0 0 111 Sj_AY808749 0 1 1 2 
2 Sj_AY811988 1 0 1 1 112 Sj_AY808751 0 1 1 2 
3 Sj_AY813185 1 0 0 0 113 Sj_AY222874 0 1 1 2 
4 Sj_AY811797 1 0 0 0 114 Smp_046290 0 0 1 1 
5 Sj_AY812161 1 1 1 2 115 Sj_AY813118 0 1 1 2 
6 Sj_AY815838 1 1 1 2 116 Sj_AY811628 0 0 0 0 
7 Sj_AY809620 1 1 1 2 117 Sj_AY809406 0 1 1 2 
8 Sj_AY813602 1 1 1 2 118 Sj_AY915861 0 0 0 0 
9 Sj_AY222951 1 1 1 2 119 Sj_AY813275 0 1 0 1 
10 Sj_AY810792 1 1 1 2 120 Sj_AY915571 0 1 1 2 
11 Sj_EF553319 1 1 1 2 121 Sj_AY809115 0 1 1 2 
12 Sj_AY816000 1 1 1 2 122 Sj_AY915907 0 0 0 0 
13 Sj_AY810537 1 1 0 1 123 Sj_AY815649 0 0 1 1 
14 Sj_AY814261 1 1 1 2 124 Sj_AY813876 0 0 0 0 
15 Sj_AY814497 1 1 0 1 125 Smp_012440 0 1 1 2 
16 Sj_AY815303 1 1 1 2 126 Sj_AY915878 0 0 0 0 
17 Sj_AY222868 1 1 1 2 127 Smp_131910 0 1 1 2 
18 Sj_AY809911 1 1 0 1 128 Sj_AY812720 0 0 0 0 
19 Sj_AY815056 1 0 1 1 129 Sj_AY915721 0 0 0 0 
20 Sj_AY810700 1 1 1 2 130 Sj_AY811479 0 1 1 2 
21 Sj_AY812195 1 0 0 0 131 Smp_141680 0 1 0 1 
22 Sj_AY815945 1 1 1 2 132 Sj_AY811014 0 0 1 1 
23 Sj_AY814817 1 1 1 2 133 Sj_AY809555 0 1 1 2 
24 Sj_AY814738 1 1 1 2 134 Sj_AY814007 0 1 1 2 
25 Sm29 1 1 1 2 135 Sj_AY815489 0 1 1 2 
26 SmTSP2 1 1 1 2 136 Sj_AY815616 0 0 1 1 
27 Smp_139970 1 1 1 2 137 Smp_130300 0 0 0 0 
28 Sj_AY812458 1 1 1 2 138 Sj_AY915793 0 0 1 1 
29 Smp_124240 1 1 1 2 139 Smp_145290 0 1 0 1 
30 Smp_056970.1 1 0 0 0 140 Sj_AY223001 0 1 0 1 
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31 Sj_AY814116 1 1 1 2 141 Smp_077720 0 0 0 0 
32 Sj_AY809550 1 1 1 2 142 Sj_AY808756 0 0 0 0 
33 Sj_AY813467 1 1 0 1 143 Sj_AY814468 0 1 0 1 
34 Sj_AY814537 1 1 1 2 144 Sj_AY816005 0 1 1 2 
35 Sj_AY808785 1 1 0 1 145 Smp_045500 0 1 0 1 
36 Sj_AY808827 1 1 1 2 146 Sj_AY812565 0 0 0 0 
37 Sj_AY812976 1 0 1 1 147 Sj_AY814600 0 0 0 0 
38 Sj_AY809019 1 1 1 2 148 Sj_AY809244 0 1 1 2 
39 Smp_156590 1 1 0 1 149 Smp_121950 0 1 0 1 
40 Smp_050270 1 1 1 2 150 Smp_030920 0 0 0 0 
41 Sj_AY812470 1 1 1 2 151 Sj_AY810132 0 1 1 2 
42 Sj_AY815442 1 1 1 2 152 Sj_AY813942 0 1 1 2 
43 Smp_136640 1 1 1 2 153 Sj_AY809972 0 0 0 0 
44 Sj_AY814430 1 1 1 2 154 Sj_AY813221 0 0 1 1 
45 Sj_AY808953 1 1 1 2 155 Sj_AY226984 0 1 1 2 
46 Smp_008310 1 1 1 2 156 Sj_AY814115 0 0 0 0 
47 Sj_AF036955 1 1 1 2 157 Sj_AY809388 0 0 0 0 
48 Sj_AY813455 1 1 1 2 158 Sj_AY811902 0 0 0 0 
49 Sj_AY815815 1 0 1 1 159 Smp_042020 0 0 1 1 
50 Smp_147140 1 1 1 2 160 Smp_000100 0 0 0 0 
51 Smp_003990 1 1 0 1 161 Sj_L23322 0 0 0 0 
52 Smp_008660.1 1 1 0 1 162 Sj_AY814882 0 0 0 0 
53 Sj_AY813641 1 1 1 2 163 Sj_AY815177 0 0 0 0 
54 Sj_AY812951 1 1 1 2 164 Smp_151490 0 0 0 0 
55 Sj_AY809028 1 1 1 2 165 Sj_AY814107 0 0 0 0 
56 Smp_096760 1 1 0 1 166 Smp_101970 0 0 0 0 
57 Sj_AY812977 1 1 1 2 167 Sj_AY223437 0 1 0 1 
58 Sj_AY812972 1 1 0 1 168 Sj_AY915388 0 1 0 1 
59 Smp_002880.1 1 0 0 0 169 Sj_AF048759 0 0 0 0 
60 Sj_AY814534 1 1 1 2 170 Sj_AY812897 0 0 0 0 
61 Sj_AY815248 1 1 0 1 171 Sj_M63706 0 1 0 1 
62 Sj_AY816003 1 1 1 2 172 Smp_037540.2 0 1 0 1 
63 Sj_AY811126 1 1 1 2 173 Sj_L08198 0 1 0 1 
64 Sj_AY810129 1 1 0 1 174 Sj_AF380366 0 0 0 0 
65 Sj_AY815196 1 1 1 2 175 Sj_AY815038 0 1 1 2 
66 Sj_AY809768 1 1 0 1 176 Sj_AY808393 0 0 0 0 
67 Sj_AY816125 1 1 1 2 177 Sj_AY813732 0 1 1 2 
68 Sj_AY808893 1 1 1 2 178 Smp_095360.3 0 0 0 0 
69 Sj_AY808459 1 1 1 2 179 Smp_153390.2 0 1 1 2 
70 Sj_AY533028 1 1 1 2 180 Sj_AY812989 0 0 0 0 
71 Sj_AF072327.1 1 1 1 2 181 Smp_017430 0 1 1 2 
72 Sj_AY815419 1 1 1 2 182 Sj_AY810680 0 0 1 1 
73 Smp_045200 1 1 0 1 183 Sj_AY808379 0 1 1 2 
74 Sj_AY808903 1 1 1 2 184 Sj_AY812658 0 0 0 0 
75 Smp_075420 1 1 1 2 185 Sj_AY813104 0 0 0 0 
76 Sj_AY810692 1 1 1 2 186 Sj_AY816048 0 0 0 0 
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77 Sj_AY812591 1 1 1 2 187 Smp_137410 0 0 0 0 
78 Sj_AY808650 1 1 1 2 188 Sj_AY813229 0 0 0 0 
79 Sj_AY814158 1 1 0 1 189 Smp_137170 0 0 0 0 
80 Smp_124050.4 1 1 1 2 190 Sj_AY810377 0 0 1 1 
81 Sj_AY815101 1 1 1 2 191 Sj_AY813612 0 0 0 0 
82 Sj_AY223099 1 1 0 1 192 Sj_AY813810 0 0 0 0 
83 Sj_AY810722 1 1 1 2 193 Sj_M14654 0 0 0 0 
84 Sj_AY813439 1 1 1 2 194 Sj_AY809239 0 0 0 0 
85 Sj_AY815834 1 1 0 1 195 Sj_AY815164 0 1 0 1 
86 Sj_AY223465 1 0 0 0 196 Sj_AY808531 0 0 0 0 
87 Sj_AY816044 1 1 1 2 197 Smp_059480 0 1 1 2 
88 Sj_AY814977 1 1 1 2 198 Sj_AY814401 0 0 0 0 
89 Smp_176200.2 1 1 1 2 199 Sj_AY813596 0 1 0 1 
90 Sj_AY808899 1 1 0 1 200 Sj_AY815791 0 1 1 2 
91 Sj_AY222926 1 1 0 1 
      92 Sj_AY812444 1 1 1 2 
      93 Sj_AY808494 1 1 0 1 
      94 Sj_AY814201 1 1 1 2 
      95 Sj_AY810705 1 1 0 1 
      96 Sj_AY809338 1 1 1 2 
      97 Sj_AY814549 1 1 0 1 
      98 Smp_140000 1 1 1 2 
      99 Sj_AY814773 1 1 1 2 
      100 Sj_AY808797 1 1 0 1 
      101 Sj_AY811460 1 0 0 0 
      102 Smp_194970 1 1 0 1 
      103 Sj_AY809286 1 1 1 2 
      104 Sj_AY814310 1 1 1 2 
      105 Sj_AY808337 1 1 1 2 
      106 Smp_004470.2 1 1 0 1 
      107 Smp_005740 1 1 1 2 
      108 Sj_AY809526 1 1 1 2 
      109 Smp_040680 1 1 1 2 
      110 Smp_151480 1 1 0 1 
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Chapter 4 Identifying Putative Drug and Vaccine Targets 
Against Schistosomiasis 
 
4.1 Foreword 
This chapter describes a comparative analysis of Schistosoma genomes and an 
integrative bioinformatics pipeline to identify putative vaccine targets against 
schistosomiasis. A set of genes were selected by comparative analysis of several parasite 
genomes, then these genes were annotated using the developed tools described in 
chapters 2 and 3. Potential antigens as drug and vaccine targets were selected using 
Gene Ontology and Swiss-Prot annotations. Finally, protein-protein and protein-chemical 
interactions were explored using STRING and STICH. 
 
4.2 Abstract 
In addition to providing a unique resource for studying evolutionary processes, 
Schistosoma genomes can be used to identify genes important for host-parasite 
interactions and to discover novel vaccine and drug targets. Conventional approaches for 
anti-schistosomiasis vaccine development have focused on a limited number of antigens. 
Recently whole genome sequence data for the three main schistosome species infecting 
humans (S. mansoni, S. haematobium and S. japonicum) became available. These 
datasets provide a unique foundation for a novel approach to anti-schistosomiasis vaccine 
development. Here in this project, putatively important protective schistosome antigens 
have been identified from genomic-based information using novel Bioinformatics methods 
in comparative analysis of the genomes of the three schistosomes infecting humans, 
Schistosoma bovis, which infects ruminants, and the related, but free-living flatworm, 
Schmidtea mediterranea. 345 core genes were identified which are present in all three 
human-infecting schistosome genomes but absent in S. bovis and S. mediterranea. 
Further, targeting immunogenic surface and secretory proteins 20 proteins as potential 
vaccine targets have been selected. These potential vaccine targets were then in silico 
characterized using Bioinformatics methods to indicate their biological relevance. These 
putative vaccine targets can be biologically validated by wet laboratory experiments in 
animals. The Python scripts, used for the analysis, are available from 
https://github.com/shihabhasan/schistocomp. 
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4.3 Introduction 
Blood flukes of the genus Schistosoma (phylum Platyhelminthes) are the cause of 
schistosomiasis, a chronic disease and a major health concern in Africa and the Asia 
Pacific Region and Africa.  It is considered by the World Health Organization as the 
second most socioeconomically devastating and second most common parasitic 
disease1,2,  causing at least 300,000 deaths annually3. Treatment relies mainly on a single  
drug, praziquantel, which  does not prevent re-infection and there is a constant concern 
that drug resistance might develop2. Three main Schistosoma species infect humans: S. 
mansoni and S. japonicum, cause intestinal/hepatic schistosomiasis whereas S. 
haematobium results in urinogenital disease59. Conventional approaches, focusing on a 
very limited number of antigens for anti-schistosomiasis vaccine development, have thus 
far failed59. Driven by the need to improve treatment and prevent infection, the genomes of 
these three schistosomes have recently become publicly available20-22. These genomic-
based datasets provide a unique resource for a novel approach to schistosomiasis vaccine 
development but it has not been clear how this information can be used to identify key 
antigens as vaccine targets.  
Schistosome tegumental surface  proteins are responsible for essential functions crucial 
for parasite survival23 and secretory peptides modulate host immune responses40. During 
the past decade, schistosome surface and secretory proteins have been considered 
sources of putative vaccine antigens. Recently, immunomics approaches have been 
utilized successfully for vaccine antigen discovery15,36. 
I hypothesise that protein-encoding  genes present in S. mansoni, S. haematobium and S. 
japonicum but absent in the genomes of Schistosoma bovis, which infects ruminants,   and 
Schmidtea mediterranea, a free-living flatworm  phylogenetically related to schistosomes64, 
might provide new insight on suitable candidates as schistosomiasis vaccine targets 
(Figure 4.1).  
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Figure 4.1 Hypothesis to identify putative vaccine targets. 
Genes present in human-infecting genomes but absent animal and non-parasitic free-living 
flatworm might be potential antigens for vaccine targets. S. mansoni, S. haematobium and S. 
japonicum infect human. Schistosoma bovis infects ruminants and Schmidtea mediterranea is a 
non-parasitic, free-living flatworm.   
 
4.4 Methods 
4.4.1 Data 
Protein sequences for the three human infecting schistosomes were collected from the 
SchistoDB65 database. The S. mansoni proteome contains 11,774 proteins, the S. 
haematobium (Egyptian strain) proteome has 11,140 proteins and the S. japonicum (Anhui 
strain) proteome comprises 12,657 proteins. The S. bovis genome has been sequenced 
and predicted 12,924 proteins for a project at QIMR Berghofer Medical Research Institute, 
Australia. The Schmidtea mediterranea proteome sequences were  collected from the 
WormBase ParaSite66 database which contains 29,850 proteins. The Gene Ontology67 
(GO) annotations for S. mansoni, extracted (on July 05, 2017) from the GO Consortium 
annotation68 using AmiGO69 ,  contains 25,959 annotations. 13,517 S.mansoni protein 
annotations were extracted from Swiss-Prot70.  
 
Chapter 4 
78 
 
4.4.2 Orthologous/core genes prediction 
I used the Reciprocal Best Hits (RBH) method incorporating NCBI BLAST71,72 to identify 
orthologous proteins among the three human infecting Schistosoma species. RBH is found 
when proteins from different organisms that are each other's top BLAST hit, each in a 
different genome, when the proteomes from those organisms are compared to each other 
genomes73.  
The steps for RBH are: i) Take two FASTA files (species A and species B), ii) Build a 
BLAST database for each, iii) Run reciprocal BLAST searches (A vs B, and B vs A), iv) 
Filter the High-scoring Segment Pairs (HSPs), and v) Then compile a list of the reciprocal 
best hits (RBH). The filter E-value of 1e-5, minimum percentage identity for BLAST 
matches of 70% and minimum percentage query coverage for BLAST matches of 70% as 
the best scoring match for BLAST searching were used (Figure 4.2). The RBH was 
performed for two species at a time among all the Schistosoma species and the core 
genes were identified. The human-infecting Schistosoma core genes present in S. bovis 
and Schmidtea mediterranea by the RBH method were identified and excluded them as 
genes of interest.  
 
  
 
Figure 4.2 RBH method to select orthologous proteins from two different genomes. 
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RBH runs reciprocal BLAST searches against the proteomes of two species (species A vs species, 
and species B vs species A). The best scoring match is selected if the High-scoring Segment Pairs 
(HSPs) have at least 70% identity, 70% alignment length and 1e-5 E-value. 
 
4.4.3 Protein annotation 
Surface and secretory proteins were predicted and selected using SchistoProt74. Then, 
Schistotarget75 was used to predict which of the surface or secretory molecules were 
immunoreactive proteins. The immunoreactive proteins were further annotated using the 
GO68 and Swiss-Prot70 data available for S. mansoni. GO Enrichment Analysis for the 
selected proteins was performed using PANTHER (protein annotation through evolutionary 
relationship) Classification System76,77. The protein-protein direct (physical) interactions, as 
well as indirect (functional) interactions were predicted using STRING78. Interactions 
between proteins and chemicals were predicted using STITCH79. 
 
4.5 Results 
4.5.1 Vaccine Target Identification 
An integrative bioinformatics pipeline was employed to identify schistosome vaccine 
targets (Figure 4.3).  
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Figure 4.3 Bioinformatics pipeline used to characterize and curate putative schistosome 
vaccine targets. 
In step1, core genes in the human-infecting S. mansoni, S. haematobium and S. japonicum 
genomes were predicted. In steps 2–3, orthologs from the free-living flatworm Schmidtea 
mediterranea and S. bovis were removed from the core genes from the three human-infecting 
schistosomes. In steps 4 and 5, surface and secretory proteins were predicted using SchistoProt; 
protein immunoreactivity was predicted using SchiatoTarget. In step 6, all possible vaccine targets 
were functionally annotated using GO, SwissProt, STRING and STICH. 
 
 
First, 6,016 orthologous proteins between S. mansoni and S. haematobium, 4,209 
orthologous proteins between S. mansoni and S. japonicum and 4,305 orthologous 
proteins between S. haematobium and S. japonicum we identified by BLAST RBH. We 
identified 2,701 core proteins in these three genomes. Then, 177 orthologous proteins 
were identified between the genomes of these three schistosome species and Schmidtea 
mediterranea. After removing these 177 orthologs from the core proteins, 2,524 proteins 
remained. 2,179 of the 2,524 proteins were also present in the S. bovis proteome. Finally, 
345 proteins (Figure 4.4; Supplementary Table 4.1), which remained after removing these 
orthologs from the 2,524 proteins selected in the previous step, were explored further. 
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Figure 4.4 Steps involved in the selection of potential vaccine targets using proteomes from 
different flatworm species. 
Step-1 uses RBH against the proteomes from the three human-infecting Schistosoma spp.to 
predict core genes. S. mediterranea orthologs were excluded from the core genes in step-2. In 
step-3, S. bovis orthologs were excluded from the genes obtained in step-2. 
 
4.5.2 Prediction of surface, secretory and immunoreactive proteins 
83 surface proteins and 106 secretory proteins were predicted from the 345 identified 
proteins. After merging both surface and secretory proteins, 135 proteins (Supplementary 
Table 4.2) remained, of which 45 were predicted to be immunreactive (Supplementary 
Table 4.3). 
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4.5.3 Protein annotation 
44 proteins were mapped to the GO database. 20 proteins (Table 4.1; Supplementary 
Table 4.4) were selected using GO annotation with biological processes and molecular 
functions, which are important for host-parasite interactions such as catalytic activity, 
transmembrane transporter activity, lipid transporter activity, serine-type peptidase activity, 
serine protease inhibitory activity, G-protein coupled receptor activity and oxidoreductase 
activity80-86. These 20 proteins were further annotated using Swiss-Prot (Table 4.1). 
 
Table 4.1 20 protein antigens, and their annotation, identified as potential schistosomiasis 
vaccine targets. 
Proteins were selected based on comparative genomics and GO annotation. 
S. mansoni 
gene ID 
S. mansoni 
UniProt Gene 
Symbols 
S. japonicum 
ortholog 
S. 
haematobium 
ortholog Annotation 
Smp_002870 G4VLJ1 Sjp_0089930 MS3_07466 G-protein modulator 
Smp_017620 G4VGX8 Sjp_0007190 MS3_05025 Amine oxidase 
Smp_018990 G4VG38 Sjp_0075950 MS3_04781 60s ribosomal protein L9 
Smp_048540 G4VSB9 Sjp_0060110 MS3_05665 Dolichol kinase 
Smp_054010 G4VHR0 Sjp_0079140 MS3_03571 Cationic amino acid transporter 
Smp_083990 G4LVW7 Sjp_0048940 MS3_02574 Cationic amino acid transporter 
Smp_124020 G4V6N7 Sjp_0094660 MS3_09149 
Heparan sulfate 6-o-
sulfotransferase 
Smp_132080 G4VP00 Sjp_0063250 MS3_07393 Sugar transporter  
Smp_132730 G4LUC7 Sjp_0108420 MS3_06574 G-protein coupled receptor 
Smp_143800 G4VSR1 Sjp_0005570 MS3_01189 Cation transporter 
Smp_145900 G4VMQ4 Sjp_0061450 MS3_00627 Dihydroceramide desaturase 
Smp_147070 G4VKU1 Sjp_0067720 MS3_02401 
Sodium-coupled neutral amino 
acid transporter 
Smp_149450 G4VKS3 Sjp_0026610 MS3_03222 trna-dihydrouridine synthase 
Smp_150380 G4VAL8 Sjp_0099280 MS3_07308 
Spingomyelin synthetase-
related 
Smp_155050 G4LY67 Sjp_0002300 MS3_00517 
Agrin, Serine protease inhibitor 
Kazal-type 5-related 
Smp_163970 G4VL47 Sjp_0023750 MS3_04617 Carboxypeptidase 
Smp_167190 G4V7D5 Sjp_0133070 MS3_05670 Calcium ion binding 
Smp_178490 G4LZX3 Sjp_0089300 MS3_08753 Solute carrier family 35 
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member d1, UDP-sugar 
transporter 
Smp_180500 G4M0E1 Sjp_0010790 MS3_08237 
Phospholipid scramblase-
related transfer protein 
Smp_199690 G4M1Z7 Sjp_0052970 MS3_09387 G-protein coupled receptor 
 
 
4.5.4 Protein-protein and protein-chemical interactions  
I next examined protein-protein and protein-chemical interactions. Smp_007900.1_mRNA 
and Smp_050940.1_mRNA, which are 60S ribosomal proteins, effective centre of the 
network (hub), had most interactions with the 20 antigens (Figure 4.5) and these might 
have potential as mRNA vaccines. Magnesium Adenosine 5'-triphosphate (MgATP), an 
adenine nucleotide containing three phosphate groups esterified to the sugar moiety, 
effective centre of the network (hub), had most interactions with the 20 antigens (Figure 
4.6) and might be a potential anti-schistosome drug target. 
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Figure 4.5 Protein-protein interactions for the 20 antigens with other proteins using 
STRING. 
Stronger associations are represented by thicker lines.  
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Figure 4.6 Protein-chemical interactions for the 20 antigens using STICH. 
Stronger associations are represented by thicker lines. Protein-protein interactions are shown in 
grey and protein-chemical interactions in green. 
 
4.6 Conclusion 
This innovative study provides novel insights into human schistosome genomes and 
identified gene functions for host-parasite interaction. By using comparative genomics 
analysis combined with an integrative bioinformatics pipeline I identified putative vaccine 
antigen candidates and drug targets by assessing their surface and secretory properties, 
immunogenicity, biological process and molecular function. These novel targets should 
now be biologically validated by wet laboratory experiments in animals and then clinically. 
It is particularly noteworthy that many of these molecules have not previously been 
identified as anti-schistosome intervention targets. The comparative genomics analysis 
approach for identifying new drug and vaccine candidates represents a valuable resource 
not only for the Schistosoma research community but the protocol I developed can be 
used as a blueprint for other important parasitic diseases including malaria.   
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Supporting information 
Supplementary Table 4.1 345 core genes of the 3 major schistosome spp. infecting humans 
which are absent in S. bovis and Schmidtea mediterranea. 
Orthologs were predicted by the RBH method. RBH runs reciprocal BLAST searches against the 
proteomes of two species (species A vs species and species B vs species A).   
The best scoring matches were selected if the High-scoring Segment Pairs (HSPs) had at least 
70% identity, 70% alignment length and an E-value of 1e-5.  
S. mansoni 
Ortholog 
S. 
japonicum 
ortholog 
S. 
haematobium 
ortholog 
Description 
Smp_165440.1 Sjp_0098730 MS3_06713 Putative netrin receptor unc5  
Smp_158970.1 Sjp_0023040 MS3_06013 DEAD box ATP-dependent RNA helicase, putative  
Smp_124030.1 Sjp_0000430 MS3_09150 Putative uncharacterized protein  
Smp_070680.1 Sjp_0059570 MS3_10545 Putative uncharacterized protein  
Smp_203970.1 Sjp_0003090 MS3_08850 Putative uncharacterized protein Smp_203970  
Smp_126350.1 Sjp_0018830 MS3_00804 Putative glutamate receptor, NMDA  
Smp_038080.1 Sjp_0004060 MS3_03297 Putative importin beta-1  
Smp_149640.1 Sjp_0027740 MS3_07138 Putative uncharacterized protein  
Smp_149450.1 Sjp_0026610 MS3_03222 Putative trna-dihydrouridine synthase  
Smp_147320.1 Sjp_0041890 MS3_06838 Putative camp-dependent protein kinase regulatory chain  
Smp_159140.1 Sjp_0034750 MS3_02005 Putative organic anion transporter  
Smp_030350.1 Sjp_0012180 MS3_05723 Subfamily S1A unassigned peptidase (S01 family)  
Smp_152790.1 Sjp_0053520 MS3_10206 Ras-related GTP binding rag A,B/gtr1  
Smp_003250.1 Sjp_0023500 MS3_01004 Putative uncharacterized protein  
Smp_069380.1 Sjp_0002050 MS3_03702 Putative histone deacetylase 4, 5  
Smp_137580.1 Sjp_0009150 MS3_07623 Helicase, putative  
Smp_125590.1 Sjp_0076780 MS3_09275 Putative uncharacterized protein  
Smp_179320.1 Sjp_0045200 MS3_08447 Eukaryotic translation initiation factor 2c,putative  
Smp_131090.1 Sjp_0115150 MS3_08947 Putative cornichon  
Smp_121640.1 Sjp_0113410 MS3_05851 Transcription initiation factor iif (Tfiif),beta subunit-related  
Smp_101310.1 Sjp_0068750 MS3_10554 Mizf protein, putative  
Smp_046980.1 Sjp_0079920 MS3_02903 Putative uncharacterized protein  
Smp_074010.1 Sjp_0080960 MS3_00563 Putative 8-oxoguanine DNA glycosylase  
Smp_025130.1 Sjp_0028480 MS3_03667 Putative rna binding motif protein  
Smp_159370.1 Sjp_0102090 MS3_01393 Family M13 unassigned peptidase (M13 family)  
Smp_033930.1 Sjp_0091400 MS3_10169 Phosphatidylcholine transfer protein, putative  
Smp_037900.1 Sjp_0006630 MS3_07488 Family S12 unassigned peptidase (S12 family)  
Smp_155330.1 Sjp_0010750 MS3_05152 Serine/threonine kinase  
Smp_085680.1 Sjp_0082080 MS3_01929 Guanylate cyclase  
Smp_175460.1 Sjp_0003880 MS3_06648 Putative uncharacterized protein  
Smp_020220.1 Sjp_0043790 MS3_00034 Putative zeta-coat protein  
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Smp_145840.1 Sjp_0018790 MS3_01354 Putative wd-repeat protein  
Smp_079700.1 Sjp_0074890 MS3_10779 Putative ga binding protein beta chain (Transcription factor 
e4tf1-47)  
Smp_067540.1 Sjp_0064510 MS3_04788 Putative uncharacterized protein  
Smp_150470.1 Sjp_0047780 MS3_04903 Putative uncharacterized protein  
Smp_044820.1 Sjp_0019750 MS3_06948 Putative uncharacterized protein  
Smp_171440.1 Sjp_0115540 MS3_05306 Putative mind bomb  
Smp_178850.1 Sjp_0073870 MS3_10823 Poly(A) polymerase, putative  
Smp_155610.1 Sjp_0006350 MS3_05713 Calmodulin-5/6/7/8 (CaM-5/6/7/8), putative  
Smp_024900.1 Sjp_0034000 MS3_05116 Putative retinoblastoma-like protein  
Smp_168130.1 Sjp_0113240 MS3_09956 Phosphatase and actin regulator, putative  
Smp_199420.1 Sjp_0088760 MS3_03989 Serine/threonine kinase  
Smp_194520.1 Sjp_0006470 MS3_02110 Putative myst histone acetyltransferase  
Smp_147920.1 Sjp_0070430 MS3_03684 Ubiquitinyl hydrolase-BAP1 (C12 family)  
Smp_136360.1 Sjp_0029860 MS3_10757 Putative dna cross-link repair protein pso2/snm1  
Smp_000170.1 Sjp_0004460 MS3_03331 Neurocalcin, putative  
Smp_125640.1 Sjp_0066360 MS3_05209 Syntaxin-12, putative  
Smp_133040.1 Sjp_0051760 MS3_09170 Putative uncharacterized protein  
Smp_012470.1 Sjp_0050140 MS3_11234 Putative 26s protease regulatory subunit  
Smp_178490.1 Sjp_0089300 MS3_08753 Solute carrier family 35 member d1, putative  
Smp_140530.1 Sjp_0060970 MS3_11377 Putative replication factor C / DNA polymerase III gamma-tau 
subunit  
Smp_150380.1 Sjp_0099280 MS3_07308 Spingomyelin synthetase-related  
Smp_017620.1 Sjp_0007190 MS3_05025 Putative uncharacterized protein  
Smp_181380.1 Sjp_0101990 MS3_10416 Putative 26s proteasome non-ATPase regulatory subunit  
Smp_141860.1 Sjp_0075110 MS3_00212 Putative heat containing protein  
Smp_086210.1 Sjp_0002580 MS3_05501 Dihydropteridine reductase  
Smp_141470.1 Sjp_0014940 MS3_00828 Putative cytochrome C oxidase assembly protein cox11  
Smp_162960.1 Sjp_0037410 MS3_10042 Putative uncharacterized protein  
Smp_146830.1 Sjp_0101190 MS3_05591 Putative uncharacterized protein  
Smp_006000.1 Sjp_0015700 MS3_01248 Putative eukaryotictranslation initiation factor 3 subunit  
Smp_048650.1 Sjp_0114570 MS3_09473 Putative histidine triad (Hit) protein  
Smp_148010.1 Sjp_0021030 MS3_06956 Putative snf2 histone linker phd ring helicase  
Smp_158920.1 Sjp_0113430 MS3_00867 Putative uracil-DNA glycosylase  
Smp_078240.1 Sjp_0110520 MS3_01456 Putative uncharacterized protein  
Smp_124310.1 Sjp_0028700 MS3_07274 Putative 5-AMP-activated protein kinase , beta subunit  
Smp_002160.1 Sjp_0000610 MS3_04916 Putative uncharacterized protein  
Smp_133450.1 Sjp_0001360 MS3_03118 Jnk stimulatory phosphatase-related  
Smp_016840.1 Sjp_0040340 MS3_00910 Putative uncharacterized protein  
Smp_106930.1 Sjp_0044680 MS3_11411 Heat shock 70 kDa protein homolog  
Smp_018640.1 Sjp_0095380 MS3_07841 Putative uncharacterized protein  
Smp_026230.1 Sjp_0029800 MS3_07822 Putative uncharacterized protein  
Smp_162940.1 Sjp_0055590 MS3_08868 Putative amine oxidase  
Smp_136470.1 Sjp_0027350 MS3_08612 Putative rho/rac guanine nucleotide exchange factor  
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Smp_020200.1 Sjp_0043800 MS3_00007 Putative dead box ATP-dependent RNA helicase  
Smp_127180.1 Sjp_0024150 MS3_08448 Putative uncharacterized protein  
Smp_166400.1 Sjp_0008030 MS3_09530 Putative dead box ATP-dependent RNA helicase  
Smp_054820.1 Sjp_0048190 MS3_03639 Putative uncharacterized protein  
Smp_071390.1 Sjp_0065450 MS3_01650 Adenylate kinase  
Smp_144950.1 Sjp_0000840 MS3_00778 Putative centrosomal protein of 41 kDa (Cep41 protein) (Testis-
specificprotein A14 protein)  
Smp_142130.1 Sjp_0134030 MS3_06448 Putative uncharacterized protein  
Smp_050130.1 Sjp_0045030 MS3_03863 Putative uncharacterized protein  
Smp_132260.1 Sjp_0026310 MS3_00944 Serine/threonine kinase  
Smp_094810.1 Sjp_0059010 MS3_04021 Peptidyl-prolyl cis-trans isomerase E  
Smp_210570.1 Sjp_0053260 MS3_05559 Mername-AA168 protein (M67 family)  
Smp_149000.1 Sjp_0045080 MS3_03862 Protein phosphatase 2C, putative  
Smp_139400.1 Sjp_0072070 MS3_01763 Putative tensin  
Smp_168670.1 Sjp_0046560 MS3_02488 cGMP-dependent protein kinase,putative  
Smp_181350.1 Sjp_0041470 MS3_04867 Huntingtin interacting protein-related  
Smp_049890.1 Sjp_0012860 MS3_07669 WD-repeat protein, putative  
Smp_153520.1 Sjp_0121100 MS3_08383 Putative uncharacterized protein  
Smp_153430.1 Sjp_0085650 MS3_10500 Putative arginyl-tRNA synthetase  
Smp_159110.1 Sjp_0067770 MS3_06941 Putative bullous pemphigoid antigen 1, isoform 5 (BPA) 
(Hemidesmosomal plaque protein) (Dystonia musculorum 
protein) (Dystonin)  
Smp_157820.1 Sjp_0065320 MS3_03496 Putative ataxia telangiectasia mutated (Atm)  
Smp_193050.1 Sjp_0029990 MS3_09933 Putative uncharacterized protein  
Smp_018890.1 Sjp_0031010 MS3_04778 Phosphoglycerate kinase  
Smp_015710.1 Sjp_0076750 MS3_05869 Putative 6-phosphofructo-2-kinase/fructose-2,6-bisphosph at 
ase  
Smp_211290.1 Sjp_0013170 MS3_03109 Putative uncharacterized protein  
Smp_130900.1 Sjp_0000570 MS3_01046 Putative alpha catenin  
Smp_029310.1 Sjp_0043510 MS3_03741 Phosphatidylinositol transfer protein  
Smp_123080.1 Sjp_0044580 MS3_05150 Putative sarcoplasmic calcium-binding protein (SCP)  
Smp_133510.1 Sjp_0116270 MS3_00213 Putative aldehyde dehydrogenase  
Smp_038300.1 Sjp_0009750 MS3_04095 Putative uncharacterized protein  
Smp_132930.1 Sjp_0111900 MS3_06787 Putative uncharacterized protein  
Smp_139430.1 Sjp_0078500 MS3_07596 Phosphoinositol 4-phosphate adaptor protein,putative  
Smp_196150.1 Sjp_0019390 MS3_10464 Selenoprotein O-like  
Smp_105760.1 Sjp_0073210 MS3_00750 Putative innexin  
Smp_086460.1 Sjp_0056170 MS3_08022 Tho2 protein, putative  
Smp_132550.1 Sjp_0071480 MS3_04780 Putative rhoptry protein  
Smp_091770.1 Sjp_0120990 MS3_09612 Protein farnesyltransferase alpha subunit,putative  
Smp_210090.1 Sjp_0082760 MS3_02097 Adapter-related protein complex 3, beta subunit  
Smp_066250.1 Sjp_0046730 MS3_01279 Putative uncharacterized protein  
Smp_155050.1 Sjp_0002300 MS3_00517 Agrin, putative  
Smp_152060.1 Sjp_0015940 MS3_05287 Putative uncharacterized protein  
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Smp_151960.1 Sjp_0085640 MS3_03306 Putative rho gtpase activating protein  
Smp_169360.1 Sjp_0045420 MS3_06492 Putative kinesin  
Smp_156160.1 Sjp_0067370 MS3_01436 Putative uncharacterized protein  
Smp_160700.1 Sjp_0060210 MS3_10140 Putative set domain protein  
Smp_035460.1 Sjp_0117330 MS3_07339 Putative nicotinate phosphoribosyltransferase  
Smp_079310.1 Sjp_0025150 MS3_03393 Transmembrane protein tmp21-related  
Smp_151060.1 Sjp_0018270 MS3_07863 Family S60 non-peptidase homologue (S60 family)  
Smp_124500.1 Sjp_0011910 MS3_05903 ADAMTS peptidase (M12 family)  
Smp_088660.1 Sjp_0008180 MS3_03445 Putative uncharacterized protein  
Smp_024000.1 Sjp_0062010 MS3_07663 Putative vacuolar protein sorting (Vps33)  
Smp_159400.1 Sjp_0022690 MS3_01380 Phospholipid transport protein  
Smp_092770.1 Sjp_0074500 MS3_10406 Coatomer subunit gamma  
Smp_141040.1 Sjp_0133750 MS3_00029 Putative striatin  
Smp_136510.1 Sjp_0022020 MS3_05045 Putative uncharacterized protein  
Smp_139530.1 Sjp_0071360 MS3_05420 Cellular tumor antigen P53, putative  
Smp_150550.1 Sjp_0104790 MS3_02206 Putative titin  
Smp_178780.1 Sjp_0106170 MS3_02166 Meso-ectoderm gene expression control protein  
Smp_129010.1 Sjp_0057760 MS3_10636 Putative uncharacterized protein  
Smp_159890.1 Sjp_0013530 MS3_09839 Metallocarboxypeptidase D peptidase unit 2 (M14 family)  
Smp_071840.1 Sjp_0030250 MS3_06507 6-phosphogluconate dehydrogenase, decarboxylating  
Smp_158300.1 Sjp_0067840 MS3_01315 Putative uncharacterized protein  
Smp_041770.1 Sjp_0000700 MS3_00771 Serine/threonine kinase  
Smp_173100.1 Sjp_0024780 MS3_03383 Axon guidance protein  
Smp_139070.1 Sjp_0099920 MS3_00607 3bp-1 related rhogap  
Smp_132090.1 Sjp_0063260 MS3_07392 Putative wd40 protein  
Smp_048540.1 Sjp_0060110 MS3_05665 Putative uncharacterized protein  
Smp_147070.1 Sjp_0067720 MS3_02401 Putative amino acid transporter  
Smp_131770.1 Sjp_0010590 MS3_03196 DEAD box ATP-dependent RNA helicase, putative  
Smp_136750.1 Sjp_0048140 MS3_09438 Putative e3 ubiquitin-protein ligase Bre1  (DBre1)  
Smp_055130.1 Sjp_0089630 MS3_09372 Putative zinc finger protein  
Smp_167650.1 Sjp_0004330 MS3_01750 Putative uncharacterized protein  
Smp_163970.1 Sjp_0023750 MS3_04617 Family S10 non-peptidase homologue (S10 family)  
Smp_037200.1 Sjp_0092900 MS3_11285 Putative uncharacterized protein  
Smp_012580.1 Sjp_0065880 MS3_10812 Putative guanine-nucleotide-exchange-factor  
Smp_134510.1 Sjp_0050230 MS3_01983 Putative uncharacterized protein  
Smp_163780.1 Sjp_0051780 MS3_06333 Putative wd-repeat protein  
Smp_042030.1 Sjp_0000940 MS3_00766 Putative vesicle transport protein SEC20  
Smp_042340.1 Sjp_0003360 MS3_06198 Catenin and plakophilin, putative  
Smp_153410.1 Sjp_0029580 MS3_05700 Putative serine/threonine protein phosphatase 2a regulatory 
subunit A  
Smp_154880.1 Sjp_0019670 MS3_10659 Putative tubulin delta chain  
Smp_123050.1 Sjp_0044540 MS3_05149 Putative regulator of G protein signaling 17, 19, 20 (Rgs17, 19, 
20)  
Smp_000510.1 Sjp_0091930 MS3_07584 Gdp-mannose pyrophosphorylase b, isoform 2  
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Smp_073470.1 Sjp_0002360 MS3_07371 Retinoid-x-receptor (RXR)  
Smp_181140.1 Sjp_0087070 MS3_02542 Putative uncharacterized protein  
Smp_164340.1 Sjp_0064280 MS3_02998 Afadin (Af-6 protein), putative  
Smp_074080.1 Sjp_0035070 MS3_00555 Serine/threonine kinase  
Smp_132080.1 Sjp_0063250 MS3_07393 Putative sugar transporter  
Smp_120140.1 Sjp_0133110 MS3_08001 Putative uncharacterized protein  
Smp_052290.1 Sjp_0089370 MS3_00113 Putative uncharacterized protein  
Smp_132500.1 Sjp_0067020 MS3_05998 Putative rab  
Smp_054410.1 Sjp_0031570 MS3_09305 Putative adenine phosphoribosyltransferase  
Smp_135530.1 Sjp_0071820 MS3_00263 Leishmanolysin-2 (M08 family)  
Smp_181240.1 Sjp_0048040 MS3_02816 Glutamyl-tRNA(Gln) amidotransferase subunit B (Mitochondrial 
and prokaryotic) pet112-related  
Smp_179050.1 Sjp_0121200 MS3_09384 Putative kinesin  
Smp_142410.1 Sjp_0077070 MS3_03946 Putative uncharacterized protein  
Smp_209040.1 Sjp_0053110 MS3_09914 Long-chain-fatty-acid--CoA ligase  
Smp_124830.1 Sjp_0069880 MS3_06673 Family C54 unassigned peptidase (C54 family)  
Smp_156060.1 Sjp_0053360 MS3_00860 Putative uncharacterized protein  
Smp_180500.1 Sjp_0010790 MS3_08237 Phospholipid scramblase-related  
Smp_123660.1 Sjp_0049060 MS3_09172 Putative peroxidasin  
Smp_084650.1 Sjp_0078000 MS3_09389 Putative uncharacterized protein  
Smp_090820.1 Sjp_0027940 MS3_05018 CDP-diacylglycerol--glycerol-3-phosphate 3-
phosphatidyltransferase  
Smp_016600.1 Sjp_0037260 MS3_00207 Putative solute carrier family 1 (Glial high affinity glutamate 
transporter)  
Smp_048380.1 Sjp_0021110 MS3_06253 Putative uncharacterized protein  
Smp_083990.1 Sjp_0048940 MS3_02574 Cationic amino acid transporter, putative  
Smp_062560.1 Sjp_0106810 MS3_08312 Putative wnt inhibitor frzb2  
Smp_155420.1 Sjp_0118290 MS3_03045 Putative uncharacterized protein  
Smp_069600.1 Sjp_0010070 MS3_02274 Putative uncharacterized protein  
Smp_061950.1 Sjp_0052690 MS3_09288 Putative u3 small nucleolar ribonucleoprotein  
Smp_162450.1 Sjp_0135150 MS3_03335 Cation efflux family protein  
Smp_137430.1 Sjp_0025810 MS3_11049 Splicing factor 3B subunit 3, 5'  
Smp_198010.1 Sjp_0085760 MS3_02502 Centaurin/arf-related  
Smp_136030.1 Sjp_0093940 MS3_07958 Putative anion exchange protein  
Smp_174710.1 Sjp_0076400 MS3_05923 Putative spindle assembly checkpoint component MAD1 
(Mitotic arrest deficient protein 1)  
Smp_194580.1 Sjp_0028000 MS3_05854 Edp1-related  
Smp_012030.1 Sjp_0129030 MS3_05333 Putative zinc finger protein  
Smp_048240.1 Sjp_0020950 MS3_09733 Putative mannose-1-phosphate guanyltransferase  
Smp_001030.1 Sjp_0031410 MS3_01351 5'-amp-activated protein kinase gamma-2 non-catalytic subunit 
transcript variant 2  
Smp_001500.1 Sjp_0071720 MS3_05483 Putative eukaryotic translation initiation factor 4e  
Smp_021160.1 Sjp_0043890 MS3_02639 Putative peptidyl-prolyl cis-trans isomerase  
Smp_160680.1 Sjp_0053900 MS3_01472 Putative uncharacterized protein  
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Smp_136320.1 Sjp_0100250 MS3_06428 Putative uncharacterized protein  
Smp_084870.1 Sjp_0027180 MS3_06338 Putative uncharacterized protein  
Smp_061210.1 Sjp_0002250 MS3_00514 Putative uncharacterized protein  
Smp_075470.1 Sjp_0064140 MS3_09296 Cysteine desulfurylase, putative  
Smp_019980.1 Sjp_0051690 MS3_08429 Putative vacuole membrane protein  
Smp_105100.1 Sjp_0057680 MS3_06302 Ribonuclease, putative  
Smp_061940.1 Sjp_0080220 MS3_09286 Putative adenylate kinase 1  
Smp_173240.1 Sjp_0012960 MS3_02209 Putative cement protein 3B variant 3  
Smp_122340.1 Sjp_0120570 MS3_07583 Kelch-like protein  
Smp_036020.1 Sjp_0007850 MS3_07682 Putative uncharacterized protein  
Smp_160470.1 Sjp_0044490 MS3_02022 Putative tbc1 domain family member 2 (Prostate antigen 
recognized and indentified by serex) (Paris-1)  
Smp_150220.1 Sjp_0097720 MS3_10047 Putative receptor protein tyrosine phosphatase n, (Ia2)  
Smp_171620.1 Sjp_0070480 MS3_05520 S-methyl-5'-thioadenosine phosphorylase  
Smp_063110.1 Sjp_0060630 MS3_07840 Putative zinc finger protein  
Smp_054010.1 Sjp_0079140 MS3_03571 Putative cationic amino acid transporter  
Smp_212140.1 Sjp_0116730 MS3_02920 Vam6/vps39 related  
Smp_130890.1 Sjp_0106650 MS3_01037 Putative transient receptor potential cation channel,subfamily 
m, member  
Smp_152500.1 Sjp_0003800 MS3_01807 Putative cyclic-nucleotide-gated cation channel  
Smp_203480.1 Sjp_0087200 MS3_09047 Putative uncharacterized protein Smp_203480  
Smp_148720.1 Sjp_0010530 MS3_02287 DNA-directed RNA polymerase  
Smp_136530.1 Sjp_0022010 MS3_05048 Putative ankyrin repeat-containing  
Smp_137370.1 Sjp_0029420 MS3_00329 Serine/threonine kinase  
Smp_032780.1 Sjp_0059720 MS3_07190 Putative dolichyl-phosphate beta-glucosyltransferase (dolp-
glucosyltransferase)  
Smp_163870.1 Sjp_0056320 MS3_03018 Doublesex and mab-3 related transcription factor  
Smp_128490.1 Sjp_0104510 MS3_06120 Putative tomosyn  
Smp_004360.1 Sjp_0011890 MS3_05904 Putative uncharacterized protein  
Smp_176390.1 Sjp_0074340 MS3_04214 Putative cadherin  
Smp_016380.1 Sjp_0057120 MS3_11331 Cytohesin-related guanine nucleotide-exchange protein  
Smp_124640.1 Sjp_0014090 MS3_09395 Putative dna2/nam7 helicase family member  
Smp_073560.1 Sjp_0025130 MS3_07914 G beta-like protein gbl  
Smp_168070.1 Sjp_0098810 MS3_00310 Tumor necrosis factor receptor related  
Smp_082120.1 Sjp_0082240 MS3_09078 ATP synthase delta chain, mitochondrial,putative  
Smp_074710.1 Sjp_0037510 MS3_02415 Putative uncharacterized protein  
Smp_020300.1 Sjp_0046610 MS3_00051 Putative dishevelled  
Smp_128130.1 Sjp_0097580 MS3_06240 Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
alpha PI3K  
Smp_200110.1 Sjp_0045250 MS3_06589 Putative uncharacterized protein Smp_200110  
Smp_036010.1 Sjp_0007840 MS3_09666 Putative uncharacterized protein  
Smp_107200.1 Sjp_0081060 MS3_08140 Putative uncharacterized protein  
Smp_034550.1 Sjp_0059270 MS3_04427 Putative alpha-actinin  
Smp_176800.1 Sjp_0007380 MS3_03148 Putative uncharacterized protein  
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Smp_151520.1 Sjp_0089670 MS3_02179 Putative dolichyl glycosyltransferase  
Smp_123710.1 Sjp_0081470 MS3_05056 Acetyl-CoA carboxylase  
Smp_162670.1 Sjp_0065560 MS3_06764 Putative uncharacterized protein  
Smp_179560.1 Sjp_0069830 MS3_05089 Multiple inositol polyphosphate phosphatase-related  
Smp_091850.1 Sjp_0096790 MS3_11422 Glucosamine-6-phosphate isomerase, putative  
Smp_092170.1 Sjp_0074640 MS3_06816 Putative uncharacterized protein  
Smp_130040.1 Sjp_0018470 MS3_02806 Pecanex-related protein  
Smp_086690.1 Sjp_0071670 MS3_10235 Kinase  
Smp_130570.1 Sjp_0027670 MS3_02532 Putative receptor tyrosine phosphatase type r2a  
Smp_099930.1 Sjp_0083430 MS3_01056 Putative f-box and wd40 domain protein  
Smp_126720.1 Sjp_0058660 MS3_08990 Putative uncharacterized protein  
Smp_180740.1 Sjp_0079290 MS3_02664 Putative zinc finger protein  
Smp_155590.1 Sjp_0006380 MS3_05716 Putative uncharacterized protein  
Smp_171870.1 Sjp_0105540 MS3_06596 Putative sugar transporter  
Smp_079390.1 Sjp_0071960 MS3_06639 Protein kinase  
Smp_158330.1 Sjp_0037670 MS3_08282 Putative uncharacterized protein  
Smp_009540.1 Sjp_0066030 MS3_10330 Putative ring finger-containing  
Smp_145900.1 Sjp_0061450 MS3_00627 Dihydroceramide desaturase  
Smp_143800.1 Sjp_0005570 MS3_01189 Transporter  
Smp_132730.1 Sjp_0108420 MS3_06574 G-protein coupled receptor, putative  
Smp_196050.1 Sjp_0114820 MS3_06214 Putative uncharacterized protein Smp_196050  
Smp_170010.1 Sjp_0035340 MS3_01416 Putative flagellar radial spoke protein  
Smp_174040.1 Sjp_0064790 MS3_08124 Neurotracting/lsamp/neurotrimin/obcam related cell adhesion 
molecule  
Smp_018280.1 Sjp_0108430 MS3_10334 Putative uncharacterized protein  
Smp_149020.1 Sjp_0045110 MS3_03870 Lim domain binding protein, putative  
Smp_126420.1 Sjp_0070840 MS3_07995 Putative uncharacterized protein  
Smp_082370.1 Sjp_0011150 MS3_03842 Putative nadp transhydrogenase  
Smp_199690.1 Sjp_0052970 MS3_09387 G-protein coupled receptor,putative  
Smp_160940.1 Sjp_0065440 MS3_01661 Putative uncharacterized protein  
Smp_179910.1 Sjp_0089480 MS3_00473 Ras-like protein  
Smp_002870.1 Sjp_0089930 MS3_07466 Putative uncharacterized protein  
Smp_197330.1 Sjp_0081390 MS3_01542 Acetyl-CoA C-acetyltransferase  
Smp_055390.1 Sjp_0059520 MS3_05635 Putative dullard protein  
Smp_127500.1 Sjp_0070050 MS3_10075 Putative uncharacterized protein  
Smp_126800.1 Sjp_0040030 MS3_03936 Putative mkiaa1688 protein  
Smp_133320.1 Sjp_0004950 MS3_07197 Ccr4-not transcription complex, putative  
Smp_175760.1 Sjp_0002640 MS3_07961 Endosomal trafficking protein, putative  
Smp_145670.1 Sjp_0075500 MS3_10068 DNAj-related  
Smp_159560.1 Sjp_0011620 MS3_01604 Putative gata binding factor  
Smp_170540.1 Sjp_0134980 MS3_04670 Putative uncharacterized protein  
Smp_140560.1 Sjp_0030940 MS3_11189 Putative uncharacterized protein  
Smp_211090.1 Sjp_0072690 MS3_07969 Putative peptide chain release factor  
Smp_169190.1 Sjp_0047050 MS3_05954 Putative tegumental protein\x3b Tegumental allergen-like 
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protein  
Smp_123780.1 Sjp_0058010 MS3_06562 Putative glypican  
Smp_155480.1 Sjp_0105530 MS3_03050 Putative heat shock protein 70 (Hsp70)-interacting protein  
Smp_197860.1 Sjp_0066490 MS3_03933 Putative gelsolin  
Smp_069170.1 Sjp_0013440 MS3_03548 Putative cation efflux protein/ zinc transporter  
Smp_046880.1 Sjp_0052190 MS3_06837 Putative glycosyltransferase  
Smp_124570.1 Sjp_0035210 MS3_08722 Leucine zipper protein, putative  
Smp_124020.1 Sjp_0094660 MS3_09149 Putative heparan sulfate 6-o-sulfotransferase  
Smp_135100.1 Sjp_0028560 MS3_02954 Putative dtdp-glucose 4-6-dehydratase  
Smp_093800.1 Sjp_0091070 MS3_03791 Putative uncharacterized protein  
Smp_104110.1 Sjp_0040660 MS3_11394 Putative rho GTPase  
Smp_211320.1 Sjp_0046960 MS3_05177 Putative soluble guanylate cyclase gcy  
Smp_153440.1 Sjp_0029560 MS3_05804 Neuropilin (Nrp) and tolloid (Tll)-like  
Smp_167190.1 Sjp_0133070 MS3_05670 Putative uncharacterized protein Smp_167190  
Smp_129950.1 Sjp_0066250 MS3_05213 Rna-binding protein 12 (Sh3/ww domain anchor protein in the 
nucleus) (Swan), putative  
Smp_171650.1 Sjp_0059410 MS3_04240 Eps-15-related  
Smp_158670.1 Sjp_0031200 MS3_05239 Putative uncharacterized protein  
Smp_168220.1 Sjp_0027270 MS3_06346 Putative uncharacterized protein  
Smp_036590.1 Sjp_0047920 MS3_00233 Putative polypyrimidine tract binding protein  
Smp_166420.1 Sjp_0008060 MS3_06923 Putative uncharacterized protein  
Smp_038640.1 Sjp_0020590 MS3_04345 Cactin-related  
Smp_146400.1 Sjp_0024890 MS3_03372 Syntaxin binding protein-1,2,3, putative  
Smp_141660.1 Sjp_0006720 MS3_06102 Putative high voltage-activated calcium channel beta subunit 2  
Smp_144130.1 Sjp_0037860 MS3_01201 Septate junction protein  
Smp_161510.1 Sjp_0008800 MS3_08477 Putative uncharacterized protein  
Smp_024290.1 Sjp_0088830 MS3_06556 Putative map kinase kinase protein DdMEK1  
Smp_139020.1 Sjp_0029160 MS3_00600 Protein kinase  
Smp_070380.1 Sjp_0055710 MS3_10499 Putative uncharacterized protein  
Smp_148530.1 Sjp_0107970 MS3_03420 Putative heat shock protein hsp16  
Smp_129260.1 Sjp_0086100 MS3_11002 Poly 
Smp_049880.1 Sjp_0100280 MS3_07670 Nuclear pore glycoprotein P62, putative  
Smp_087560.1 Sjp_0032790 MS3_04593 Putative uncharacterized protein  
Smp_053550.1 Sjp_0052010 MS3_06215 Putative uncharacterized protein  
Smp_170530.1 Sjp_0084910 MS3_04667 Upstream transcription factor 1, usf1, putative  
Smp_071950.1 Sjp_0019810 MS3_08816 Tetratricopeptide repeat protein, tpr, putative  
Smp_021170.1 Sjp_0043880 MS3_02636 VPS13C protein, putative  
Smp_168090.1 Sjp_0100660 MS3_10683 Putative uncharacterized protein  
Smp_087620.1 Sjp_0054960 MS3_04595 Putative programmed cell death 6-interacting protein  
Smp_012350.1 Sjp_0070310 MS3_11409 Venom allergen-like (VAL) 11 protein  
Smp_125990.1 Sjp_0085480 MS3_09587 Putative uncharacterized protein  
Smp_142890.1 Sjp_0069480 MS3_04099 Putative hect E3 ubiquitin ligase  
Smp_090070.1 Sjp_0085730 MS3_02507 WD-repeat protein, putative  
Smp_082800.1 Sjp_0030400 MS3_08257 Sly1-related  
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Smp_134230.1 Sjp_0093830 MS3_09190 Putative geranylgeranyl pyrophosphate synthase  
Smp_131970.1 Sjp_0063890 MS3_02420 Putative uncharacterized protein  
Smp_093920.1 Sjp_0129510 MS3_07544 Putative uncharacterized protein  
Smp_154690.1 Sjp_0048310 MS3_04706 Ribosomal protein related  
Smp_030710.1 Sjp_0055890 MS3_06743 Serine/threonine-protein phosphatase  
Smp_134370.1 Sjp_0015320 MS3_07853 Putative rna 3' terminal phosphate cyclase  
Smp_199400.1 Sjp_0069800 MS3_05091 Myosin regulatory light chain 2 smooth muscle,putative  
Smp_016410.1 Sjp_0088510 MS3_08949 Putative ran-binding protein  
Smp_173060.1 Sjp_0018530 MS3_07261 Pak-interacting exchange factor, beta-pix/cool-1, putative  
Smp_036500.1 Sjp_0106460 MS3_00211 CAR\x3b Putative nuclear receptor nhr-48  
Smp_098560.2 Sjp_0052120 MS3_06205 Putative uncharacterized protein  
Smp_168590.1 Sjp_0054800 MS3_02999 Macrophage scavenger receptor-related  
Smp_150210.1 Sjp_0026510 MS3_09307 Putative autocrine motility factor receptor,amfr  
Smp_138670.1 Sjp_0038050 MS3_09404 39S ribosomal protein L19, mitochondrial, putative  
Smp_123470.1 Sjp_0100570 MS3_00446 Nalp (Nacht, leucine rich repeat and pyrin domain containing)-
related  
Smp_175720.1 Sjp_0130370 MS3_03583 Tripartite motif protein trim9, putative  
Smp_040800.1 Sjp_0039430 MS3_08104 Putative glycyl-tRNA synthetase  
Smp_166960.1 Sjp_0042790 MS3_06050 Putative ubiquitin-protein ligase BRE1  
Smp_176420.1 Sjp_0030500 MS3_08694 Ras guanine nucleotide exchange factor ,putative  
Smp_088950.1 Sjp_0060680 MS3_10049 Hypoxia upregulated 1 (Hyou1)-related  
Smp_160710.1 Sjp_0054490 MS3_07504 Putative upstream stimulatory factor  
Smp_018990.1 Sjp_0075950 MS3_04781 Putative 60s ribosomal protein L9  
Smp_128860.1 Sjp_0050160 MS3_10980 Lysyl oxidase-like  
Smp_063000.1 Sjp_0012640 MS3_01088 Smdr1  
Smp_157350.1 Sjp_0049520 MS3_01308 Protein kinase  
Smp_147240.1 Sjp_0031690 MS3_02755 Putative wd40 protein  
 
 
Supplementary Table 4.2 135 proteins were predicted as surface or secretory proteins by 
SchistoProt and SchistoTarget. 
Protein ID Surface Prediction Secretory Prediction 
Smp_000170.1 Surface Protein Secretory Protein 
Smp_001030.1 Surface Protein Secretory Protein 
Smp_003250.1 Surface Protein Secretory Protein 
Smp_004360.1 Surface Protein Secretory Protein 
Smp_006000.1 Surface Protein Secretory Protein 
Smp_015710.1 Surface Protein Secretory Protein 
Smp_016600.1 Surface Protein Secretory Protein 
Smp_018890.1 Surface Protein Secretory Protein 
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Smp_018990.1 Surface Protein Secretory Protein 
Smp_019980.1 Surface Protein Secretory Protein 
Smp_021160.1 Surface Protein Secretory Protein 
Smp_026230.1 Surface Protein Secretory Protein 
Smp_029310.1 Surface Protein Secretory Protein 
Smp_033930.1 Surface Protein Secretory Protein 
Smp_034550.1 Surface Protein Secretory Protein 
Smp_048380.1 Surface Protein Secretory Protein 
Smp_048540.1 Surface Protein Secretory Protein 
Smp_061210.1 Surface Protein Secretory Protein 
Smp_061940.1 Surface Protein Secretory Protein 
Smp_067540.1 Surface Protein Secretory Protein 
Smp_070380.1 Surface Protein Secretory Protein 
Smp_071390.1 Surface Protein Secretory Protein 
Smp_071840.1 Surface Protein Secretory Protein 
Smp_079310.1 Surface Protein Secretory Protein 
Smp_084650.1 Surface Protein Secretory Protein 
Smp_087560.1 Surface Protein Secretory Protein 
Smp_094810.1 Surface Protein Secretory Protein 
Smp_104110.1 Surface Protein Secretory Protein 
Smp_105100.1 Surface Protein Secretory Protein 
Smp_105760.1 Surface Protein Secretory Protein 
Smp_106930.1 Surface Protein Secretory Protein 
Smp_123080.1 Surface Protein Secretory Protein 
Smp_123470.1 Surface Protein Secretory Protein 
Smp_124020.1 Surface Protein Secretory Protein 
Smp_124570.1 Surface Protein Secretory Protein 
Smp_126720.1 Surface Protein Secretory Protein 
Smp_135100.1 Surface Protein Secretory Protein 
Smp_140560.1 Surface Protein Secretory Protein 
Smp_141470.1 Surface Protein Secretory Protein 
Smp_145900.1 Surface Protein Secretory Protein 
Smp_150380.1 Surface Protein Secretory Protein 
Smp_151520.1 Surface Protein Secretory Protein 
Smp_151960.1 Surface Protein Secretory Protein 
Smp_152790.1 Surface Protein Secretory Protein 
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Smp_169190.1 Surface Protein Secretory Protein 
Smp_178490.1 Surface Protein Secretory Protein 
Smp_179910.1 Surface Protein Secretory Protein 
Smp_180500.1 Surface Protein Secretory Protein 
Smp_193050.1 Surface Protein Secretory Protein 
Smp_196050.1 Surface Protein Secretory Protein 
Smp_199400.1 Surface Protein Secretory Protein 
Smp_199420.1 Surface Protein Secretory Protein 
Smp_200110.1 Surface Protein Secretory Protein 
Smp_203970.1 Surface Protein Secretory Protein 
Smp_001500.1 Surface Protein Non-Secretory Protein 
Smp_017620.1 Surface Protein Non-Secretory Protein 
Smp_020220.1 Surface Protein Non-Secretory Protein 
Smp_030710.1 Surface Protein Non-Secretory Protein 
Smp_038300.1 Surface Protein Non-Secretory Protein 
Smp_044820.1 Surface Protein Non-Secretory Protein 
Smp_046980.1 Surface Protein Non-Secretory Protein 
Smp_048650.1 Surface Protein Non-Secretory Protein 
Smp_054410.1 Surface Protein Non-Secretory Protein 
Smp_073560.1 Surface Protein Non-Secretory Protein 
Smp_091770.1 Surface Protein Non-Secretory Protein 
Smp_091850.1 Surface Protein Non-Secretory Protein 
Smp_098560.2 Surface Protein Non-Secretory Protein 
Smp_107200.1 Surface Protein Non-Secretory Protein 
Smp_120140.1 Surface Protein Non-Secretory Protein 
Smp_127500.1 Surface Protein Non-Secretory Protein 
Smp_131970.1 Surface Protein Non-Secretory Protein 
Smp_134510.1 Surface Protein Non-Secretory Protein 
Smp_136320.1 Surface Protein Non-Secretory Protein 
Smp_149450.1 Surface Protein Non-Secretory Protein 
Smp_158330.1 Surface Protein Non-Secretory Protein 
Smp_158970.1 Surface Protein Non-Secretory Protein 
Smp_162960.1 Surface Protein Non-Secretory Protein 
Smp_163870.1 Surface Protein Non-Secretory Protein 
Smp_166400.1 Surface Protein Non-Secretory Protein 
Smp_168220.1 Surface Protein Non-Secretory Protein 
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Smp_170010.1 Surface Protein Non-Secretory Protein 
Smp_171620.1 Surface Protein Non-Secretory Protein 
Smp_209040.1 Surface Protein Non-Secretory Protein 
Smp_000510.1 Non-Surface Protein Secretory Protein 
Smp_002870.1 Non-Surface Protein Secretory Protein 
Smp_012470.1 Non-Surface Protein Secretory Protein 
Smp_018640.1 Non-Surface Protein Secretory Protein 
Smp_030350.1 Non-Surface Protein Secretory Protein 
Smp_035460.1 Non-Surface Protein Secretory Protein 
Smp_036010.1 Non-Surface Protein Secretory Protein 
Smp_037900.1 Non-Surface Protein Secretory Protein 
Smp_048240.1 Non-Surface Protein Secretory Protein 
Smp_050130.1 Non-Surface Protein Secretory Protein 
Smp_054010.1 Non-Surface Protein Secretory Protein 
Smp_061950.1 Non-Surface Protein Secretory Protein 
Smp_069170.1 Non-Surface Protein Secretory Protein 
Smp_074010.1 Non-Surface Protein Secretory Protein 
Smp_075470.1 Non-Surface Protein Secretory Protein 
Smp_083990.1 Non-Surface Protein Secretory Protein 
Smp_085680.1 Non-Surface Protein Secretory Protein 
Smp_086210.1 Non-Surface Protein Secretory Protein 
Smp_088950.1 Non-Surface Protein Secretory Protein 
Smp_093800.1 Non-Surface Protein Secretory Protein 
Smp_125640.1 Non-Surface Protein Secretory Protein 
Smp_125990.1 Non-Surface Protein Secretory Protein 
Smp_126350.1 Non-Surface Protein Secretory Protein 
Smp_128860.1 Non-Surface Protein Secretory Protein 
Smp_130040.1 Non-Surface Protein Secretory Protein 
Smp_132080.1 Non-Surface Protein Secretory Protein 
Smp_132500.1 Non-Surface Protein Secretory Protein 
Smp_132730.1 Non-Surface Protein Secretory Protein 
Smp_132930.1 Non-Surface Protein Secretory Protein 
Smp_136360.1 Non-Surface Protein Secretory Protein 
Smp_138670.1 Non-Surface Protein Secretory Protein 
Smp_143800.1 Non-Surface Protein Secretory Protein 
Smp_144130.1 Non-Surface Protein Secretory Protein 
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Smp_146400.1 Non-Surface Protein Secretory Protein 
Smp_146830.1 Non-Surface Protein Secretory Protein 
Smp_147070.1 Non-Surface Protein Secretory Protein 
Smp_150210.1 Non-Surface Protein Secretory Protein 
Smp_155050.1 Non-Surface Protein Secretory Protein 
Smp_155420.1 Non-Surface Protein Secretory Protein 
Smp_155610.1 Non-Surface Protein Secretory Protein 
Smp_159370.1 Non-Surface Protein Secretory Protein 
Smp_159400.1 Non-Surface Protein Secretory Protein 
Smp_159890.1 Non-Surface Protein Secretory Protein 
Smp_162450.1 Non-Surface Protein Secretory Protein 
Smp_163970.1 Non-Surface Protein Secretory Protein 
Smp_167190.1 Non-Surface Protein Secretory Protein 
Smp_173100.1 Non-Surface Protein Secretory Protein 
Smp_178780.1 Non-Surface Protein Secretory Protein 
Smp_179560.1 Non-Surface Protein Secretory Protein 
Smp_199690.1 Non-Surface Protein Secretory Protein 
Smp_211090.1 Non-Surface Protein Secretory Protein 
Smp_211320.1 Non-Surface Protein Secretory Protein 
  
Supplementary Table 4.3 SchistoTarget predicted 45 proteins have immunoreactivity among 
the 135 proteins. 
Immunoreactive proteins 
Smp_006000.1 Smp_017620.1 Smp_132080.1 
Smp_018990.1 Smp_048650.1 Smp_132730.1 
Smp_048380.1 Smp_120140.1 Smp_132930.1 
Smp_048540.1 Smp_127500.1 Smp_136360.1 
Smp_070380.1 Smp_149450.1 Smp_143800.1 
Smp_105760.1 Smp_162960.1 Smp_147070.1 
Smp_124020.1 Smp_163870.1 Smp_155050.1 
Smp_140560.1 Smp_168220.1 Smp_159400.1 
Smp_145900.1 Smp_002870.1 Smp_163970.1 
Smp_150380.1 Smp_030350.1 Smp_167190.1 
Smp_151520.1 Smp_036010.1 Smp_173100.1 
Smp_178490.1 Smp_054010.1 Smp_178780.1 
Smp_180500.1 Smp_083990.1 Smp_179560.1 
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Smp_196050.1 Smp_125990.1 Smp_199690.1 
Smp_200110.1 Smp_130040.1 Smp_211320.1 
 
 
Supplementary Table 4.4  20 proteins were selected as potential vaccine targets using GO 
annotation.        
Proteins were selected on the basis of biological processes and molecular functions which are 
important for host-parasite interactions such as catalytic activity, transmembrane transporter 
activity, lipid transporter activity, serine-type peptidase activity, serine protease inhibitory actvity, G-
protein coupled receptor and oxidoreductase activity.  
Gene ID PANTHER GO-Slim Molecular Function PANTHER GO-Slim Biological Process 
Smp_002870 
protein binding(GO:0005515); small GTPase 
regulator activity(GO:0005083) cellular process(GO:0009987) 
Smp_017620 
  
Smp_018990 
RNA binding(GO:0003723); structural constituent of 
ribosome(GO:0003735) 
biosynthetic process(GO:0009058); cellular 
process(GO:0009987); translation(GO:0006412) 
Smp_048540 
  
Smp_054010 
amino acid transmembrane transporter 
activity(GO:0015171); transmembrane transporter 
activity(GO:0022857) 
amino acid transport(GO:0006865); anion 
transport(GO:0006820); cellular 
process(GO:0009987) 
Smp_083990 
amino acid transmembrane transporter 
activity(GO:0015171); transmembrane transporter 
activity(GO:0022857) 
amino acid transport(GO:0006865); anion 
transport(GO:0006820); cellular 
process(GO:0009987) 
Smp_124020 transferase activity(GO:0016740) 
biosynthetic process(GO:0009058); cellular 
process(GO:0009987); protein metabolic 
process(GO:0019538); sulfur compound metabolic 
process(GO:0006790) 
Smp_132080 transmembrane transporter activity(GO:0022857) cellular process(GO:0009987) 
Smp_132730 
  Smp_143800 transporter activity(GO:0005215) 
 
Smp_145900 oxidoreductase activity(GO:0016491) 
biosynthetic process(GO:0009058); cellular 
process(GO:0009987); lipid metabolic 
process(GO:0006629); nitrogen compound 
metabolic process(GO:0006807) 
Smp_147070 
amino acid transmembrane transporter 
activity(GO:0015171); transmembrane transporter 
activity(GO:0022857) 
amino acid transport(GO:0006865); anion 
transport(GO:0006820); cellular 
process(GO:0009987) 
Smp_149450 
  Smp_150380 catalytic activity(GO:0003824) lipid metabolic process(GO:0006629) 
Smp_155050 
  
Smp_163970 serine-type peptidase activity(GO:0008236) 
catabolic process(GO:0009056); cellular 
process(GO:0009987); proteolysis(GO:0006508) 
Smp_167190 calcium ion binding(GO:0005509); calcium- cellular process(GO:0009987) 
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dependent phospholipid binding(GO:0005544); 
calmodulin binding(GO:0005516); extracellular 
matrix structural constituent(GO:0005201); receptor 
binding(GO:0005102) 
Smp_178490 transmembrane transporter activity(GO:0022857) 
cellular process(GO:0009987); nucleobase-
containing compound transport(GO:0015931) 
Smp_180500 lipid transporter activity(GO:0005319) 
anion transport(GO:0006820); biological 
regulation(GO:0065007); cellular component 
organization(GO:0016043); cellular 
process(GO:0009987) 
Smp_199690 
G-protein coupled receptor activity(GO:0004930); 
binding(GO:0005488); signal transducer 
activity(GO:0004871) 
regulation of biological process(GO:0050789); 
response to endogenous stimulus(GO:0009719) 
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Chapter 5 General discussion and conclusion 
 
This chapter discussed and summarised the overall PhD research works and findings. 
This PhD thesis covers three individual projects that are building up on each other to 
achieve the three aims of the research. Chapter 1 describes the theoretical background 
that is required to understand the thesis topics and gives a good and comprehensive 
overview of schistosomiasis, its causes, and consequences. Chapters 2 to chapter 4 
describe each one of the three aims of the PhD research. Chapter 2 fulfils the aim-1 which 
is the development of a method for the identification of schistosome-specific surface 
proteins and secreted peptides. Aim 2 is achieved in chapter 3, the development of a 
method for the identification of Schistosoma immunoreactive proteins. The final aim of the 
PhD research is mentioned in chapter 4, the application of the developed methods in an 
integrative bioinformatics pipeline to identify putative vaccine targets against 
schistosomiasis. 
Schistosomiasis is a parasitic disease caused by parasitic Schistosoma. This disease is 
the second most devastating parasitic disease after malaria worms and more than 200 
million people are infected worldwide. Despite of deadly effect on mass population, 
schistosomiasis is considered one of the Neglected Tropical Diseases (NTDs). No 
vaccines are available and treatment relies mainly on one drug, praziquantel. This drug 
effectively disrupts the tegument of adult worms, but not juvenile parasites and even mass 
treatment does not prevent reinfection. Vaccines that induce long-term immunity represent 
an essential component for the future control of schistosomiasis with the final goal of 
complete elimination. Driven by the need to improve disease treatment and prevention, the 
genomes of several Schistosoma species have recently become publicly available. 
Moreover, several whole-genome sequencing projects of additional Schistosoma species 
will soon be completed.  
Surface-associated proteins and secreted peptides play a key role in parasite physiology 
and pathogenesis and are the major targets for vaccine development. The laborious task 
of identifying these important classes of proteins can be highly accelerated using 
computational tools that evaluate the specific sequence properties of surface proteins and 
secreted peptides. However, currently available methods for this task have their limitations 
as they show only modest prediction accuracy for Schistosoma species. SchistoProt, a 
machine-learning classifier for the identification of Schistosoma surface proteins and 
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secreted peptides, have been developed. SchistoProt provides a user-friendly web-
interface and achieves a superior detection accuracy compared to other existing tools. 
Results are presented as interactive tables, charts and figures. This project results 
demonstrate that a genus-specific classifier can excel in the detection of surface proteins 
and secreted peptides compared with general tools for this task. As such, SchistoProt 
assists in studying the molecular mechanisms of host infection, analysing anti-schistosome 
protective immunity and the rapid prioritization of candidate vaccine targets. 
Schistosome protein microarrays allow to compare antibody signatures in different disease 
pathologies as the pilot Schistosoma immunomics study. SchistoTarget enables us to 
identify Schistosoma proteins immunoreactivity using the small size of protein microarray 
data by machine learning based approach. The prediction accuracy of SchistoTarget can 
be further improved by training on future protein microarrays data for antibody responses, 
if available. 
The innovative integrative approach developed with the comparative studies of three 
human-infecting schistosomes, animal-infecting S. bovis and non-parasitic free-living 
flatworm Schmidtea mediterranea reveals the interesting candidate genes for vaccine 
targets. These genes are further filtered using the tools developed in this PhD project, 
SchistoProt and SchistoTarget, to select only surface or secretory proteins. Gene Ontology 
and Swiss-Prot annotations provide the useful information to select potential antigens as 
drug and vaccine targets. Further, applying STRING and STICH, protein-protein and 
protein-chemical interactions are explored which provided putative vaccines and drug 
targets. 
The results of this PhD project are expected to significance advances in schsitosomiasis 
vaccinology. The selected 20 antigens as putative vaccine targets against schistosomiasis 
should now be biologically validated by wet laboratory experiments in animals and then 
clinically. The protocol developed in this PhD project can be used as a blueprint for other 
parasitic diseases such as malaria. 
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